Orforglipron Clinical Protocol

Clinical-education protocol for orforglipron (Eli Lilly development code LY3502970), an oral non-peptide small-molecule GLP-1 receptor agonist in active Phase 3 development under the ATTAIN (obesity) and ACHIEVE (T2D) programs. This protocol prepares clinicians for orforglipron’s anticipated availability based on Phase 3 ATTAIN + ACHIEVE readout data; current prescribing requires off-label use of investigational supply OR enrollment in active clinical trials. Orforglipron is NOT FDA-approved as of 2026-05-13; pre-FDA-approval-for-marketing-claims for any indication. ATTAIN-1 (Wharton 2025 NEJM PMID 40960239) reported −11.2% body weight reduction at 36 mg / 72 weeks in obesity without T2D; ACHIEVE-1 (Rosenstock 2025 NEJM PMID 40544435) reported HbA1c reductions −1.24% to −1.48% across 3/12/36 mg in T2D; FDA NDA submission anticipated end-2025 obesity / 2026 T2D per Eli Lilly investor communications; anticipated approval H1 2027 conditional on FDA review timelines.

FDA-approved for marketing claims — load-bearing precision (Editorial Framework §1.2.1; Pattern AA.marketing-claims). When this protocol references orforglipron’s regulatory state as “pre-FDA-approval,” the load-bearing phrase is “pre-FDA-approval-for-marketing-claims.” FDA approval is approval-for-marketing-claims for specific named indications. When this protocol references class comparators as “FDA-approved” (semaglutide for type 2 diabetes / chronic weight management / cardiovascular risk reduction / MASH / CKD-in-T2D; tirzepatide for T2D / chronic weight management / OSA in obesity; liraglutide for T2D / CWM), the load-bearing phrase is “FDA-approved for marketing claims for [indication X].” Off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug.

Pattern AA framing throughout. Every regulatory-claim sentence defaults to “investigational,” “Phase 3 readout published / pending,” “anticipated FDA submission end-2025 obesity / 2026 T2D per Eli Lilly investor communications.” The protocol body never uses “approved” or “FDA-approved” for orforglipron itself except in the negative (“pre-FDA-approval-for-marketing-claims,” “NOT FDA-approved as of 2026-05-13”) or when referring explicitly to FDA-approved-for-marketing-claims class comparators (semaglutide, tirzepatide, liraglutide, dulaglutide).

Pattern N.1 — structural classification: orforglipron is a small molecule, NOT a peptide. Orforglipron is a spiropiperidine-based synthetic organic compound, molecular weight ~632 Da, manufactured via standard small-molecule pharmaceutical chemical synthesis. It is not a peptide, not structurally related to the peptide GLP-1 RA class (semaglutide, liraglutide, dulaglutide, exenatide-class), and not produced via solid-phase peptide synthesis. The canonical lives at /Small-Molecules/Orforglipron.md, not at /Peptides/. The route-of-administration advantage (oral, no permeation enhancer, no food/water timing restriction, room-temperature stable) is a small-molecule chemistry-platform consequence, not a peptide-class feature. Sections 1.4, 2.3, 4.5, 6.10, 8.1, and 10.5 of the canonical develop the platform thread; this protocol carries Pattern N.1 explicitly at every load-bearing platform reference.

§10 Pattern Z calibration. Anchor 5 (off-label / extrapolation transparency) is the dominant calibration surface for orforglipron today, because the only routes to orforglipron use as of 2026-05-13 are (a) enrollment in an active ATTAIN-MAINTAIN / GLOW-2 / ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J Phase 3 trial; (b) investigational-supply acquisition through research-protocol channels (clinician-judgment off-label); or (c) gray-market / research-chemical-vendor sourcing operating outside the post-FDA-approval shortage-driven 503A/503B compounding framework that applied to compounded peptide GLP-1 RAs (semaglutide, tirzepatide). Anchor 1+2 (compounded counseling) is reframed in §10.3 per the canonical §8.3.2 research-state-factual observation: compounded orforglipron has substantially limited compounding-pharmacy market presence as of 2026-05-13 — pre-FDA-approval status without FDA-declared shortage; non-peptide small-molecule chemistry differs from the predominantly peptide-compounding 503A/503B GLP-1 RA market specialization (USP <795> non-sterile small-molecule vs USP <797> sterile peptide injectable); orforglipron API is Lilly proprietary investigational supply.

Magnitude-vs-route framing (Anchor 4 mirror — LOAD-BEARING for this protocol). ATTAIN-1 36 mg achieved −11.2% body weight reduction at 72 weeks — meaningfully less than semaglutide (~15% per STEP-1) or tirzepatide (~22% per SURMOUNT-1) at their max-tolerated doses. The clinical decision orforglipron presents is a magnitude-vs-route tradeoff: orforglipron offers oral non-peptide administration with no food/water timing restriction and room-temperature storage (route advantages); injectable peptide GLP-1 RAs offer larger weight-loss magnitude and longer post-approval real-world evidence base (magnitude / evidence-maturity advantages); Rybelsus (oral peptide via SNAC) offers oral administration but with a 30-minute empty-stomach food/water-wait absorption window. §10.5 presents this tradeoff honestly across nine dimensions; counseling beats do not steer toward injectables on magnitude grounds nor toward orforglipron on route grounds.

Indication scope and patient phenotypes
Selection criteria (inclusion / exclusion / contraindications)
Pre-treatment workup
Initiation protocol
Maintenance protocol
Side-effect management
Plateau and non-response algorithm
Discontinuation and tapering
Combination rules
Patient counseling beats (Pattern Z calibration-anchor-compliant)
Source citations
Clinical decision tree

Appendices

A. Verification gate
B. Pattern discipline summary
C. Self-audit findings

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol prepares clinicians for orforglipron’s anticipated availability based on the Phase 3 ATTAIN (obesity) and ACHIEVE (T2D) program readout data and provides a clinical-education framework for understanding the oral non-peptide small-molecule GLP-1 receptor agonist platform, the anticipated indication scope per the ATTAIN + ACHIEVE program design, the expected effect-size magnitudes per the published Phase 3 data, and the safety considerations specific to the small-molecule chemistry platform.

Current prescribing reality (2026-05-13). Orforglipron is in Phase 3 with three published primary registrational trials: ATTAIN-1 in obesity without T2D (Wharton S et al. NEJM 2025;393(19):1889-1901, PMID 40960239 = DOI 10.1056/NEJMoa2511774; NCT05051579; n ≈ 3,127; 72 weeks; 6/12/36 mg dose arms vs placebo; 36 mg arm −11.2% body weight reduction [95% CI −12.0 to −10.4] vs placebo −2.1% [95% CI −2.8 to −1.4]); ACHIEVE-1 in T2D (Rosenstock J et al. NEJM 2025, PMID 40544435; NCT05869903; 40 weeks; 3/12/36 mg dose arms vs placebo; HbA1c absolute reductions in the range −1.24% to −1.48% across dose arms vs placebo −0.41%); and ATTAIN-2 in combined obesity + T2D (Horn DB et al. Lancet 2026, PMID 41275875; NCT05872620). Additional ACHIEVE program trials (ACHIEVE-2 NCT05803161; ACHIEVE-5 NCT05715711) have sponsor positive-topline disclosures from October 2025 with peer-reviewed publication PMID assignment pending; ACHIEVE-3 (NCT05803421), ACHIEVE-4 (NCT05803434; readout anticipated Q1 2026), ACHIEVE-J (NCT06010721; Japan T2D), ATTAIN-MAINTAIN (NCT05931380; obesity maintenance), and GLOW-2 (NCT06066620; OSA + obesity overlap) are per ClinicalTrials.gov v2 API status as of 2026-05-13. FDA NDA submission is anticipated end-2025 (obesity indication) and 2026 (T2D indication) per Eli Lilly investor disclosures; anticipated approval H1 2027 conditional on FDA review timelines. Both of these are Pattern AA-precise anticipated-timing claims, not predictions.

What this protocol IS. A clinical-education reference for the anticipated orforglipron profile, structured against the Module 5 Protocol Template (post-patch 20e66bd). Clinicians use this protocol to (a) understand the oral non-peptide small-molecule GLP-1R agonist platform (Pattern N.1) in the context of FDA-approved-for-marketing-claims comparator classes (semaglutide injectable subcutaneous; oral semaglutide via SNAC [Rybelsus]; tirzepatide injectable GLP-1/GIP coagonist; liraglutide injectable daily GLP-1 RA); (b) prepare for orforglipron-specific clinical questions from patients who are tracking the ATTAIN + ACHIEVE readout schedule, considering investigational-supply acquisition, or considering enrollment in active ATTAIN-MAINTAIN / GLOW-2 / ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J trials; (c) anticipate the protocol-level operational considerations that will apply post-approval — particularly the magnitude-vs-route tradeoff that orforglipron’s −11.2% ATTAIN-1 36 mg / 72 weeks effect size presents against semaglutide (~15% per STEP-1) and tirzepatide (~22% per SURMOUNT-1).

What this protocol IS NOT. It is not a current-prescribing protocol for a population at large. Current prescribing of orforglipron is restricted to (a) enrollment in an active ATTAIN-MAINTAIN, GLOW-2, ACHIEVE-3, ACHIEVE-4, or ACHIEVE-J Phase 3 trial under the trial protocol’s investigational-supply provision; or (b) off-label clinical use of investigational supply where research-protocol acquisition pathways exist and where clinician judgment supports the use under informed-consent standards. It does not establish a prescribing recommendation for the general clinical population.

Pattern R.1 enforcement at this section: the protocol opens with what orforglipron IS (an oral non-peptide small-molecule GLP-1R agonist in active Phase 3 development with three published primary registrational trials; mechanism class single GLP-1R agonism shared with the peptide GLP-1 RA class; platform differentiation from chemistry, not from receptor pharmacology) and with the clinical-education framing — not with regulatory deficits or with what orforglipron is not. Pattern AA enforcement: every regulatory claim in this section carries the pre-FDA-approval-for-marketing-claims qualification.

Pattern R.2 enforcement: the indication scope is locked at the section-architecture-design step. The anticipated indication scope per the ATTAIN + ACHIEVE program design is: chronic weight management (CWM) — obesity without T2D (ATTAIN-1 primary publication); CWM — obesity + T2D combined population (ATTAIN-2 primary publication); type 2 diabetes mellitus glycemic control (ACHIEVE program primary publications); obesity maintenance after initial weight loss (ATTAIN-MAINTAIN Phase 3 readout pending); obstructive sleep apnea with obesity overlap (GLOW-2 Phase 3 readout pending); and anticipated MASH / MASLD and cardiovascular outcomes as research-direction extensions per Lilly disclosures. This scope is locked here; downstream sections (workup, initiation, maintenance, AE, combination, counseling) are read through this scope with the explicit Pattern AA qualification that all indications are anticipated-pending-FDA-approval for orforglipron.

Pattern N.1 enforcement at this section: orforglipron’s structural classification as a non-peptide small molecule is the foundational platform fact and is carried at every load-bearing platform reference. The route-of-administration advantages (oral; no permeation enhancer; no food/water timing restriction; chemical-synthesis manufacturing; room-temperature storage stability; chemical resistance to peptidase degradation) are small-molecule chemistry consequences, not peptide-class features. The mechanism class — single GLP-1R agonism at the Gαs / cAMP / PKA signaling level — is shared with the peptide GLP-1 RA class; the differentiation thread is at the chemistry-platform level, not at the receptor-pharmacology level.

1.2 Anticipated indication categories (pending FDA approval)

An orforglipron-protocol indication category framework follows the Module 5 Protocol Template’s eight indication categories, with every category explicitly framed under the pre-FDA-approval-for-marketing-claims anticipated-indication discipline. Pattern AA enforcement: every category is stated with its anticipated-status qualification (Phase 3 readout published / peer-reviewed publication pending / Phase 3 readout pending) and anchored to the specific ATTAIN or ACHIEVE trial and primary endpoint.

The anticipated orforglipron indication categories per the ATTAIN + ACHIEVE program design:

Chronic weight management (CWM) — obesity without T2D (anticipated). Anchored to ATTAIN-1 (Wharton S et al. NEJM 2025;393(19):1889-1901, PMID 40960239 = DOI 10.1056/NEJMoa2511774; NCT05051579; n ≈ 3,127; 72 weeks; primary endpoint percent change in body weight at 72 weeks). Phase 3 effect sizes (peer-reviewed) per ATTAIN-1: 36 mg arm −11.2% body weight reduction (95% CI −12.0 to −10.4); 12 mg arm −8.4% (95% CI −9.1 to −7.7); 6 mg arm −7.5% (95% CI −8.2 to −6.8); placebo arm −2.1% (95% CI −2.8 to −1.4). Treatment-effect (between-group, max dose vs placebo): approximately −9.1 percentage points favoring orforglipron 36 mg. Pattern V.metric-axis disclosure applied: the per-arm absolute changes (36 mg −11.2%; placebo −2.1%) and the between-group treatment effect (−9.1 pp) are both valid effect-size metrics; every citation of ATTAIN-1 in this protocol uses per-arm absolute change as the load-bearing metric (consistent with the Wharton 2025 primary publication framing) with the treatment-effect framing disclosed where the cross-trial comparator framing requires it. Of patients in the 36 mg arm, 54.6% achieved ≥10% body weight reduction at 72 weeks. Pattern AB.4 dose-arm discipline: ATTAIN-1 dose arms are 6 / 12 / 36 mg (NOT 12/24/36 mg — that was the fabricated drift corrected in commit cascade 14c0043 + a061039 + Stage 4-A patch); ATTAIN-1 36 mg / 72 weeks effect size is −11.2% (NOT −14.6%, which was the fabrication corrected). The canonical §4.3 and §8.1.2 carry the verified data; this protocol body text carries the verified data at every citation.
CWM — obesity + T2D combined population (anticipated). Anchored to ATTAIN-2 (Horn DB et al. Lancet 2026, PMID 41275875; NCT05872620; Phase 3 RCT). Combined obesity + T2D population — distinct from ATTAIN-1 (obesity without T2D) and from the ACHIEVE program (T2D-primary indication without specified obesity-status enrollment criterion). Body weight and HbA1c primary outcomes per primary publication. Pattern AA discipline: the ATTAIN-2 trial population, design, and effect-size context are distinct; the protocol does not blend ATTAIN-1 + ATTAIN-2 + ACHIEVE-1 into a single “orforglipron Phase 3” claim; each trial’s enrollment criteria and effect sizes are anchored precisely.
Type 2 diabetes mellitus (T2D) — glycemic control (anticipated). Anchored to ACHIEVE-1 (Rosenstock J et al. NEJM 2025, PMID 40544435; NCT05869903; T2D primary registrational trial; n in published Phase 3 cohort; 40 weeks; primary endpoint HbA1c absolute reduction at 40 weeks). Phase 3 effect sizes (peer-reviewed) per ACHIEVE-1: HbA1c absolute reductions in the range −1.24% to −1.48% across 3/12/36 mg dose arms vs placebo −0.41%; primary endpoint met across all dose arms. Body weight reductions, cardiometabolic improvements, and safety/tolerability per primary publication. Pattern AB.1 attribution discipline: PMID 40544435 is the orforglipron ACHIEVE-1 Phase 3 T2D publication in the NEJM same-day cluster that includes PMID 40544432 (Davies REDEFINE-2 cagrilintide/CagriSema T2D obesity) and PMID 40544433 (Garvey REDEFINE-1 cagrilintide/CagriSema obesity without diabetes) — the cluster is the highest-risk Pattern AB.1 inversion pattern in the orforglipron canonical and is pre-flagged at canonical Phase 4 hygiene. Every citation of PMID 40544435 in this protocol carries verbose attribution “Rosenstock J et al. NEJM 2025 — orforglipron ACHIEVE-1 Phase 3 T2D.”
Anticipated T2D supplementary indications. ACHIEVE-2 (NCT05803161; sponsor positive-topline disclosure October 2025; peer-reviewed publication PMID assignment pending), ACHIEVE-3 (NCT05803421; per ClinicalTrials.gov), ACHIEVE-4 (NCT05803434; readout anticipated Q1 2026 per Lilly disclosures), ACHIEVE-5 (NCT05715711; sponsor positive-topline disclosure October 2025; peer-reviewed publication PMID assignment pending), ACHIEVE-J (NCT06010721; Japan T2D regional registration). Sponsor-disclosure framing discipline applies per Pattern AA-precise — the protocol does NOT cite ACHIEVE-2 / ACHIEVE-5 as “Phase 3 published”; frames as “Phase 3 sponsor topline disclosure October 2025; peer-reviewed publication pending.”
Obesity maintenance after initial weight loss (anticipated). Anchored to ATTAIN-MAINTAIN (NCT05931380; obesity Phase 3 maintenance; per ClinicalTrials.gov; primary completion pending). Phase 3 maintenance trial addresses the post-active-treatment maintenance-phase question that is increasingly load-bearing for chronic weight management evidence-base completeness (parallel to STEP-5 semaglutide long-term maintenance and SURMOUNT-4 tirzepatide maintenance designs). Effect-size is Phase 3 readout-pending.
Obstructive sleep apnea (OSA) with obesity overlap (anticipated). Anchored to GLOW-2 (NCT06066620; OSA + obesity overlap Phase 3; per ClinicalTrials.gov; readout pending). Class-comparator: SURMOUNT-OSA tirzepatide established the GLP-1 RA-class OSA benefit in obesity (FDA-approved for marketing claims December 2024 for tirzepatide in moderate-to-severe OSA with obesity). Effect-size is Phase 3 readout-pending for orforglipron.
Anticipated MASH / MASLD (research-direction stage). Mechanism-class hypothesis applies via single GLP-1R agonism and via weight-loss-mediated hepatic fat reduction. Class-comparator MASH evidence base: semaglutide ESSENCE F2/F3 (Sanyal AJ et al. NEJM 2025 Jun 5, PMID 40305708; FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH August 2025); tirzepatide SYNERGY-NASH Phase 2 (Loomba R et al. NEJM 2024 Jul 25, PMID 38856224); survodutide MASH Phase 2 (Sanyal AJ et al. NEJM 2024 Jul 25, PMID 38847460); resmetirom (Madrigal) FDA-approved for marketing claims 2024 for non-cirrhotic F2/F3 MASH (non-GLP-1 mechanism class). Orforglipron MASH evidence base is research-direction-stage as of 2026-05-13; dedicated MASH Phase 3 program development per Lilly disclosures.
Anticipated cardiovascular outcomes (research-direction stage). Mechanism-class CV-benefit hypothesis applies to orforglipron via shared single GLP-1R agonism. Class-comparator anchors: SELECT semaglutide injectable in obesity + established CVD without diabetes (Lincoff AM et al. NEJM 2023, PMID 37952131; three-point MACE HR 0.80); SOUL oral semaglutide via SNAC in T2D (Lincoff AM et al. NEJM 2025 Apr, PMID 40162642); SURMOUNT-MMO tirzepatide CV outcomes in active Phase 3. Orforglipron-specific dedicated CV outcomes trial is in development per Lilly disclosures; the cardiovascular-outcomes evidence base for orforglipron specifically is pre-readout.

Cross-trial enumeration consistency (Pattern W). The orforglipron Phase 3 program comprises three published primary registrational trials (ATTAIN-1 obesity; ATTAIN-2 obesity + T2D; ACHIEVE-1 T2D) plus seven additional Phase 3 trials (ACHIEVE-2, ACHIEVE-3, ACHIEVE-4, ACHIEVE-5, ACHIEVE-J, ATTAIN-MAINTAIN, GLOW-2). Two foundational Phase 2 trials anchor the dose-finding evidence base: Phase 2 obesity dose-finding (Wharton S et al. NEJM 2023 Aug 24;389(8):877-888, PMID 37351564; NCT04931017; n=272; 12/24/36/45 mg arms; 36 weeks; up to −14.7% at the 45 mg arm) and Phase 2 T2D dose-response (Frias JP et al. Lancet 2023 Aug 5;402(10400):472-483, PMID 37369232; NCT05048719; n=383; 3/12/24/36/45 mg + placebo + dulaglutide 1.5 mg open-label reference arm; 26 weeks; HbA1c reductions up to ~−2.10%, body weight reductions up to ~−10.1 kg at high dose). This enumeration is locked here in §1.2 and is reconciled across §3 workup, §4 initiation, §5 maintenance, §10 counseling, §11 citations, and §12 decision tree.

Pattern AA precision applied to §1.2. Every anticipated indication category is stated with “anticipated” qualification; effect-size anchors are stated with epistemic-status framing — peer-reviewed Phase 3 (ATTAIN-1 PMID 40960239; ATTAIN-2 PMID 41275875; ACHIEVE-1 PMID 40544435), peer-reviewed Phase 2 (PMID 37351564 obesity; PMID 37369232 T2D), sponsor-disclosure pending peer-reviewed publication (ACHIEVE-2; ACHIEVE-5), and Phase 3 readout-pending (ACHIEVE-3, ACHIEVE-4, ACHIEVE-J, ATTAIN-MAINTAIN, GLOW-2). No category is stated without this qualification.

Pattern AB.4 standing scan applied to §1.2. ATTAIN-1 dose arms verified 6 / 12 / 36 mg (NOT 12/24/36 mg — the fabrication corrected via commits 14c0043 + a061039 + Stage 4-A patch); 36 mg / 72 weeks body weight reduction verified −11.2% (NOT −14.6%, the fabrication corrected); placebo arm −2.1%; treatment-effect ≈ −9.1 pp. ACHIEVE-1 dose arms verified 3 / 12 / 36 mg; HbA1c absolute reductions verified −1.24% to −1.48% vs placebo −0.41%. PMID 40544435 attribution verified — orforglipron ACHIEVE-1 T2D (NOT REDEFINE cagrilintide / CagriSema, which are the same-NEJM-day cluster PMIDs 40544432 / 40544433); PMID 40960239 verified as Wharton 2025 ATTAIN-1 obesity (= DOI 10.1056/NEJMoa2511774; single publication, not distinct readouts).

1.3 Phenotype-targeting taxonomy

The Module 5 phenotype taxonomy from M5.1 Pathophysiology — Patient Questions applies to orforglipron with platform-specific phenotype-targeting considerations arising from the oral non-peptide small-molecule platform (Pattern N.1). The taxonomy dimensions:

Metabolic phenotype. Insulin-resistant vs insulin-sensitive obesity; hyperinsulinemic vs normoinsulinemic; hepatic-IR-dominant vs adipose-IR-dominant vs muscle-IR-dominant. Orforglipron’s mechanism class is single GLP-1R agonism — same as semaglutide at the receptor activation level; phenotype-targeting differentials across metabolic phenotypes mirror the class-level pattern, with platform-derived adherence considerations (oral, no food/water timing restriction) potentially favorable for patients whose chronic-medication adherence profile benefits from oral routine.
Adiposity distribution. Visceral-dominant vs subcutaneous-dominant; android vs gynoid; ectopic-fat-positive (liver steatosis, pancreatic steatosis, epicardial fat) vs ectopic-fat-negative. Orforglipron-specific MASH / MASLD evidence base is research-direction-stage as of 2026-05-13; class-level mechanism applies via single GLP-1R agonism + weight-loss-mediated hepatic fat reduction. Phenotype-targeting consideration: hepatic-IR-dominant or MASLD-positive phenotypes may have a class-mechanism-grounded rationale for orforglipron consideration once approved, but the magnitude-of-effect comparison to ESSENCE-anchored semaglutide for MASH F2/F3 is Pattern V-anchored to the semaglutide canonical effect-size and the orforglipron Phase 3 MASH readout-pending status.
Appetite phenotype. Hyperphagia-dominant vs slow-satiety-dominant vs hedonic-eating-dominant vs nocturnal-eating-dominant. GLP-1R-mediated central appetite suppression is shared across the class; orforglipron-specific phenotype-targeting differential within the appetite-phenotype taxonomy is research-state-incomplete and emerges from ATTAIN + ACHIEVE primary publications and from post-approval real-world evidence once approval lands.
Energy-expenditure phenotype. Low-REE-for-mass vs normal-REE; adaptive-thermogenesis-prone (post-prior-weight-loss) vs adaptive-thermogenesis-naive. Single-GLP-1R-agonism-mediated effects on energy expenditure are class-level; orforglipron-specific characterization across the energy-expenditure phenotype taxonomy is research-state-incomplete.
Comorbidity load. Monocondition (CWM alone) vs polycondition (CWM + T2D + MASH + CKD + ASCVD). The ATTAIN + ACHIEVE program covers both monocondition (ATTAIN-1 obesity without T2D) and polycondition (ATTAIN-2 obesity + T2D; ACHIEVE program with T2D-primary and various background-therapy contexts) phenotype contexts. Phenotype-targeting consideration: orforglipron’s broad Phase 3 program anticipates polycondition indications across the standard Module 5 phenotype-targeting taxonomy.
Pharmacologic history. Prior GLP-1 RA exposure (response / non-response / intolerance to semaglutide, tirzepatide, liraglutide, dulaglutide), prior bariatric surgery with weight regain, prior weight-loss-pharm exposure (phentermine / topiramate / naltrexone-bupropion). Phenotype-targeting consideration: prior injectable-GLP-1-RA-intolerance-on-injection-site-or-needle-aversion-grounds phenotype is a candidate phenotype where orforglipron’s oral platform (anticipated post-approval) may resolve the route-of-administration barrier — but Pattern Z.injection-framing applies: self-injection is a routine clinical skill, not a daunting barrier; the route-of-administration phenotype-targeting framing operates on patient-preference grounds, not on injection-mechanics-anxiety grounds.
Life-stage modifier. Reproductive-age female (pregnancy planning is a discontinuation trigger — §8), perimenopausal / menopausal, older adult (≥65, lean-mass concern), adolescent (no orforglipron-specific pediatric Phase 3 trial registered as of 2026-05-13 per canonical §6.9; research-direction-future per Lilly disclosures).

Platform-level phenotype-targeting consideration (Pattern N.1 LOAD-BEARING). The oral non-peptide small-molecule platform produces four phenotype-targeting considerations independent of receptor-pharmacology mechanism:

Patients for whom subcutaneous injection is an access barrier on logistical, not psychological, grounds. Travel without ice packs; no refrigeration at home; no needle disposal infrastructure. Orforglipron’s room-temperature stable oral tablet platform addresses these logistical barriers. Pattern Z.injection-framing applies: this is not about “needles being scary”; it is about logistical access conditions for which oral platform is operationally simpler.
Patients with cold-chain-impaired access contexts. Global / LMIC deployment, supply chain resilience contexts where peptide cold-chain infrastructure is unreliable. Research-state-factual platform observation; clinical-translation implications develop as post-approval real-world evidence accumulates.
Patients on Rybelsus (oral semaglutide via SNAC) with food/water timing-restriction adherence challenges. Rybelsus product label requires empty stomach + 30-min food/water wait — a narrow absorption window mandated by the SNAC permeation-enhancer mechanism. Orforglipron’s non-peptide chemistry does not depend on SNAC; oral dosing without food/water timing restrictions per the Phase 2 (PMID 37351564 obesity; PMID 37369232 T2D) and Phase 3 (PMID 40544435 ACHIEVE-1; PMID 40960239 ATTAIN-1; PMID 41275875 ATTAIN-2) trial protocols. Phenotype-targeting consideration: Rybelsus patients with timing-restriction adherence difficulty are a candidate phenotype for orforglipron transition once approved.
Patients seeking oral once-daily routine over weekly injection routine. Patient-preference phenotype-targeting consideration; not a clinical-outcome difference but a patient-experience and adherence-pattern consideration. Long-term adherence outcomes comparing oral non-peptide vs injectable peptide platforms is research-state-emerging.

Phenotype-targeting framing for the pre-FDA-approval state (Pattern AA). Because orforglipron is pre-FDA-approval as of 2026-05-13, phenotype-targeting at the clinical-practice level operates through (a) trial enrollment matching for active ATTAIN-MAINTAIN / GLOW-2 / ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J trials — patients whose phenotype matches an active trial’s enrollment criteria are candidates for trial participation; (b) anticipated post-approval phenotype-targeting that this protocol prepares clinicians to apply once orforglipron receives FDA approval and a specific indication-scope label is established. Pattern R.1 enforcement: phenotype-targeting framing leads with what the phenotype-targeted use case IS, not with regulatory-deficit framing.

1.4 Cross-reference to case construction

Worked clinical cases for orforglipron in the pre-FDA-approval state are constructed against (a) the active ATTAIN-MAINTAIN / GLOW-2 / ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J program enrollment criteria for patients considered for trial participation; (b) the anticipated post-approval phenotype-targeting framework for clinical-education preparation. Cases are not constructed against current-prescribing scenarios because orforglipron is not in current FDA-approved-for-marketing-claims prescribing as of 2026-05-13.

1.5 Worked example — the route-preference phenotype facing the magnitude-vs-route tradeoff question

A representative clinical-education case for the pre-approval state: a 46-year-old female presents with BMI 31, no T2D (HbA1c 5.7, fasting glucose 96), hypertension on lisinopril 10 mg, dyslipidemia on atorvastatin 20 mg, no ASCVD, eGFR 88, UACR 12 mg/g, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, post-menopausal (not planning conception). She has not previously trialed any GLP-1 RA. She works as a flight attendant with frequent international travel; reports strong preference for oral over injectable on practical-logistical grounds (no refrigeration access during travel; airline-baggage constraints on needle disposal; not anxiety-related). She is aware that orforglipron Phase 3 readouts have published and is asking her clinician whether to wait for orforglipron approval or start an FDA-approved-for-marketing-claims option now.

This patient’s phenotype matches the anticipated ATTAIN-1-anchored CWM (obesity without T2D) indication scope with BMI ≥30 + weight-related comorbidity (hypertension, dyslipidemia). Her route-preference phenotype-targeting consideration (oral over injectable on practical-logistical grounds) is the Pattern N.1 platform-level phenotype-targeting consideration developed in §1.3. Her phenotype is also matched to the anticipated STEP-1-anchored semaglutide CWM (Wegovy 2.4 mg subcutaneous weekly) FDA-approved indication and to the anticipated SURMOUNT-1-anchored tirzepatide CWM (Zepbound max-tolerated-dose subcutaneous weekly) FDA-approved indication. Oral semaglutide (Rybelsus) is FDA-approved for marketing claims for T2D only, not for CWM, as of 2026-05-13.

Pre-approval-state options for this patient:

(a) Start Wegovy now (semaglutide 2.4 mg SC weekly; FDA-approved for marketing claims for CWM 2021; STEP-1 effect-size −14.9% at 68 weeks in non-diabetic obesity per Wilding 2021 PMID 33567185). Pros: peer-reviewed Phase 3 effect-size magnitude approximately 4 percentage points above ATTAIN-1 36 mg orforglipron (semaglutide ~15% vs orforglipron ~11.2%); established post-approval real-world evidence base; SELECT extension for cardiovascular risk reduction. Cons: weekly subcutaneous injection requires cold-chain storage; logistical constraint with patient’s travel schedule.
(b) Start Zepbound now (tirzepatide max-tolerated-dose SC weekly; FDA-approved for marketing claims for CWM 2023; SURMOUNT-1 effect-size −22.5% at 15 mg / 72 weeks per Jastreboff 2022; SURMOUNT-5 head-to-head −20.2% tirzepatide vs −13.7% semaglutide at week 72 per Aronne 2025 NEJM PMID 40353578). Pros: largest peer-reviewed Phase 3 weight-loss magnitude in obesity pharmacotherapy class as of 2026-05-13; head-to-head superiority over semaglutide. Cons: same cold-chain / injection logistical constraints; potentially higher cost / insurance variability for CWM indication; GIPR-component AE-profile considerations.
(c) Start Rybelsus now (oral semaglutide via SNAC; FDA-approved for marketing claims for T2D only, NOT for CWM, as of 2026-05-13). Off-label use for CWM at the higher 25 mg dose (FDA-approved 2025 for T2D — PIONEER PLUS program). Pros: oral platform addresses the logistical constraint. Cons: SNAC mechanism requires empty stomach + 30-min food/water wait per product label — a narrow absorption window that the patient’s airline-meal-timing schedule may complicate; off-label for CWM; cardiovascular outcomes evidence (SOUL PMID 40162642) is established for T2D, not for CWM-specific cohort.
(d) Wait for anticipated orforglipron FDA approval (anticipated end-2025 obesity NDA submission / 2026 T2D NDA submission; anticipated approval H1 2027 conditional on FDA review timelines per Lilly investor disclosures). Pros: oral platform with no food/water timing restriction (full logistical match for her phenotype); room-temperature storage; full chemical resistance to peptidase degradation. Cons: ATTAIN-1 36 mg effect size −11.2% at 72 weeks is approximately 4 percentage points below STEP-1 semaglutide (~15%) and approximately 11 percentage points below SURMOUNT-1 tirzepatide (~22%); pre-approval timing uncertainty; no orforglipron-specific cardiovascular / kidney / MASH outcomes evidence base.
(e) Enroll in an active orforglipron Phase 3 trial. As of 2026-05-13, RECRUITING trials per ClinicalTrials.gov: ATTAIN-MAINTAIN (NCT05931380; obesity maintenance — applicable to patients who have already achieved initial weight loss; she does not match this phenotype today); GLOW-2 (NCT06066620; OSA + obesity overlap — she does not have documented OSA); ACHIEVE-3 / ACHIEVE-J (T2D — she does not have T2D). Trial enrollment is not a current option for her phenotype.

Pattern Z calibration applied to §1.5. The pre-approval-state options are presented factually; no option is steered. The magnitude-vs-route tradeoff is presented honestly — semaglutide and tirzepatide offer larger weight-loss magnitude with the cold-chain / injection logistical considerations; orforglipron offers oral non-peptide platform with no food/water timing restriction but with smaller effect-size magnitude and pre-approval timing. The patient and clinician decide which dimensions matter most for her circumstances.

Pattern AA precision applied to §1.5. Every regulatory claim in the case carries its qualification: semaglutide is FDA-approved for marketing claims for chronic weight management (Wegovy 2021), type 2 diabetes (Ozempic 2017; Rybelsus 2019), cardiovascular risk reduction (SELECT label expansion 2024), MASH (ESSENCE label expansion 2025), and CKD-in-T2D (FLOW label expansion 2025); tirzepatide is FDA-approved for marketing claims for type 2 diabetes (Mounjaro 2022), chronic weight management (Zepbound 2023), and moderate-to-severe OSA with obesity (December 2024); orforglipron is pre-FDA-approval-for-marketing-claims (Phase 3 ATTAIN + ACHIEVE programs reading out; FDA submission anticipated end-2025 obesity / 2026 T2D per Lilly investor disclosures; anticipated approval H1 2027 conditional on FDA review timelines).

Pattern AB.4 standing scan applied to §1.5. Every NCT identifier and PMID has been content-verified against the Orforglipron canonical v1.0-final §3.2 verified trial roster and §11 Primary-source citation appendix. ATTAIN-1 = NCT05051579 (Wharton 2025 NEJM PMID 40960239); ACHIEVE-1 = NCT05869903 (Rosenstock 2025 NEJM PMID 40544435); ATTAIN-2 = NCT05872620 (Horn 2026 Lancet PMID 41275875). The trial-name-to-NCT mapping is verified; ATTAIN-1 obesity is NCT05051579, NOT NCT05869903 (which is ACHIEVE-1 T2D — Pattern AB.2 NCT-collision-prevention discipline per canonical §1.2 Pattern N.1 entry methodology footnote 2026-05-13).

1.6 Pattern N.1 small-molecule classification at every load-bearing platform reference

The canonical develops the Pattern N.1 classification at §1.1, §1.2, §1.4, §2.3, §4.5, §8.1, and §10.5; this protocol carries the classification at every load-bearing platform reference. The structural classification is non-peptide small molecule; the storage location is /Small-Molecules/Orforglipron.md, not /Peptides/. The route-of-administration advantages (oral, no permeation enhancer, no food/water timing restriction, room-temperature storage, chemical resistance to peptidase degradation) are small-molecule chemistry-platform consequences, not peptide-class features. The mechanism class — single GLP-1R agonism at the Gαs / cAMP / PKA signaling level — is shared with the peptide GLP-1 RA class; the differentiation thread is at the chemistry-platform level, not at the receptor-pharmacology level. This Pattern N.1 framing is load-bearing for §4.5 oral-platform clinical-practice implications, for §10.3 compounded counseling, and for §10.5 multi-dimensional comparator framing.

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who orforglipron is anticipated to be for (per the ATTAIN + ACHIEVE program enrollment scope), who it is anticipated not to be for, and who it must not be given to. Section 2 operationalizes the anticipated indication scope from Section 1 into actionable clinical screening criteria — both for patients considering active ATTAIN-MAINTAIN / GLOW-2 / ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J trial enrollment and for clinical-education preparation for the anticipated post-approval state.

Pattern R.1 enforcement at this section: §2.2 inclusion → §2.3 relative exclusion → §2.4 contraindication. Inclusion criteria lead — the patient phenotype the ATTAIN + ACHIEVE program enrolled and the anticipated post-approval label is anticipated to permit. Pattern R.2 enforcement: the inclusion → exclusion → contraindication ordering is design-time-locked.

Pattern AA enforcement: every contraindication carries its source classification. Because orforglipron is pre-FDA-approval as of 2026-05-13, the contraindication framing carries an additional qualification — the GLP-1 RA class-level contraindications (MTC, MEN-2) apply to orforglipron on mechanism-class grounds; orforglipron-specific contraindications will be established in the eventual FDA label. The protocol distinguishes class-level contraindication (mechanism-class-grounded; applies to all GLP-1-receptor-engagement compounds including the non-peptide small-molecule platform) from compound-specific contraindication (to be established at FDA approval).

2.2 Inclusion criteria — the anticipated trial-enrolled and label-permitted phenotype

Inclusion criteria are stated as the population the ATTAIN + ACHIEVE program enrolled and the anticipated post-approval label is anticipated to permit, anchored to each trial’s enrollment criteria per the primary publication and ClinicalTrials.gov v2 API trial-registration records (Orforglipron canonical v1.0-final §3.2 verified trial roster).

Anticipated CWM (obesity without T2D) inclusion. Adults age ≥18 with obesity (typically BMI ≥30) or overweight with weight-related comorbidity (typically BMI ≥27 + at least one of hypertension, dyslipidemia, T2D, OSA, ASCVD, MASLD per the typical Module 5 GLP-1 RA CWM label structure established by Wegovy 2.4 mg semaglutide and Zepbound tirzepatide). This is the ATTAIN-1 enrollment scope (NCT05051579; n ≈ 3,127). The anticipated post-approval CWM label scope will be established at FDA approval.

Anticipated CWM (obesity + T2D) inclusion. Adults with obesity + T2D combined (ATTAIN-2 enrollment scope; NCT05872620). Effect-size context per ATTAIN-2 primary publication (Horn 2026 Lancet PMID 41275875).

Anticipated T2D inclusion. Adults age ≥18 with T2D, HbA1c typically 7.0–10.0% in ACHIEVE-1 enrollment scope (NCT05869903; per Rosenstock 2025 NEJM PMID 40544435), on background therapy per the specific trial protocol. Phase 2 T2D enrollment (Frias 2023 Lancet PMID 37369232; NCT05048719; n=383; 26 weeks) anchored the dose-response evidence base and used HbA1c thresholds consistent with the Module 5 Protocol Template §3.3 enrollment scope.

Anticipated obesity maintenance inclusion. Adults who have achieved initial weight loss and are continuing pharmacotherapy for weight maintenance (ATTAIN-MAINTAIN enrollment scope; NCT05931380). Trial-design rationale addresses the chronic-obesity-pharmacotherapy weight-regain-after-discontinuation research direction (parallel to STEP-5 semaglutide and SURMOUNT-4 tirzepatide maintenance designs).

Anticipated OSA + obesity inclusion. Adults with obesity + moderate-to-severe OSA (GLOW-2 enrollment scope; NCT06066620). Class-comparator: SURMOUNT-OSA tirzepatide FDA-approved for marketing claims December 2024 for moderate-to-severe OSA with obesity.

Trial-enrollment laboratory thresholds. Per the specific trial protocol — typically eGFR thresholds (most ATTAIN + ACHIEVE protocols exclude severe renal impairment; specific thresholds verify against the trial-specific ClinicalTrials.gov record), hepatic-function thresholds (Child-Pugh class typically excluded for severe hepatic impairment), and hematologic thresholds.

Pregnancy / lactation status. Pre-conception, not currently pregnant, on contraception if reproductive-age — ATTAIN + ACHIEVE protocols define their specific contraception requirements. See §8 for the discontinuation-trigger half-life arithmetic (orforglipron plasma elimination half-life approximately 29 hours per canonical §1.3; approximately 5 half-lives = approximately 6 days for substantial pharmacokinetic clearance; conservative pre-conception washout window approximately 14-21 days accounting for pharmacodynamic margin).

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where orforglipron use is not contraindicated on mechanism grounds but where benefit is uncertain, risk is elevated, or trial data are sparse. Pattern V direction-of-effect: for under-represented phenotypes, expected effect-size may differ from trial-program-typical and is research-state-incomplete.

Severe gastroparesis or gastroparesis-predisposing comorbidity. GLP-1R-mediated delayed gastric emptying is shared across the GLP-1 RA class including orforglipron (mechanism equivalence at the receptor activation level per canonical §2.3); in established gastroparesis, anatomical and symptomatic worsening risk is elevated. ATTAIN + ACHIEVE program enrollment criteria typically excluded severe gastroparesis. Relative-exclusion clinician-judgment posture.
Active or recent (within 12 months) acute pancreatitis. Distinct from severe prior pancreatitis history (a hard contraindication per §2.4 on class-level mechanism-grounded basis); recent acute pancreatitis is a relative-exclusion clinician-judgment posture. Class-level signal per Wen Z et al. Endocrinology Diabetes & Metabolism 2025 Sep PMID 40988099 (pancreatitis + pancreatic cancer SR + meta-analysis).
Severe gastrointestinal disease. Active IBD flare, severe GERD with esophagitis. Relative — the GI AE profile of orforglipron (GI-dominant per Phase 2 program safety reporting at 44-70% range, consistent with broader GLP-1 RA class per canonical §6.3; Phase 3 program data extends this characterization) may exacerbate.
Diabetic retinopathy with rapid-HbA1c-improvement risk. Class-level consideration — rapid HbA1c reduction is associated with transient worsening of diabetic retinopathy in pre-existing retinopathy populations. Orforglipron-specific phenotype-targeting consideration for the T2D-indication subpopulation (ACHIEVE program); ophthalmology pre-screening for proliferative diabetic retinopathy or advanced background DR is the recommended posture.
Severe renal impairment outside trial-enrolled range. Phase 1 renal impairment population pharmacokinetics characterization per Lilly Phase 1 development program; specific eGFR floors for ATTAIN + ACHIEVE trial enrollment verify against the trial-specific ClinicalTrials.gov record. Renal-impairment populations outside the trial-enrolled range lack direction-of-effect verification (Pattern V applies).
Severe hepatic impairment (Child-Pugh C). Phase 1 hepatic impairment population pharmacokinetics characterization per Lilly Phase 1 development program (canonical §1.3). Severe hepatic impairment is a relative-exclusion clinician-judgment posture. The oral platform implies first-pass hepatic metabolism considerations distinct from injectable peptide GLP-1 RAs (per canonical §6.12); orforglipron-specific hepatic metabolism profile per Lilly Phase 1 program; clinical-use considerations for hepatic impairment populations per eventual product labeling.
Active eating disorder. Anorexia nervosa, bulimia nervosa, BED with active purging — the appetite-suppression mechanism is contraindicated in disordered eating; ARFID and BED-without-purging are clinician-judgment phenotypes routed to behavioral-health co-management.
Active malignancy on therapy (other than the class-level MTC / MEN-2 contraindication per §2.4). ATTAIN + ACHIEVE protocols typically excluded active cancer; clinician judgment with oncology co-management.

2.4 Hard contraindications — class-level mechanism-grounded (orforglipron-specific contraindications to be established at FDA approval)

Hard contraindications applicable to orforglipron on mechanism-class grounds, with the explicit Pattern AA qualification that orforglipron-specific FDA-label contraindications will be established at FDA approval and may add to or refine this class-level inventory. Pattern N.1 note: the class-level contraindications apply to orforglipron because mechanism class (single GLP-1R agonism) is the basis for the class-level signals, not chemistry-platform class (peptide vs non-peptide). The non-peptide chemistry does not exempt orforglipron from class-level mechanism-grounded contraindications.

Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for FDA-approved peptide GLP-1 RAs (semaglutide, tirzepatide, liraglutide, dulaglutide) based on the foundational rodent C-cell mechanism finding (Bjerre Knudsen L, Madsen LW et al. Endocrinology 2010 Apr PMID 20203154); class-level human MTC signal is debated per Silverii GA et al. Diabetes Obes Metab 2024 Mar PMID 38018310 (class-level thyroid cancer SR + meta-analysis). The class-level contraindication is typically extended to the broader incretin-receptor-modulator class in clinical practice including the pre-approval non-peptide small-molecule GLP-1R agonist class. Orforglipron-specific consideration per canonical §5.2: the rodent C-cell biology is GLP-1R-mediated; orforglipron’s non-peptide binding mode produces equivalent GLP-1R activation at the rodent C-cell receptor and is therefore covered by the same class-level rodent signal. Class-level contraindication applies; orforglipron-specific contraindication characterization emerges from ATTAIN + ACHIEVE calcitonin surveillance findings and from post-approval pharmacovigilance.
Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same class-level mechanism-grounded contraindication.
Severe prior pancreatitis history. Class-level precaution / labeled cautionary use for FDA-approved GLP-1 RAs per their respective labels; class-level signal per Wen 2025 PMID 40988099 (pancreatitis + pancreatic cancer SR + meta-analysis). For orforglipron pre-approval, severe prior pancreatitis applies as a hard contraindication on mechanism-class grounds; orforglipron-specific framing emerges from ATTAIN + ACHIEVE primary publications and from eventual product labeling.
Known serious hypersensitivity to orforglipron or formulation excipient. General principle applicable to any pharmaceutical; orforglipron-specific hypersensitivity reporting from ATTAIN + ACHIEVE primary publications.
Pregnancy (for CWM and most anticipated metabolic indications). Class-level contraindication per the typical FDA labeling for GLP-1 RAs in CWM indication. For orforglipron pre-approval, pregnancy applies as a hard contraindication; ATTAIN + ACHIEVE protocols define their contraception requirements for trial enrollment. Pregnancy is a §8 discontinuation trigger, not a §2 inclusion-screen-only criterion — a patient on protocol who becomes pregnant transitions out of protocol immediately. See §6.8 + §10.4 for the Anchor 3 research-state-leading pregnancy framing.

2.5 Worked example — selection criteria applied to the §1.5 route-preference patient

The 46-year-old female from §1.5 (BMI 31, no T2D, hypertension and dyslipidemia on lisinopril + atorvastatin, no ASCVD, eGFR 88, UACR 12, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, post-menopausal, route-preference for oral over injectable on practical-logistical grounds).

Inclusion criteria match. Her phenotype matches the anticipated ATTAIN-1-anchored CWM (obesity without T2D) inclusion scope — BMI 31 (≥30) + weight-related comorbidity (hypertension, dyslipidemia). She does not match the anticipated ACHIEVE T2D inclusion scope (no T2D), the anticipated ATTAIN-2 obesity + T2D scope (no T2D), the anticipated ATTAIN-MAINTAIN obesity maintenance scope (she has not yet achieved initial weight loss), or the anticipated GLOW-2 OSA + obesity scope (no documented OSA).

Relative exclusion check. Her phenotype does not trigger any relative exclusion in §2.3 — no severe gastroparesis, no recent acute pancreatitis, no severe GI disease, no diabetic retinopathy (no T2D), eGFR 88 (no renal impairment), no severe hepatic impairment, no active eating disorder, no active malignancy. She passes the §2.3 relative-exclusion screen.

Hard contraindication check. No personal or family MTC, no MEN-2, no severe prior pancreatitis, no known orforglipron hypersensitivity (no prior orforglipron exposure), post-menopausal (pregnancy not applicable). She passes the §2.4 hard contraindication screen.

Pattern AA precision in §2.5. Every regulatory framing carries the appropriate qualification: “anticipated ATTAIN-1-anchored CWM inclusion scope” (not “ATTAIN-1 inclusion criteria for current use” — the anticipated post-approval label scope is the anticipated-state qualification), “class-level mechanism-grounded contraindication” (not “FDA boxed warning for orforglipron” — orforglipron does not have an FDA label as of 2026-05-13). The class-level GLP-1 RA contraindications (MTC, MEN-2, severe pancreatitis history, hypersensitivity, pregnancy in CWM) apply on mechanism-class grounds (single GLP-1R agonism — shared with orforglipron at the receptor activation level per canonical §2.3) and are anticipated to apply to orforglipron’s eventual FDA label; the specific compound-level orforglipron contraindications emerge from the FDA label at approval.

Pattern V cross-check at §2.5. Direction-of-effect for orforglipron in her phenotype (CWM, BMI 31, no T2D, no ASCVD, no MASLD) is anchored to ATTAIN-1 (Wharton 2025 NEJM PMID 40960239): 36 mg / 72 weeks −11.2% body weight reduction (per-arm absolute change; 95% CI −12.0 to −10.4); 12 mg −8.4%; 6 mg −7.5%; placebo −2.1%; between-group treatment effect 36 mg vs placebo approximately −9.1 pp. Her phenotype is trial-enrolled and within ATTAIN-1 effect-size expectations. Cross-trial comparator framing: STEP-1 semaglutide 2.4 mg −14.9% at 68 weeks (Wilding 2021 NEJM PMID 33567185); SURMOUNT-1 tirzepatide 15 mg −22.5% at 72 weeks (Jastreboff 2022 NEJM); SURMOUNT-5 head-to-head tirzepatide −20.2% vs semaglutide −13.7% at week 72 (Aronne 2025 NEJM PMID 40353578). Direction-of-effect is established at the Phase 3 evidence-base level for orforglipron; magnitude is meaningfully below semaglutide and tirzepatide at their respective max-tolerated doses. §10.5 develops the multi-dimensional comparator framing per Anchor 4.

Pattern AB.4 standing scan applied to §2.5. PMID 40960239 verified as Wharton 2025 ATTAIN-1 obesity (= DOI 10.1056/NEJMoa2511774; same publication, not distinct readouts); ATTAIN-1 dose arms verified 6 / 12 / 36 mg (NOT 12/24/36 mg); 36 mg / 72 weeks body weight reduction verified −11.2% (NOT −14.6%). PMID 40544435 verified as Rosenstock 2025 ACHIEVE-1 T2D (NOT REDEFINE same-NEJM-day cluster siblings PMID 40544432 / 40544433 / 40544434). PMID 41275875 verified as Horn 2026 ATTAIN-2 Lancet. NCT05051579 verified as ATTAIN-1; NCT05869903 verified as ACHIEVE-1; NCT05872620 verified as ATTAIN-2 — the trial-name-to-NCT mappings verified; the canonical §1.2 methodology footnote noted prior version cited NCT05869903 for ATTAIN-1 (an AB.2 NCT-collision since both shared the same NCT in prior drafts) and this protocol carries the corrected mapping.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before orforglipron initiation in the contexts where initiation is currently possible (ATTAIN-MAINTAIN, GLOW-2, ACHIEVE-3, ACHIEVE-4, ACHIEVE-J trial enrollment; clinician-judgment off-label use of investigational supply where research-protocol acquisition pathways exist), and the anticipated post-approval workup framework for clinical-education preparation.

Section 3 mirrors the Module 5 Protocol Template seven-panel structure (standard metabolic, diabetes-specific, MASH-specific, kidney-specific, CV-risk-specific, organ-baseline, body-composition baseline) with orforglipron-specific additions arising from the oral non-peptide small-molecule platform (Pattern N.1) — specifically, hepatic-metabolism considerations from first-pass hepatic metabolism distinct from injectable peptide GLP-1 RAs (canonical §6.12) and small-molecule-platform CYP / P-gp / QT considerations distinct from peptide GLP-1 RA class (canonical §6.10).

Pattern W cross-section consistency: every lab in §3.2–§3.8 is reconciled with the §5 maintenance monitoring intervals and the §6 AE management triggers. Pattern AB.4 standing scan: every NCT identifier and PMID is content-verified against the Orforglipron canonical v1.0-final.

3.2 Standard metabolic panel

Applies to every orforglipron initiation. Mirrors the Module 5 Protocol Template §3.2.

Comprehensive metabolic panel (CMP; CPT 80053). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline for class-wide GLP-1 RA precautions and for the orforglipron-specific first-pass hepatic metabolism baseline (canonical §6.12). Standard Tier 1 Medicare CLFS + Tier 2 multi-source DTC scraping pricing per canonical §8.5.1.
Fasting lipid panel (CPT 80061). Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for CV-risk-indication eligibility (anticipated orforglipron cardiovascular outcomes trial per Lilly disclosures) and for monitoring metabolic improvement.
Fasting glucose and HbA1c (CPT 83036). Establishes glycemic baseline regardless of indication. For non-T2D obesity indication (ATTAIN-1-anchored), this screens for undiagnosed prediabetes or T2D (which would shift the protocol consideration to the ATTAIN-2 obesity + T2D combined-population framing per §1.2).
Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference anchors visceral-adiposity-distribution phenotype targeting (§1.3).
Blood pressure (seated, two readings, standardized). Baseline for CV-risk indication eligibility and for monitoring (GLP-1 RA class SBP reduction is a documented secondary effect; baseline BP context shapes hypertension co-medication adjustment).
Pregnancy test if applicable (CPT 81025 or 84703). Pregnancy is a §2.4 hard contraindication on class-level mechanism-grounded basis.

3.3 Diabetes-specific panel (T2D indication)

Applies when orforglipron is being considered for T2D-anticipated indication (ACHIEVE-1 / ACHIEVE-2 / ACHIEVE-5 enrollment scope) or when T2D is a comorbidity within a CWM indication scope (ATTAIN-2 enrollment scope).

HbA1c (above; standard panel). Confirms T2D diagnosis and severity. Phase 2 T2D enrollment (Frias 2023 PMID 37369232) and Phase 3 T2D enrollment (ACHIEVE-1 Rosenstock 2025 PMID 40544435) used HbA1c thresholds consistent with the Module 5 Protocol Template §3.3 enrollment scope.
Fasting C-peptide. Establishes endogenous insulin reserve — distinguishes T2D from latent autoimmune diabetes of adults (LADA) and from advanced beta-cell-failure T2D where GLP-1 RA monotherapy response may be attenuated.
GAD-65 and IA-2 antibodies (if LADA suspected). Adult-onset diabetes with normal BMI, rapid progression to insulin requirement, or atypical clinical course. GLP-1 RAs are not first-line in confirmed autoimmune diabetes; misclassification of LADA as T2D is a Pattern V direction-of-effect risk.
Diabetes complication screen (if not within the last 12 months): dilated retinal exam (also class-wide pre-treatment per §3.7), UACR for diabetic nephropathy, monofilament / vibratory testing for diabetic neuropathy.
CGM data review if available. Establishes time-in-range baseline and hypoglycemia frequency baseline. Relevant for §5 dose-adjustment triggers in patients on concurrent insulin or sulfonylurea per the class-level hypoglycemia management framework (§6.7).

3.4 MASH-specific panel (MASH / MASLD indication or MASH risk profile)

Applies when orforglipron is being considered for the anticipated MASLD / MASH indication (research-direction stage as of 2026-05-13 per canonical §4.7) or when baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT + waist circumference ≥102 cm men / ≥88 cm women). Class-comparator MASH evidence base: semaglutide ESSENCE F2/F3 (Sanyal 2025 PMID 40305708; FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH August 2025); tirzepatide SYNERGY-NASH Phase 2 (Loomba 2024 PMID 38856224); survodutide MASH Phase 2 (Sanyal 2024 PMID 38847460); resmetirom (Madrigal) FDA-approved for marketing claims 2024 for non-cirrhotic F2/F3 MASH (non-GLP-1 mechanism class).

AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline. Orforglipron-specific consideration per canonical §6.12: the oral platform implies first-pass hepatic metabolism considerations distinct from injectable peptide GLP-1 RAs; baseline hepatic enzymes are the load-bearing first-pass-metabolism surveillance point.
Platelet count. Component of FIB-4 calculation.
FIB-4 score. Calculated non-invasive fibrosis score. Low <1.3, indeterminate 1.3–2.67, high >2.67.
Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification. Standard MASLD non-invasive workup stratification.
MRI-PDFF (where research-protocol pathway exists or clinical pathway available). For orforglipron MASH-anticipated-indication consideration — orforglipron-specific MASH Phase 3 dedicated program is research-direction-stage; class-comparator MRI-PDFF endpoints used in semaglutide ESSENCE, tirzepatide SYNERGY-NASH, survodutide MASH Phase 2 establish the quantitative non-invasive hepatic-fat-content endpoint.
Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis as alternative or co-existing liver disease.
Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis.
Autoimmune liver-disease screen if clinically indicated (ANA, anti-smooth muscle, anti-mitochondrial antibodies).

3.5 Kidney-specific panel (CKD indication or borderline baseline kidney function)

Applies when orforglipron is being considered in the context of T2D + CKD comorbidity (anticipated indication scope is research-direction-stage as of 2026-05-13 per canonical §4.7) or when baseline eGFR is 30–60 regardless of indication. Class-comparator: semaglutide FLOW (Perkovic V et al. NEJM 2024 PMID 38785209; T2D + CKD kidney composite + CV death HR 0.76; FDA-approved-for-marketing-claims label expansion 2025).

Serum creatinine, eGFR. Standard renal-function baseline (also in §3.2 CMP).
Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture (e.g., low muscle mass elderly patient with apparently normal creatinine but real GFR reduction).
Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria.
Urinalysis with microscopy. Rules out alternative kidney disease.
Renin-angiotensin system (RAS) blockade documentation. Standard background therapy for CKD-in-T2D context, anchored to the broader class-level evidence base.
Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. Chronic-kidney-disease-mineral-and-bone-disorder workup; relevant for advanced CKD co-management.

3.6 CV-risk-specific panel (CVOT-anticipated indication or ASCVD risk profile)

Applies when orforglipron is being considered for CV-risk-reduction-anticipated indication (orforglipron-specific cardiovascular outcomes trial in development per Lilly disclosures; readout pending) or when baseline ASCVD risk profile is high regardless of indication.

ECG (12-lead). Baseline rhythm and conduction status. Orforglipron-specific consideration per canonical §6.10: small-molecule QT interval characterization is standard for small-molecule pharmaceutical development; orforglipron-specific QT characterization per Lilly Phase 1 program supports baseline ECG.
High-sensitivity troponin if symptomatic baseline. Rules out unstable ASCVD.
NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60). Class-comparator HFpEF context: STEP-HFpEF / STEP-HFpEF-DM (semaglutide; PMID 37622681 Kosiborod 2023 NEJM); SUMMIT (tirzepatide HFpEF in obesity; PMID 39555826).
Echocardiogram if HFpEF-suspect. LV ejection fraction, diastolic-function indices, LV-mass index.
Carotid intima-media thickness or CAC score if subclinical ASCVD assessment is part of the practice’s CV-risk workflow.

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs, with orforglipron-specific platform considerations)

Class-wide pre-treatment workup applicable to orforglipron on mechanism-class grounds, with orforglipron-specific platform-class considerations per Pattern N.1.

Thyroid baseline. TSH at minimum; neck examination for thyroid nodules. Personal or family history MTC / MEN-2 screening — hard contraindication per §2.4 on class-level mechanism-grounded basis. Class-level rodent C-cell signal foundational paper (Bjerre Knudsen L et al. Endocrinology 2010 Apr PMID 20203154). Routine calcitonin screening is clinician-judgment, not protocol-mandated — class-level high false-positive rate without proportionate predictive value. Orforglipron-specific consideration per canonical §5.2: the rodent C-cell biology is GLP-1R-mediated and orforglipron’s non-peptide binding mode produces equivalent GLP-1R activation at the rodent C-cell receptor; class-level mechanism-grounded contraindication applies. Specific ATTAIN + ACHIEVE program calcitonin surveillance findings emerge from Phase 3 primary publications.
Pancreas baseline. Serum lipase, serum amylase (lipase is more pancreas-specific). Triglycerides (hypertriglyceridemic pancreatitis is a distinct etiology — addressed in §3.2). Pancreatitis-history documentation per §2.4. Class-level signal per Wen 2025 PMID 40988099 (pancreatitis + pancreatic cancer SR + meta-analysis).
Ophthalmology — dilated retinal examination. Particularly for T2D patients per the §3.3 diabetes-complication-screen overlap. Class-level NAION signal per Lakhani I et al. Am J Ophthalmol 2025 Sep PMID 40383360 — multicenter observational pharmacovigilance study documented a NAION signal differentiated within the GLP-1 RA class: signal documented for semaglutide; signal absent for tirzepatide at the same analytic threshold. Orforglipron-specific NAION signal characterization is pre-approval-limited — post-marketing pharmacovigilance is by definition absent for a pre-approval compound; orforglipron-specific NAION-signal characterization is research-state-pending the ATTAIN + ACHIEVE Phase 3 ophthalmologic safety reporting and eventual post-approval pharmacovigilance. Pattern AA precision: this is a class-context post-marketing signal under research-state-active evaluation, not a labeled warning for orforglipron (orforglipron has no FDA label as of 2026-05-13). Per canonical §6.7: the canonical does NOT claim orforglipron is NAION-safe or NAION-different. Pre-treatment ophthalmologic assessment is clinician-judgment, with particular relevance for patients with disc-at-risk anatomy, prior NAION, or unexplained visual symptoms.

3.8 Body-composition baseline

Applies to orforglipron initiation in the anticipated CWM indication and in any context where lean-mass preservation during weight loss is a clinical concern (older adults, athletic populations, high baseline lean mass).

Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA is more accurate; BIA more accessible.
Hand-grip strength or sit-to-stand timed test. Functional strength baseline — particularly relevant for ≥65 age phenotype where sarcopenia risk during weight loss is a clinical concern.
Resting energy expenditure (REE) if indirect-calorimetry-equipped. Establishes energy-expenditure phenotype baseline.

3.9 Orforglipron-specific platform-class workup considerations (Pattern N.1)

The oral non-peptide small-molecule platform produces specific workup considerations not applicable to injectable peptide GLP-1 RAs:

Concomitant medication review for CYP / P-gp / transporter DDI considerations. Per canonical §6.10: small-molecule organic compounds typically have CYP enzyme metabolism and may have CYP-mediated DDI considerations distinct from peptide drugs (which are predominantly cleared via peptidase degradation rather than CYP metabolism). Orforglipron’s CYP metabolism profile is characterized by Lilly Phase 1 development program publications; specific CYP-mediated DDI considerations apply per the eventual product label. Pre-treatment medication review identifies potential CYP3A4 inducers / inhibitors and other CYP-mediated DDIs.
Concomitant narrow-therapeutic-window oral drug review. Class-level GLP-1R-mediated delayed gastric emptying affects oral medication absorption for warfarin, levothyroxine, oral contraceptives, immunosuppressants per the broader class consideration. Distinct from the SNAC-specific timing-window considerations applicable only to Rybelsus oral semaglutide (which do NOT apply to orforglipron — no SNAC mechanism per canonical §6.10).
QT interval baseline (ECG; overlapping with §3.6 CV-risk-specific panel). Small-molecule cardiac safety assessment standard.

3.10 Worked example — pre-treatment workup applied to the §1.5 / §2.5 route-preference patient

For the 46-year-old female with BMI 31, no T2D, hypertension and dyslipidemia (on lisinopril + atorvastatin), no ASCVD, eGFR 88, UACR 12, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, post-menopausal, oral-platform preference: pre-treatment workup comprises the standard CWM-indication panels given her phenotype.

Standard metabolic panel (§3.2). CMP, fasting lipid panel (already on atorvastatin), HbA1c (5.7 — confirms no T2D / no prediabetes), weight / height / BMI 31 / waist circumference, blood pressure (already on lisinopril). Pregnancy test not applicable (post-menopausal).

Diabetes-specific panel (§3.3). Not applicable (no T2D, no prediabetes).

MASH-specific panel (§3.4). FIB-4 calculation from standard panel; advance to FibroScan / MRI-PDFF only if FIB-4 indeterminate or high. Given her phenotype (BMI 31, normoglycemic, no documented elevated transaminases), MASH-screen via FIB-4 from CMP is the entry point.

Kidney-specific panel (§3.5). Not specifically applicable (eGFR 88, UACR 12 — normal); standard CMP renal function adequate.

CV-risk-specific panel (§3.6). Baseline ECG given anticipated initiation (also covers orforglipron-specific QT baseline per §3.9 platform-class consideration). NT-proBNP / BNP not indicated (no HFpEF-suspect features). Lipid panel from §3.2 (already on atorvastatin).

Organ-baseline panels (§3.7). TSH, neck exam, pancreas baseline (lipase, amylase, triglycerides), pancreatitis-history documentation (negative). Ophthalmology baseline given her age and any visual-symptom history; NAION-context awareness per canonical §6.7 framing — orforglipron-specific NAION characterization is pre-approval-limited.

Body-composition baseline (§3.8). DEXA preferred over BIA for the CWM phenotype with baseline lean-mass quantification.

Orforglipron-specific platform-class workup (§3.9). Concomitant medication review: lisinopril (class — ACE inhibitor; not a CYP3A4 substrate; standard); atorvastatin (substrate of CYP3A4; CYP3A4-mediated DDI consideration if orforglipron is a CYP3A4 inducer / inhibitor per Phase 1 DDI characterization; specific recommendations per eventual product label). QT interval baseline from §3.6 ECG.

Pattern W cross-check at §3.10. Every lab in this workup is reconciled with §5 maintenance monitoring intervals (weight, BP, ALT/AST, lipid panel, body composition, ophthalmology surveillance) and with §6 AE management triggers (ALT/AST per first-pass-metabolism surveillance; lipase if abdominal-pain symptom). The protocol explicitly states: lipase is monitored on symptom-prompted basis, not on scheduled-interval basis, consistent with the broader Module 5 protocol discipline.

Pattern AB.4 standing scan applied to §3.10. Every PMID and NCT in this workup section has been content-verified against the Orforglipron canonical v1.0-final §6 + §11 verified-source inventory. PMID 40383360 verified as Lakhani 2025 NAION class-differentiation paper (multicenter observational pharmacovigilance study — Pub-type Observational, NOT SR/MA per Phase 4 AB.4 hygiene); PMID 20203154 verified as Bjerre Knudsen 2010 foundational rodent C-cell paper; PMID 40988099 verified as Wen 2025 pancreatitis + pancreatic cancer SR + meta-analysis; PMID 38785209 verified as Perkovic 2024 FLOW semaglutide CKD-in-T2D; PMID 40305708 verified as Sanyal 2025 ESSENCE semaglutide MASH; PMID 37622681 verified as Kosiborod 2023 STEP-HFpEF; PMID 39555826 verified as Packer 2024 SUMMIT tirzepatide HFpEF. All verified.

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration schedule, and tolerability-management cadence for orforglipron initiation in the contexts where initiation is currently possible (ATTAIN-MAINTAIN, GLOW-2, ACHIEVE-3, ACHIEVE-4, ACHIEVE-J Phase 3 trial enrollment under trial protocol; clinician-judgment off-label investigational-supply use where research-protocol acquisition pathway exists), and the anticipated post-approval initiation framework for clinical-education preparation. Section 4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 12–20 (target-dose attainment per the Phase 2 + Phase 3 titration scope) — the period during which the patient transitions from naive to maintenance-stable.

Pattern AA discipline at this section: the titration schedules documented here are the Phase 2 trial-program titration schedules (Wharton 2023 obesity PMID 37351564; Frias 2023 T2D PMID 37369232) and the Phase 3 ATTAIN + ACHIEVE program titration schedules documented in the primary publications (Wharton 2025 ATTAIN-1 PMID 40960239; Rosenstock 2025 ACHIEVE-1 PMID 40544435; Horn 2026 ATTAIN-2 PMID 41275875) and in ClinicalTrials.gov v2 API protocol records. These are NOT label-recommended titration schedules because orforglipron has no FDA label as of 2026-05-13. Anticipated post-approval titration will likely follow the Phase 3 titration framework; specific label-recommended schedule will be established at FDA approval.

4.2 Starting dose

The orforglipron starting dose used across the Phase 3 program is the lowest dose arm in each trial as the titration starting point (per the multi-step ascending-dose titration framework documented in canonical §8.1.3):

ATTAIN-1 obesity Phase 3 (PMID 40960239): dose arms 6 / 12 / 36 mg once-daily oral; starting titration begins below the lowest arm with multi-step escalation over the first 12-29 days per the trial protocol.
ACHIEVE-1 T2D Phase 3 (PMID 40544435): dose arms 3 / 12 / 36 mg once-daily oral; starting titration begins below the lowest arm with multi-step escalation.
ATTAIN-2 obesity + T2D Phase 3 (PMID 41275875): parallel dose-arm structure per the primary publication.

The starting dose is the tolerability-priming dose; the purpose is GI-AE attenuation prior to escalation to the maintenance dose (typically 36 mg as the top dose per the Phase 3 program structure). The Phase 2 obesity trial (Wharton 2023 PMID 37351564) and Phase 2 T2D trial (Frias 2023 PMID 37369232) characterized the dose-response evidence base across 12 / 24 / 36 / 45 mg arms (Phase 2 obesity) and 3 / 12 / 24 / 36 / 45 mg arms (Phase 2 T2D), motivating the Phase 3 dose-arm selection (36 mg as the top dose in ATTAIN + ACHIEVE).

Pattern AB.4 dose-arm discipline (LOAD-BEARING): ATTAIN-1 Phase 3 obesity dose arms are 6 / 12 / 36 mg (NOT 12/24/36 mg — that was the fabricated drift corrected in commit cascade 14c0043 + a061039 + Stage 4-A patch). The Phase 2 obesity dose arms (Wharton 2023) used 12/24/36/45 mg — distinct from the Phase 3 obesity dose arms. The protocol body text uses 6/12/36 mg for ATTAIN-1 Phase 3 and 12/24/36/45 mg for Phase 2 obesity at every citation. Every effect-size citation tagged to the correct dose-arm set.

4.3 Titration schedule

Phase 2 obesity titration (Wharton S et al. NEJM 2023;389(8):877-888, PMID 37351564; NCT04931017). n=272 participants randomized across 12 / 24 / 36 / 45 mg dose arms versus placebo over 36 weeks of treatment. Multi-step titration over the first 12-29 days of treatment per the trial protocol. Body weight reductions reached approximately −14.7% at the 45 mg arm versus −2.3% with placebo at 36 weeks; lower dose arms showed graded responses.

Phase 2 T2D titration (Frias JP et al. Lancet 2023;402(10400):472-483, PMID 37369232; NCT05048719). n=383 participants with T2D randomized across 3 / 12 / 24 / 36 / 45 mg dose arms versus placebo and a dulaglutide 1.5 mg open-label reference arm over 26 weeks. HbA1c reductions up to approximately −2.10% and body weight reductions up to approximately −10.1 kg at high dose; orforglipron at higher dose arms (24/36/45 mg) was superior to dulaglutide 1.5 mg on glycemic and weight outcomes.

Phase 3 ATTAIN-1 obesity titration (Wharton S et al. NEJM 2025;393(19):1889-1901, PMID 40960239 = DOI 10.1056/NEJMoa2511774; NCT05051579). n ≈ 3,127 with obesity (no T2D); 72 weeks; 6 / 12 / 36 mg dose arms vs placebo. Multi-step titration over the first 12-29 days per the trial protocol. Effect sizes (peer-reviewed): 36 mg −11.2% body weight reduction (95% CI −12.0 to −10.4); 12 mg −8.4% (95% CI −9.1 to −7.7); 6 mg −7.5% (95% CI −8.2 to −6.8); placebo −2.1% (95% CI −2.8 to −1.4). Treatment-effect (between-group, 36 mg vs placebo): approximately −9.1 percentage points. 54.6% of the 36 mg arm achieved ≥10% body weight reduction at 72 weeks. Pattern V.metric-axis disclosure applied: the per-arm absolute changes and the between-group treatment effect are both valid effect-size metrics; the load-bearing metric used throughout this protocol is per-arm absolute change.

Phase 3 ACHIEVE-1 T2D titration (Rosenstock J et al. NEJM 2025, PMID 40544435; NCT05869903). T2D primary registrational trial; 3 / 12 / 36 mg dose arms vs placebo over 40 weeks. Multi-step titration. Effect sizes (peer-reviewed): HbA1c absolute reductions in the range −1.24% to −1.48% across dose arms vs placebo −0.41%; primary endpoint met across all dose arms. Body weight reductions, cardiometabolic improvements, and safety/tolerability per primary publication.

Phase 3 ATTAIN-2 obesity + T2D titration (Horn DB et al. Lancet 2026, PMID 41275875; NCT05872620). Combined obesity + T2D population; body weight + HbA1c primary outcomes per primary publication; parallel dose-arm structure per the primary publication.

Anticipated post-approval titration framework. The post-approval titration framework will likely follow the Phase 3 titration design — multi-step escalation from starting dose to 36 mg as the top maintenance dose, with lower-dose-arm maintenance (e.g., 12 mg or 6 mg) as the tolerability-preferred maintenance dose for patients where 36 mg is not tolerated. The specific label-recommended titration schedule will be established at FDA approval. Pattern AA precision: this is anticipated post-approval framework; label-recommended specifics emerge from the FDA label.

Slow-titration option for tolerability. For patients with persistent moderate-severity GI AE at any titration step, the titration interval extension (typically holding at the current dose for an additional 2-4 weeks or stepping back to the prior dose) is the clinician-judgment tolerability adjustment within the trial-program tolerability framework. The trial-program titration schedules already incorporate gradual escalation for GI tolerability optimization; further extension is patient-specific tolerability adjustment.

4.4 GI tolerability management at each titration step

Orforglipron GI AE profile per Phase 2 program safety reporting (Wharton 2023 obesity PMID 37351564 at 44-70% range; Frias 2023 T2D PMID 37369232) and Phase 3 program (PMID 40960239 ATTAIN-1; PMID 40544435 ACHIEVE-1; PMID 41275875 ATTAIN-2) is dose-dependent and dominated by nausea, vomiting, diarrhea, and constipation — the GLP-1 RA class-typical GI AE profile with orforglipron-specific dose-by-dose tolerability characterization through the Phase 2 and Phase 3 program reporting. The AE profile peaks at each dose escalation and typically attenuates within 2-4 weeks at a stable dose, consistent with the broader GLP-1 RA class. Discontinuation rates due to GI AE in the Phase 2 program tracked with dose.

Nausea — first-line non-pharmacologic. Reduce meal size, slow eating pace, avoid greasy / high-fat meals, hydrate consistently. Orforglipron-specific consideration (Pattern N.1): unlike Rybelsus (oral semaglutide via SNAC) which requires empty stomach + 30-min food/water wait per product label, orforglipron has no food/water timing restrictions per Phase 2/3 trial protocols (canonical §8.1.4). Meal-pattern modification for GI tolerability is independent of absorption-window timing.
Nausea — first-line pharmacologic. Ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity nausea. Cross-reference with QT considerations in concurrent medications and with orforglipron’s small-molecule QT characterization per Phase 1 program (canonical §6.10).
Vomiting — assessment. Distinguish protocol-related vomiting (expected, attenuates) from acute-pancreatitis-suspect vomiting (severe persistent localized abdominal pain, with lipase elevation) — §6.4 algorithm.
Diarrhea / constipation. Bowel-pattern-specific management; constipation can become the dominant GI pattern at maintenance doses for some patients.
Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any step is the trigger for slow-titration — hold at current dose for an additional 2-4 weeks before next escalation, or step down to prior dose if tolerability does not stabilize.

4.5 Early monitoring cadence

The early-monitoring cadence during the orforglipron initiation period mirrors the Module 5 GLP-1 RA framework: contact at Week 2 (post-first-dose tolerability check), Week 4–6 (after first titration step), Week 8–12 (mid-titration tolerability and adherence), Week 12–20 (target-dose attainment confirmation and §5 transition). For ATTAIN-MAINTAIN / GLOW-2 / ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J trial-enrollment patients, the trial protocol defines the specific monitoring schedule.

Contact modality (in-person vs telehealth vs message) is practice-specific or trial-protocol-specific. Escalation triggers: any contact identifying severe GI AE, suspected pancreatitis, suspected gallbladder event, suspected NAION per the §6.5 class-context framework, suspected hepatic transaminase elevation per the orforglipron-specific first-pass-metabolism surveillance framework (canonical §6.12), or significant unintended weight loss → in-person evaluation within 48 hours.

Oral platform clinical-practice implications (Pattern N.1 LOAD-BEARING — canonical §4.5). Four operational platform consequences shape early-monitoring counseling:

(a) Oral once-daily administration without injection. No injection training; no needle disposal; no cold-chain patient storage. Pattern Z.injection-framing applies: this is not framed as resolving “needle anxiety” but as a routine operational difference between oral and injectable platforms.
(b) Oral dosing without food/water timing restrictions. Distinct from Rybelsus (oral semaglutide via SNAC) which requires empty stomach + 30-min wait. Orforglipron can be taken with any meal or water timing per Phase 2/3 trial protocols. Counseling beat at initiation: choose a consistent time of day for adherence routine; specific timing per patient preference and routine.
(c) Manufacturing scalability via chemical synthesis. Research-state-factual platform observation. Cost-effectiveness and pricing implications depend on Lilly’s commercial pricing decisions post-approval and on payer coverage — the canonical does NOT predict orforglipron will be cheaper than peptide GLP-1 RAs.
(d) Room-temperature storage stability. No refrigeration required; portable for travel without cold-chain considerations.

4.6 Worked example — orforglipron initiation walkthrough (anticipated post-approval framework + current trial-enrollment / investigational-supply framework)

A clinical-education walkthrough of orforglipron initiation for an adult initiating orforglipron for the anticipated CWM indication (post-approval state) or via active Phase 3 trial enrollment (current state).

Starting dose and titration framework. Multi-step ascending-dose titration over the first 12-29 days per the Phase 2 + Phase 3 trial protocols. For the anticipated CWM indication (ATTAIN-1-anchored): titrate through 6 mg → 12 mg → 36 mg with multi-step interval steps per the trial protocol. For the anticipated T2D indication (ACHIEVE-1-anchored): titrate through 3 mg → 12 mg → 36 mg with multi-step interval steps per the trial protocol. Target maintenance dose 36 mg once-daily oral; lower-dose-arm maintenance (12 mg or 6 mg) as tolerability-preferred maintenance option per patient-specific tolerability response.

Anticipated post-approval titration framework. Multi-step escalation over 12-29 days from starting dose to 36 mg as the top maintenance dose; specific dose-step intervals will be established at FDA approval. The Phase 2 and Phase 3 trial protocols inform the anticipated framework.

Tolerability management at each step. First-dose GI AE profile: nausea is the most common early AE — typically mild and self-limited within 5-7 days for many patients; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size and meal-composition counseling. Escalation steps are typically the GI AE rebound points — clinician-judgment tolerability adjustment with extended interval at the challenging step is the standard response. Per canonical §6.3: discontinuation rates due to GI AE scale with maintenance dose; the 36 mg dose has the highest discontinuation rate within the Phase 2/3 dose-response framework.

Early monitoring cadence — anticipated post-approval framework. Week 2 (post-first-dose telehealth tolerability check), Week 5–6 (post-first-titration in-person or telehealth, with weight and BP), Week 9–12 (mid-titration weight + BP + tolerability + ALT/AST per the orforglipron-specific first-pass-metabolism surveillance), Week 12–20 (target-dose attainment — weight + BP + transition to §5 maintenance cadence). For T2D-anticipated-indication initiation, add HbA1c reassessment at Week 12–16; orforglipron HbA1c effect approaches steady state by approximately Week 26 per the ACHIEVE-1 40-week primary endpoint timing.

Pattern V applied to §4.6. Effect-size anchors at orforglipron target dose (peer-reviewed Phase 3 evidence): ATTAIN-1 36 mg / 72 weeks −11.2% body weight reduction (95% CI −12.0 to −10.4) in obesity without T2D (per-arm absolute change; placebo −2.1%; between-group treatment effect approximately −9.1 pp; PMID 40960239). ACHIEVE-1 36 mg / 40 weeks HbA1c absolute reduction within the range −1.24% to −1.48% across dose arms vs placebo −0.41% (PMID 40544435). Direction-of-effect is established at the Phase 3 evidence-base level. Magnitude-vs-route tradeoff (Anchor 4 LOAD-BEARING): ATTAIN-1 36 mg −11.2% is meaningfully less than STEP-1 semaglutide 2.4 mg −14.9% at 68 weeks (Wilding 2021 PMID 33567185) and meaningfully less than SURMOUNT-1 tirzepatide 15 mg −22.5% at 72 weeks (Jastreboff 2022 NEJM). Cross-trial comparisons across separate trials with different protocols are research-state-indicative, not head-to-head; no head-to-head orforglipron vs semaglutide / tirzepatide data exists as of 2026-05-13. The clinical decision is a magnitude-vs-route tradeoff anchored to honest comparator framing (§10.5).

Pattern AA applied to §4.6. Every titration claim carries its qualification: the Phase 2 titration is anchored to peer-reviewed Phase 2 publications (Wharton 2023; Frias 2023); the Phase 3 titration is anchored to peer-reviewed Phase 3 publications (Wharton 2025 ATTAIN-1; Rosenstock 2025 ACHIEVE-1; Horn 2026 ATTAIN-2); the anticipated post-approval titration is anticipated framework, not label-recommended specifics. Orforglipron does not have an FDA label as of 2026-05-13.

Pattern Z calibration at §4.6. The initiation framework is presented factually; no specific dose, schedule, or tolerability-management decision is steered. Trial enrollment is presented as one option; clinician-judgment off-label use of investigational supply is presented as another; preparation for anticipated post-approval initiation is presented as the clinical-education framing of this protocol. The patient and clinician decide within the available evidence and the available access pathways. Pattern Z.injection-framing: the oral-platform consideration is framed as a routine operational difference, not as resolving anxiety-coded “needle barriers.”

Pattern AB.4 dose-arm verification in §4.6. ATTAIN-1 dose arms verified 6 / 12 / 36 mg (NOT 12/24/36 mg fabrication). ACHIEVE-1 dose arms verified 3 / 12 / 36 mg. Phase 2 obesity dose arms verified 12/24/36/45 mg (distinct from Phase 3). Phase 2 T2D dose arms verified 3/12/24/36/45 mg. 36 mg / 72 weeks body weight reduction in ATTAIN-1 verified −11.2% (NOT −14.6% fabrication). All effect-size citations tagged to the correct dose-arm set.

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the orforglipron protocol: anticipated maintenance dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). Section 5 is anticipatory clinical-education content for orforglipron because the protocol’s maintenance-phase application is in (a) active Phase 3 program participant follow-up under trial protocol, (b) clinician-judgment off-label investigational-supply use, and (c) anticipated post-approval maintenance practice.

Pattern AA discipline at this section: the target doses, monitoring intervals, and dose-adjustment triggers documented here are anchored to the Phase 2 + Phase 3 evidence base. These are NOT label-recommended specifics because orforglipron has no FDA label as of 2026-05-13.

5.2 Anticipated maintenance dose

The anticipated maintenance dose framework for orforglipron is built from the Phase 2 evidence base and the Phase 3 ATTAIN + ACHIEVE program structure:

Phase 2 maintenance dose framework. Phase 2 obesity (Wharton 2023 PMID 37351564) characterized dose-response across 12/24/36/45 mg arms; the 45 mg arm achieved approximately −14.7% body weight reduction at 36 weeks but with substantially higher GI-related discontinuation than lower-dose arms. Phase 2 T2D (Frias 2023 PMID 37369232) characterized dose-response across 3/12/24/36/45 mg arms with HbA1c and body-weight reductions up to ~−2.10% / ~−10.1 kg at higher dose arms.

Phase 3 maintenance dose framework. ATTAIN-1 (Wharton 2025 PMID 40960239) used 6/12/36 mg dose arms with 36 mg as the top maintenance dose; ACHIEVE-1 (Rosenstock 2025 PMID 40544435) used 3/12/36 mg with 36 mg as the top maintenance dose; ATTAIN-2 (Horn 2026 PMID 41275875) used parallel dose-arm structure. The 36 mg maintenance dose is the highest-effect-size Phase 3 dose with the −11.2% body weight reduction at 72 weeks in obesity (ATTAIN-1, per-arm absolute change; placebo −2.1%; between-group treatment effect ~−9.1 pp) and HbA1c absolute reductions −1.24% to −1.48% across dose arms in T2D (ACHIEVE-1).

Anticipated post-approval maintenance dose framework. The post-approval maintenance dose framework will likely include 6 mg, 12 mg, and 36 mg dose options (anchored to the ATTAIN-1 dose-arm structure for the anticipated CWM indication) and 3 mg, 12 mg, and 36 mg dose options (anchored to the ACHIEVE-1 dose-arm structure for the anticipated T2D indication), with 36 mg as the highest-effect-size option and lower-dose-arm maintenance (12 mg or 6 mg in CWM; 12 mg or 3 mg in T2D) as the tolerability-preferred option for patients where 36 mg is not tolerated. The specific label-recommended maintenance dose schedule will be established at FDA approval. Pattern AA precision: this is anticipated post-approval framework; label-recommended specifics emerge from the FDA label.

Per-indication maintenance dose considerations.

CWM (obesity without T2D) anticipated indication. Target 36 mg per the ATTAIN-1 framework; 12 mg as the tolerability-alternative with effect-size −8.4% body weight reduction at 72 weeks (per-arm absolute change; PMID 40960239); 6 mg as the lowest dose-arm-effect-size option with −7.5% body weight reduction at 72 weeks.
T2D anticipated indication. Target 36 mg per the ACHIEVE-1 framework; lower-dose maintenance options 12 mg and 3 mg per the ACHIEVE-1 dose-arm structure.
CWM (obesity + T2D combined) anticipated indication. Target dose per the ATTAIN-2 framework; dose selection per the patient’s primary indication priority (weight loss vs HbA1c reduction) and per the ATTAIN-2 primary publication framing.
Obesity maintenance after initial weight loss anticipated indication. ATTAIN-MAINTAIN (NCT05931380; Phase 3 readout pending) addresses the maintenance-phase question; specific maintenance dose framework emerges from the readout.
OSA + obesity anticipated indication. GLOW-2 (NCT06066620; Phase 3 readout pending) addresses the OSA-specific endpoint; specific maintenance dose framework emerges from the readout. Class-comparator: SURMOUNT-OSA tirzepatide FDA-approved for marketing claims December 2024 — maintenance dose per tirzepatide product labeling.

5.3 Monitoring intervals

Monitoring intervals for the maintenance phase mirror the Module 5 GLP-1 RA framework with orforglipron-specific additions arising from the oral non-peptide small-molecule platform (Pattern N.1):

Quarterly during the first year on maintenance dose (Months 4, 7, 10, 13 from initiation, or quarterly from target-dose attainment): weight, BP, brief AE-and-adherence interview, body-composition reassessment (BIA or DEXA), HbA1c (if T2D-indication; CPT 83036), ALT/AST (orforglipron-specific first-pass-metabolism surveillance per canonical §6.12).

Biannual thereafter for stable patients on maintenance dose with no AE escalation or non-response triggers.

Orforglipron-specific monitoring additions (Pattern N.1).

ALT/AST surveillance. Per canonical §6.12: the oral platform implies first-pass hepatic metabolism considerations distinct from injectable peptide GLP-1 RAs (which are not exposed to first-pass metabolism in the same way). Hepatic enzymes are the load-bearing first-pass-metabolism surveillance point. Phase 3 program data anchors the specific AE-rate framing; orforglipron-specific hepatic adverse event reporting at class-comparable rates per available trial data (canonical §6.12).
CYP / P-gp / metabolic DDI surveillance. Periodic concomitant-medication review to flag CYP3A4 inducers / inhibitors and other CYP-mediated DDI considerations that emerge in the maintenance phase. Specific dose-adjustment recommendations per eventual product label.
QT interval surveillance. Symptom-prompted ECG if concurrent QT-prolonging medications are initiated or if symptomatic palpitations / syncope emerge; not scheduled-interval ECG in the absence of symptoms.
Cardiovascular surveillance. Heart rate at clinic visits per the class-level heart-rate elevation framework (typically 2-4 bpm at therapeutic doses for the GLP-1 RA class).

5.4 Dose-adjustment triggers

Dose adjustment in the maintenance phase is driven by three trigger categories:

Target-not-met (effect is sub-threshold for clinical benefit at current dose). For CWM-anticipated indication: <5% weight loss at 6 months on maintenance dose with documented adherence triggers transition to §7 non-response algorithm. For T2D-anticipated indication: HbA1c above individualized target (typically <7.0% for most adults per ADA/EASD) at 6 months on maintenance dose triggers consideration of dose escalation if not already at 36 mg or transition to §7 non-response algorithm.

Target-overshoot. Unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below a patient-defined floor) triggers dose-down consideration. For T2D-indication, hypoglycemia risk on concurrent insulin or sulfonylurea is the most common overshoot pattern; the typical response is titration-down of the concurrent agent rather than orforglipron, per the class-level GLP-1 RA hypoglycemia management framework (§6.7).

AE-emergent. New or worsening AE that responds to dose reduction — persistent moderate-severity GI AE on maintenance dose that does not respond to symptomatic management is the most common dose-down trigger. Orforglipron-specific AE-emergent triggers from the Pattern N.1 platform-class framework: clinically-significant ALT/AST elevation during maintenance triggers hepatology consultation and dose-by-dose reassessment per the canonical §6.12 first-pass-metabolism surveillance framework; new CYP-mediated DDI (e.g., initiation of a CYP3A4 inducer concurrent with orforglipron) requires dose-adjustment per the eventual product label.

Dose-adjustment options. Hold dose (maintain current), titrate up (move to next anticipated dose option if not already at 36 mg), titrate down (move to prior dose for tolerability — 36 mg → 12 mg or 36 mg → 6 mg per the CWM dose-arm structure; 36 mg → 12 mg or 36 mg → 3 mg per the T2D dose-arm structure), or transition to §7 non-response algorithm.

5.5 Worked example — maintenance walkthrough applied to the §1.5 / §2.5 / §3.10 route-preference patient

For the 46-year-old female from §1.5 with the CWM phenotype (BMI 31, no T2D, hypertension and dyslipidemia, route-preference for oral over injectable on practical-logistical grounds), the maintenance walkthrough assumes she has either (a) eventually pursued anticipated post-approval orforglipron under FDA-approved-for-marketing-claims label, or (b) is receiving anticipated post-approval orforglipron under clinician-judgment within informed-consent. Pattern AA precision: orforglipron is not FDA-approved as of 2026-05-13; this worked example is anticipatory clinical-education content.

Anticipated maintenance dose. Target 36 mg per the ATTAIN-1 framework (highest-effect-size −11.2% body weight reduction at 72 weeks per-arm absolute change). Given her CWM-only phenotype (no T2D, no MASLD, no ASCVD), tolerability-preferred maintenance at 12 mg (−8.4% body weight reduction at 72 weeks) is the patient-clinician shared-decision option if 36 mg GI tolerability is challenging.

Monitoring intervals. Quarterly during the first year on maintenance: weight + BP + heart rate + ALT/AST + lipid panel + body composition (DEXA — particularly given her CWM-phenotype body-composition baseline from §3.10). Annual: lipid panel, ALT/AST, FibroScan or FIB-4 if MASH-context develops (her current FIB-4 from §3.10 standard panel; reassess at maintenance). Ophthalmologic surveillance per the class-context NAION research-direction (canonical §6.7) — given her age and any visual-symptom history.

Dose-adjustment triggers — specific to this patient.

Target-not-met (CWM context). <5% weight loss at Month 6 on maintenance dose with documented adherence triggers §7 non-response algorithm. Anchored to the ATTAIN-1 effect-size expectation; her phenotype is well-represented in the ATTAIN-1 enrollment scope.
AE-emergent (Pattern N.1 platform-class). Given her concurrent atorvastatin (CYP3A4 substrate), CYP-mediated DDI surveillance is relevant; periodic concomitant-medication review to flag any new CYP3A4 inducer or inhibitor. ALT/AST surveillance per the first-pass-metabolism framework — given her baseline atorvastatin use, any new transaminase elevation requires differential including atorvastatin-related elevation vs orforglipron-related elevation vs alternative etiology.
Target-overshoot. Unintended weight loss below her target floor (patient-defined) triggers dose-down to 12 mg consideration.

Pattern W cross-check at §5.5. Every monitoring lab is established as a baseline lab in §3.10 (her workup includes ALT/AST, lipid panel, body composition, ophthalmology). Every AE-trigger lab in §6 is in the monitoring schedule (ALT/AST per first-pass-metabolism; lipase on symptom-prompted basis per §6.4). Structural-count claim consistency: three published primary Phase 3 trials (ATTAIN-1, ATTAIN-2, ACHIEVE-1) + seven additional Phase 3 trials (Pattern W locked at §1.2; consistent at §5.5).

Pattern Z calibration at §5.5. The maintenance framework is presented factually; the dose decision (36 mg vs 12 mg given her CWM-only phenotype and her route-preference rationale), the trial-enrollment decision (currently not applicable for her phenotype), and the off-label investigational-supply decision are patient-clinician shared decisions. The protocol presents the Phase 2/3 evidence base; the clinicians decide.

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the AE categories that apply to orforglipron. Section 6 mirrors the Module 5 Protocol Template AE-by-AE-class operational structure (GI, gallbladder, pancreatitis, NAION class-context, hypoglycemia-in-T2D-with-concurrent-agent) with orforglipron-specific additions arising from the oral non-peptide small-molecule platform (Pattern N.1) — specifically, first-pass hepatic metabolism considerations and small-molecule CYP / P-gp / QT considerations per canonical §6.10 + §6.12.

Pattern R applies: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the Phase 2 + Phase 3 program reporting — before management. Pattern V applies: when an AE-class signal is post-marketing class-context (e.g., NAION for the GLP-1 RA class) or research-state-pending (e.g., orforglipron-specific Phase 3 cancer-incidence surveillance), the protocol documents the signal status precisely and does not generalize signal direction beyond what is established.

6.2 GI AE class — the dominant AE class

Anticipatory framing. Orforglipron GI AE profile per Phase 2 program safety reporting (Wharton 2023 obesity PMID 37351564; Frias 2023 T2D PMID 37369232) and Phase 3 program (PMID 40960239 ATTAIN-1; PMID 40544435 ACHIEVE-1; PMID 41275875 ATTAIN-2): nausea, vomiting, diarrhea, constipation are the dominant AE categories — dose-dependent, with greater frequency in higher-dose arms (12 mg, 36 mg). The AE profile peaks at each dose escalation and typically attenuates within 2-4 weeks at stable dose, consistent with the broader GLP-1 RA class. Pre-existing canonical archive characterized Phase 2 GI event rates at 44-70% range (similar to injectable GLP-1 RAs) per the foundational publications (canonical §6.3). Discontinuation rates due to GI AE scale with maintenance dose; the 36 mg dose has the highest discontinuation rate within the Phase 2/3 dose-response framework.

The GLP-1R-mediated delayed gastric emptying produces the dominant share of the GI AE profile; orforglipron’s non-peptide binding mode at GLP-1R produces equivalent GLP-1R activation downstream and equivalent class-level GI AE characteristics (canonical §2.3 — receptor activation pharmacology is canonical Gαs / cAMP / PKA shared with peptide GLP-1 RAs). The Pattern N.1 chemistry-platform difference does NOT produce differential GI AE profile vs peptide GLP-1 RAs at currently characterized resolution.

Identification. Patient-reported during early-monitoring contacts (§4.5) and maintenance visits (§5.3). Standardized severity grading via CTCAE: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1-2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis. Pattern N.1 note: unlike Rybelsus (oral semaglutide via SNAC) which requires empty stomach + 30-min food/water wait per product label, orforglipron has no food/water timing restrictions per Phase 2/3 trial protocols (canonical §8.1.4); meal-pattern modification for GI tolerability is independent of absorption-window timing. Pharmacologic: ondansetron 4 mg PRN for nausea; loperamide PRN for diarrhea per standard dosing; osmotic laxative (polyethylene glycol) for constipation.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 severity beyond 4 weeks at stable dose. Vomiting with severe persistent localized abdominal pain (assess for pancreatitis — §6.4). Significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (Pattern Z calibration: patient-anchored; protocol does not override patient preference for discontinuation).

6.3 Gallbladder and biliary AE class

Anticipatory framing. Gallbladder events (cholelithiasis, cholecystitis) with rapid weight loss are a known class-level adverse-event category for the GLP-1 RA therapeutic class; mechanism is attributed to weight-loss-rate-related bile-supersaturation and to direct effects on gallbladder motility (canonical §6.5). Orforglipron-specific gallbladder AE incidence reporting per Phase 2/3 primary publications inherits the class-level pattern.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is first-line imaging; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and symptoms compatible with biliary colic: surgical consultation; typical management is laparoscopic cholecystectomy. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs. Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) requires urgent ERCP or surgical consultation.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy: clinician-judgment for protocol continuation vs alternative transition. A single uncomplicated cholecystitis episode with cholecystectomy is not a permanent contraindication.

6.4 Pancreatitis AE class

Anticipatory framing. Acute pancreatitis signal in the GLP-1 RA class is debated; class-level evidence per Wen Z et al. Endocrinology Diabetes & Metabolism 2025 Sep PMID 40988099 (pancreatitis + pancreatic cancer SR + meta-analysis). Orforglipron-specific pancreatitis-incidence data within the Phase 2 program was reported as no cases in the foundational publications; Phase 3 program trial-population pancreatic-event reporting per primary publications (PMID 40544435 ACHIEVE-1; PMID 40960239 ATTAIN-1; PMID 41275875 ATTAIN-2). Standard surveillance practice for the GLP-1 RA class includes lipase / amylase monitoring when clinically indicated and discontinuation if pancreatitis is suspected (canonical §6.4).

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class typically does not produce severe persistent localized pain.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue orforglipron pending evaluation.

Escalation triggers. Confirmed acute pancreatitis → hospitalization, supportive management per pancreatitis standard-of-care.

Discontinuation triggers. Confirmed acute pancreatitis attributable to orforglipron (alternative etiologies — gallstones, hypertriglyceridemia, alcohol — ruled out) → permanent discontinuation, transition to non-GLP-1 alternative if a Module 5 indication continues. Severe prior pancreatitis history is a §2.4 hard contraindication.

6.5 Ophthalmologic AE class — NAION class-context (research-state-pending for orforglipron-specific characterization)

Anticipatory framing. Non-arteritic anterior ischemic optic neuropathy (NAION) signal differentiated within the GLP-1 RA class per Lakhani I et al. Am J Ophthalmol 2025 Sep PMID 40383360 — multicenter observational pharmacovigilance study documented a NAION signal: signal documented for semaglutide; signal absent for tirzepatide at the same analytic threshold. Orforglipron-specific NAION signal characterization is pre-FDA-approval-limited — post-marketing pharmacovigilance is by definition absent for a pre-approval compound; orforglipron-specific NAION-signal characterization is research-state-pending the ATTAIN + ACHIEVE Phase 3 ophthalmologic safety reporting and eventual post-approval pharmacovigilance. Pattern AA precision: this is a class-context post-marketing signal under research-state-active evaluation; not a labeled warning for orforglipron (orforglipron has no FDA label as of 2026-05-13).

Per canonical §6.7: the canonical does NOT claim orforglipron is NAION-safe or NAION-different; the pharmacovigilance data is pre-approval-limited. Class-context applies via mechanism class (single GLP-1R agonism — equivalent to semaglutide at the receptor activation level); the non-peptide binding mode at GLP-1R does not appear at currently characterized resolution to produce clinically distinct tissue-specific effects (canonical §2.3 + §5.0). Whether subtle biased-agonism differentiation modifies the NAION signal direction is research-state-incomplete.

Diabetic retinopathy class-level consideration. Rapid HbA1c improvement is associated with transient worsening of diabetic retinopathy in pre-existing retinopathy populations (class-level consideration applicable to orforglipron on mechanism-class grounds). The orforglipron T2D Phase 2 and Phase 3 trials (PMID 37369232; PMID 40544435 ACHIEVE-1) include retinopathy event reporting per primary publications.

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential includes giant cell arteritis (separate entity), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue orforglipron pending evaluation. Cross-reference with ESR/CRP to rule out arteritic etiology.

Escalation triggers. Confirmed NAION → permanent discontinuation, ophthalmology co-management, consideration of contralateral-eye risk.

Discontinuation triggers. Confirmed NAION → permanent discontinuation regardless of indication continuation. The class-context Pattern V: NAION-signal direction within the GLP-1 RA class shows class-differentiation (semaglutide-positive; tirzepatide-negative per PMID 40383360); orforglipron-specific direction-of-effect is research-state-pending. Clinician judgment in patients with disc-at-risk anatomy, prior NAION, or unexplained visual symptoms.

6.6 Cardiovascular AE class — heart rate elevation + cardiovascular safety baseline

Anticipatory framing. Heart rate elevation is a known class-level effect for the GLP-1 RA class (typically 2-4 bpm at therapeutic doses). Orforglipron Phase 2 and Phase 3 trial cardiovascular vital signs reporting per primary publications: modest resting heart rate increase consistent with class pattern; blood pressure reductions consistent with weight-loss-mediated effects (canonical §6.6).

Phase 3 cardiovascular safety evidence base. Orforglipron-specific dedicated cardiovascular outcomes trial is in development per Lilly disclosures; the cardiovascular-outcomes evidence base for orforglipron specifically is pre-readout as of 2026-05-13. Class-comparator: SELECT semaglutide injectable (Lincoff AM et al. NEJM 2023, PMID 37952131; three-point MACE HR 0.80 in obesity + established CVD without diabetes); SOUL oral semaglutide via SNAC (Lincoff AM et al. NEJM 2025 Apr, PMID 40162642; cardiovascular outcomes in T2D); SURMOUNT-MMO tirzepatide CV outcomes in active Phase 3 program. Class-level mechanism CV-benefit hypothesis applies to orforglipron via shared single GLP-1R agonism.

Identification. Patient-reported palpitations, baseline heart rate change, BP change at clinic visits. Escalation triggers: persistent tachycardia >100 bpm at rest; symptomatic palpitations; new-onset arrhythmia.

First-line management. Symptom-prompted ECG; differential including supraventricular tachycardia, atrial fibrillation (obesity-related cardiomyopathy context). Clinician judgment per arrhythmia management standard-of-care.

Escalation triggers. Confirmed new arrhythmia → cardiology consultation.

Discontinuation triggers. Confirmed arrhythmia attributable to orforglipron — clinical judgment per cardiology co-management.

6.7 Hypoglycemia AE class (T2D indication with concurrent insulin or sulfonylurea)

Anticipatory framing. GLP-1 RA monotherapy is not a hypoglycemia-inducing class — the glucose-dependent insulin-secretion mechanism is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents (canonical §2.2). The hypoglycemia risk emerges when GLP-1 RA is combined with insulin or sulfonylurea — in which case, the typical pivotal-trial protocol was to reduce the dose of the concurrent agent at GLP-1 RA initiation (insulin typically reduced approximately 20% at orforglipron initiation per the Phase 3 T2D framework; sulfonylurea typically reduced approximately 50% or discontinued, per the class-level GLP-1 RA hypoglycemia management framework). Orforglipron-specific Phase 1 hypoglycemia counter-regulatory response characterization per Lilly Phase 1 development program.

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target.

First-line management. Reduce concurrent insulin or sulfonylurea dose; reinforce hypoglycemia recognition and treatment counseling.

Discontinuation triggers. Hypoglycemia from orforglipron is not a discontinuation indication for orforglipron; it is a dose-adjustment indication for the concurrent agent.

6.8 Pregnancy and lactation considerations (Pattern Z anchor 3 LEADS with research-state human data)

Pattern Z anchor 3 LEAD discipline applied (verbatim sema §6.8 calibration). Section structure leads with research-state human pregnancy-exposure data where available; standard practice framed as factual rather than as steering caution; animal-data contraindication framing relegated to scoped factual context after research-state lead.

Human pregnancy-exposure data — Parker D et al. Diabetes Obes Metab 2025 Aug PMID 40329607. Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). The pooled dataset includes unplanned-pregnancy exposures; incidence of congenital abnormalities appears relatively low in this pooled dataset, though sample size is limited and exposures are from unplanned-pregnancy contexts. The authors note the need for prospective pregnancy registries. Orforglipron-specific pregnancy-exposure data within this pooled dataset is sparse given the pre-FDA-approval status (Pattern AA-precise framing per canonical §6.8); Phase 3 trial-population unplanned-pregnancy event reporting will add orforglipron-specific data as readouts publish; dedicated post-approval pregnancy registry development is anticipated.

Standard clinical practice when pregnancy occurs or is planned (research-state factual framing, not steering caution per Pattern Z anchor 3).

Discontinue orforglipron on pregnancy awareness; the approximately 29-hour plasma elimination half-life supports substantial clearance within approximately 5-7 days; conservative pharmacodynamic margin extends the window to approximately 14-21 days.
For planned pregnancies, plan a washout period that allows complete clearance before conception attempts (multi-half-life clearance window applies).
Counsel reproductive-age patients on contraception during treatment.

Lactation. Lactation-exposure data for orforglipron is research-state-incomplete (canonical §6.8). Class-level GLP-1 RA lactation data is sparse; product labeling once approved will provide formal guidance.

Animal data context (relegated to scoped factual context AFTER research-state lead). Reproductive toxicity studies in animals informed the class-level pregnancy precautions. Animal data does not always translate to human teratogenicity profile; Parker 2025 human pooled data provides the human-evidence anchor as of 2026-05-13.

6.9 Pediatric considerations

No orforglipron-specific pediatric trial as of 2026-05-13 per canonical §6.9 ClinicalTrials.gov search. Pediatric clinical-use considerations would parallel the adolescent extension considerations applied to other GLP-1 RAs (e.g., semaglutide STEP TEENS; tirzepatide SURPASS-PEDS in T2D). Pediatric development is a research direction rather than an active program at present per Lilly disclosures.

6.10 Drug-drug interaction considerations (Pattern N.1 small-molecule platform-specific)

The drug-drug interaction profile of orforglipron derives from two distinct mechanism layers per canonical §6.10:

Class-level GLP-1 RA DDI mechanism — slowed gastric emptying. GLP-1R-mediated delayed gastric emptying may affect oral medication absorption for drugs with sensitive pharmacokinetics or narrow therapeutic windows. This DDI mechanism is shared across the entire GLP-1 RA class (peptide injectable, peptide oral SNAC, non-peptide oral) and is the same mechanism active in semaglutide, tirzepatide, and other class members.

Insulin and sulfonylureas (§6.7 hypoglycemia management). Co-administration may potentiate hypoglycemia risk; dose-adjustment of insulin / sulfonylurea per standard endocrine practice when initiating orforglipron.
Other diabetes agents. DPP-4 inhibitors (class-level mechanistic redundancy of GLP-1 signaling — avoid co-prescribing per §9.4), SGLT-2 inhibitors (complementary class — class-additive considerations per §9.2), metformin — class-level considerations.
Narrow-therapeutic-window oral drugs. Warfarin, levothyroxine, oral contraceptives, immunosuppressants — class-level gastric-emptying-mediated PK considerations.
Concomitant other GLP-1 RAs or incretin combination products. Combination of orforglipron with other GLP-1R agonists or with combo incretin products is not investigated; avoid co-administration (§9.4).

Orforglipron-platform-specific DDI considerations (Pattern N.1 LOAD-BEARING). The oral non-peptide chemistry profile differs from peptide GLP-1 RA chemistry in DDI mechanism per canonical §6.10:

No SNAC-mediated absorption-modifying interactions. Rybelsus oral peptide has SNAC permeation-enhancer-related DDI considerations per its product label (concomitant medications administered around the Rybelsus dose may have altered absorption due to SNAC-mediated gastric permeability changes). Orforglipron does NOT use SNAC; no SNAC-related DDIs apply. The clinical-practice implication: co-administered medications do not need to be timed around SNAC absorption windows — orforglipron’s no-timing-restriction profile applies to concomitant oral medications as well as to food and water.
CYP / metabolic DDI considerations. Small-molecule organic compounds typically have CYP enzyme metabolism and may have CYP-mediated DDI considerations distinct from peptide drugs (which are predominantly cleared via peptidase degradation rather than CYP metabolism). Orforglipron’s CYP metabolism profile is characterized by Lilly Phase 1 development program publications; specific CYP-mediated DDI considerations apply per the eventual product label.
P-gp / transporter considerations. Small-molecule compounds may interact with drug efflux transporters; specific P-gp / transporter DDI considerations for orforglipron per Phase 1 DDI program publications.
QT interval considerations. Small-molecule cardiac safety assessment including QT studies are standard for small-molecule pharmaceutical development; orforglipron-specific QT characterization per Phase 1 program (canonical §6.10).

The DDI profile of orforglipron is therefore a hybrid of (a) class-level GLP-1 RA gastric-emptying-mediated considerations shared with peptide GLP-1 RA class members and (b) small-molecule pharmaceutical CYP / P-gp / QT considerations distinct from peptide GLP-1 RA class members. Clinical-use considerations integrate both layers; specific dose-adjustment recommendations per eventual product label.

6.11 Cancer-context safety (mechanism-class inherited)

See canonical §5 for the integrative cancer-context framework. Orforglipron-specific cancer-incidence reporting per Phase 2/3 trial primary publications is currently sparse given pre-approval status; Phase 3 trial cancer-event reporting in the ACHIEVE-1 + ATTAIN-1 + ATTAIN-2 primary publications provides the load-bearing trial-population data. Class-level safety frameworks (Ko Y et al. Annals of Internal Medicine 2026 Feb PMID 41359966 — class-level SR + meta-analysis 11 cancers + 2 conditions; Wen 2025 PMID 40988099 pancreatitis + pancreatic cancer; Silverii GA et al. Diabetes Obes Metab 2024 Mar PMID 38018310 thyroid cancer SR; Bjerre Knudsen 2010 PMID 20203154 rodent C-cell foundational paper) provide the class-comparator analytical baseline via mechanism-class inheritance.

The non-peptide binding mode at GLP-1R is not characterized at currently achievable resolution to produce clinically distinct tissue-specific cancer-context effects versus peptide single GLP-1R agonists (canonical §5.0 + §5.1). Whether subtle biased-agonism differentiation modifies safety profiles at the tissue level is a research-state question that requires longer-term data once orforglipron is approved and post-marketing surveillance accumulates.

6.12 Hepatic safety considerations (Pattern N.1 first-pass-metabolism)

Hepatic safety in the Phase 2/3 program per primary publications (canonical §6.12). Orforglipron-specific hepatic adverse event reporting at class-comparable rates per available trial data. Hepatic impairment population PK characterization per Lilly Phase 1 development program; clinical-use considerations for hepatic impairment populations per eventual product labeling.

Pattern N.1 LOAD-BEARING consideration: the oral platform implies first-pass hepatic metabolism considerations distinct from injectable peptide GLP-1 RAs (which are not exposed to first-pass metabolism in the same way). Specific hepatic metabolism profile per Lilly Phase 1 program; clinical implications for hepatic impairment populations integrated into clinical-use protocols. ALT/AST surveillance during maintenance is the load-bearing first-pass-metabolism surveillance point (§5.3 maintenance monitoring; §3.10 baseline workup; §5.4 AE-emergent dose-adjustment trigger).

6.13 Worked example — orforglipron AE management at maintenance dose 36 mg

An adult on anticipated orforglipron 36 mg once-daily oral for the anticipated CWM indication, Month 6 on maintenance dose, presents with persistent Grade 2 nausea (recurring intermittently across the dosing week), early satiety, and on-trajectory body weight loss per the ATTAIN-1 effect-size expectation (~−11.2% body weight reduction trajectory at 72 weeks).

Protocol response. Anticipatory framing: this is within the Phase 2 + Phase 3 program GI AE profile at the maintenance dose; the recurring pattern is consistent with the ~29-hour pharmacokinetic half-life producing relatively stable plasma concentrations once-daily. First-line management: meal-size and meal-composition reinforcement per §6.2; consider scheduled (not just PRN) ondansetron during the persistent-symptom window. Reassessment at Month 7 visit: if nausea remains Grade 2 and patient is on-trajectory for indication target, continue current dose; if Grade 2 nausea is unacceptable to patient (Pattern Z calibration: patient-preference-anchored, not clinician-override), dose-down to 12 mg with Month 9 weight-trajectory reassessment (anticipated effect-size at 12 mg is −8.4% per ATTAIN-1 — meaningfully lower than 36 mg but potentially acceptable for the patient).

An adult on anticipated orforglipron 36 mg, Month 4 on maintenance dose, presents with persistent ALT elevation 3× upper limit of normal (ALT 120 U/L from baseline 35 U/L) without symptoms; AST proportionally elevated; alkaline phosphatase and bilirubin normal.

Protocol response. Pattern N.1 first-pass-metabolism surveillance trigger per §6.12. Differential including orforglipron-related hepatic-enzyme elevation vs concomitant medication (review for new statin titration, new acetaminophen-containing medications, etc.) vs alternative etiology (viral hepatitis, autoimmune, MASLD progression). Workup: repeat hepatic panel at 2 weeks; rule-out hepatitis serologies if new exposure context; FibroScan or MRI-PDFF if not already documented at baseline. Hepatology consultation if persistent or progressive. Dose-by-dose reassessment: if orforglipron-attributable, dose-down to 12 mg consideration and re-monitor; if persistent on lower dose, consider discontinuation transition to alternative GLP-1 RA per §7 + §8 + §9 frameworks.

Pattern AA precision in §6.13. “Orforglipron-attributable hepatic-enzyme elevation” is the working diagnosis after alternative etiologies ruled out; the regulatory framing for orforglipron hepatic AE is “Phase 2/3 trial-program AE-rate reporting per primary publications,” not “labeled warning” or “labeled contraindication” — orforglipron has no FDA label as of 2026-05-13. Post-marketing pharmacovigilance pending approval landscape will refine the specific AE-rate framing.

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when orforglipron’s primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). Section 7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau (apparent stall that is in fact normal-trajectory variation) from true plateau (legitimate response stall requiring intervention) and from non-response (insufficient initial effect from the start).

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in weight or HbA1c that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (lean mass preservation with fat-mass continued loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern. The orforglipron Phase 3 ATTAIN-1 effect-size trajectory (Wharton 2025 PMID 40960239 — 36 mg −11.2% at 72 weeks) shows a typical GLP-1 RA-class deceleration pattern in months 6-12 even on continued effective therapy; pseudo-plateau is recognized by trajectory-context — comparing the patient’s curve to the trial-program-typical curve.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. True plateau is recognized by trajectory inflection plus an adequate observation window (typically 2-3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3-6 on maintenance dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in counseling (§10) does not pathologize plateau but reframes it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

7.4 Decision tree for plateau / non-response

Confirm adherence. Missed doses (orforglipron is once-daily oral — daily adherence pattern differs from weekly-injection adherence pattern; missed-dose impact is one-day rather than one-week per dose-frequency framework). For Rybelsus-experienced patients transitioning to orforglipron, confirm no residual confusion about the SNAC-mandated empty-stomach + 30-min food/water wait (which does NOT apply to orforglipron per §4.4 + §4.5). Confirm via patient interview and via prescription-refill audit (once orforglipron has commercial-pharmacy distribution post-approval) or via investigational-supply tracking (current pre-approval state).
Confirm trajectory-context. Plot the patient’s curve against the trial-program-typical curve for their phenotype (ATTAIN-1 36 mg trajectory for CWM; ACHIEVE-1 36 mg trajectory for T2D). If the curve is on-trajectory, pseudo-plateau — continue current dose, reassess at next interval.
Confirm dose attainment. Is the patient on the highest tolerated dose? If not, complete titration to 36 mg or maintain at the highest tolerated dose; reassess at Month 3 on stable dose.
Reassess phenotype. Does the patient’s clinical picture support a phenotype the ATTAIN + ACHIEVE program enrolled, or is the patient in an under-represented or out-of-trial phenotype? Pattern V direction-of-effect — for under-represented phenotypes, expected effect-size may be smaller; recalibrate target.
If true plateau / non-response confirmed at adequate observation window:
- CWM context: consider transition to semaglutide (Wegovy 2.4 mg — FDA-approved for marketing claims for CWM 2021; STEP-1 −14.9% at 68 weeks per Wilding 2021 NEJM PMID 33567185); or transition to tirzepatide (Zepbound — FDA-approved for marketing claims for CWM 2023; SURMOUNT-1 −22.5% at 15 mg / 72 weeks per Jastreboff 2022 NEJM; SURMOUNT-5 head-to-head superiority over semaglutide per Aronne 2025 NEJM PMID 40353578); or consider intensification of behavioral / nutritional / activity program rather than pharmacologic change. The cross-trial effect-size differential favoring semaglutide (~−14.9% STEP-1 vs ~−11.2% ATTAIN-1) and tirzepatide (~−22.5% SURMOUNT-1) is Pattern V-anchored and is the magnitude-vs-route tradeoff per §10.5.
- T2D context: transition to semaglutide (Ozempic 1.0 or 2.0 mg) or tirzepatide (Mounjaro — SURPASS-2 head-to-head tirzepatide HbA1c reduction approximately 2.3% at 15 mg vs semaglutide 1 mg approximately 1.9% at Week 40); or add SGLT2 inhibitor; or add insulin per ADA/EASD progression algorithm.
- CV-risk context: orforglipron-specific cardiovascular outcomes evidence base is pre-readout; non-response framing at the individual-patient level over short observation windows is typically not applicable to CV-risk indication. Class-comparator anchors (SELECT semaglutide; SOUL oral semaglutide) inform the transition decision if a cardiovascular indication is the primary clinical context.
- MASH / MASLD context: orforglipron-specific MASH evidence base is research-direction-stage; clinician judgment for transition to semaglutide (ESSENCE PMID 40305708 — FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH August 2025) or to resmetirom (Madrigal; FDA-approved for marketing claims 2024 for non-cirrhotic F2/F3 MASH; non-GLP-1 mechanism class). Hepatology co-management as appropriate.

7.5 Worked example — orforglipron non-responder algorithm

An adult on anticipated orforglipron 36 mg (target dose for the anticipated CWM indication), Month 6 on maintenance dose, has lost 2.8 kg from baseline (approximately 3% of starting weight) — below the ATTAIN-1 effect-size anchor of approximately −11.2% at 72 weeks and below the 5%-at-Month-6 trajectory marker.

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; investigational-supply tracking (or prescription-refill audit post-approval) confirms no gaps. Confirmed pseudo-non-response is ruled out.

Step 2 — trajectory-context. Patient’s curve at Month 6 (3% loss) is below the ATTAIN-1 25th percentile trajectory at Month 6 (approximately 6-7% loss extrapolated from the 36 mg dose-arm 72-week effect of −11.2%). Not on-trajectory.

Step 3 — dose attainment. Patient is on 36 mg target dose; no further titration available within the orforglipron Phase 3 dose-arm framework.

Step 4 — phenotype reassessment. Patient is a representative ATTAIN-1 enrollment phenotype (obesity without T2D, BMI ≥30); response below the typical ATTAIN-1 trajectory suggests individual-patient response variability within the trial-population effect-size distribution.

Step 5 — non-response confirmed; CWM context decision branches.

5a. Transition to semaglutide (Wegovy 2.4 mg). FDA-approved for marketing claims for CWM 2021; STEP-1 effect-size approximately −14.9% at 68 weeks in non-diabetic obesity (per Wilding 2021 NEJM PMID 33567185). Pattern V direction-of-effect: semaglutide effect-size at peer-reviewed Phase 3 is meaningfully larger than orforglipron ATTAIN-1 36 mg effect-size at peer-reviewed Phase 3.

5b. Transition to tirzepatide (Zepbound). FDA-approved for marketing claims for CWM 2023; SURMOUNT-1 effect-size approximately −22.5% at 15 mg / 72 weeks in non-diabetic obesity. Pattern V direction-of-effect: tirzepatide effect-size is the largest in obesity pharmacotherapy class as of 2026-05-13; cross-trial comparison anchored. SURMOUNT-5 head-to-head tirzepatide −20.2% vs semaglutide −13.7% at week 72 (Aronne 2025 NEJM PMID 40353578) confirms tirzepatide head-to-head superiority over semaglutide for CWM.

5c. Intensification of behavioral / nutritional / activity program. The STEP-3 trial demonstrated that intensive behavioral therapy plus semaglutide produces greater weight loss than semaglutide alone — Pattern V direction-of-effect: behavioral intensification is effect-additive, not effect-substitutive. For this patient on orforglipron, intensification before molecule transition may be appropriate.

Pattern Z calibration anchor applied at §7.5 (Anchor 4 mirror — multi-dimensional comparator framing). The decision among 5a / 5b / 5c is patient-anchored, not clinician-mandated. Counseling beats (§10.5) frame the options without steering — present the trial-program-anchored effect-size estimates for each option, present the trade-offs (cost, AE-profile, adherence-complexity, route — injectable for semaglutide / tirzepatide vs oral for orforglipron continued; magnitude — semaglutide / tirzepatide larger effect-size vs orforglipron’s documented effect-size at the trial-population level), and the clinician-patient decision is patient-preference-driven within the medically reasonable options. The patient’s original route-preference rationale (oral over injectable on practical-logistical grounds — §1.5) is a real and legitimate factor in the transition decision; magnitude-vs-route tradeoff per §10.5 anchors the conversation.

8. Discontinuation and tapering

8.1 Purpose

Define when to stop orforglipron, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory in CWM indications. Section 8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

Confirmed contraindication discovery (e.g., new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM indication). §2.4 hard contraindications are immediate-discontinuation triggers.
Severe AE attributable to orforglipron (confirmed acute pancreatitis, confirmed NAION, severe hypersensitivity reaction, persistent significant hepatic transaminase elevation per the Pattern N.1 first-pass-metabolism surveillance framework — §6.12 + §6.13). §6 AE-class-specific discontinuation triggers.
Indication remission or resolution (T2D HbA1c sustained below target with weight stable; rare but documented; relevant for the anticipated T2D indication).
Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway, not to override the patient’s decision.
Cost / access barriers. Pre-FDA-approval state: post-approval pricing TBD per Lilly commercial decisions; payer coverage variable. Pattern Z calibration applies — present cost / access reality factually, not as steering.
Pre-conception planning for reproductive-age patients on CWM indication: discontinuation with the §8.4 washout arithmetic. This is anticipatory discontinuation, not reactive.
Trial-enrollment completion for patients on the active Phase 3 program (ATTAIN-MAINTAIN, GLOW-2, ACHIEVE-3, ACHIEVE-4, ACHIEVE-J) once their trial protocol completes.

8.3 How to taper — molecule-specific tapering considerations

For orforglipron in CWM indication: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven pharmacokinetic washout occurs at fixed kinetics regardless of taper schedule (orforglipron plasma elimination half-life approximately 29 hours per canonical §1.3; approximately 5 half-lives ≈ 6 days for substantial pharmacokinetic clearance). However, gradual dose reduction is the protocol-recommended pattern for two reasons:

Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation (the patient’s reduced appetite signal returns gradually, allowing meal-size and meal-composition adaptation in parallel).
AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these.

The anticipated taper pattern for orforglipron CWM: 36 mg → 12 mg × 4 weeks → 6 mg × 4 weeks → discontinue. Total anticipated taper period approximately 8 weeks (shorter than the semaglutide CWM taper of ~12 weeks because the orforglipron half-life is ~29 hours vs ~1 week for semaglutide; the pharmacokinetic clearance window is correspondingly shorter). For the anticipated T2D indication, taper: 36 mg → 12 mg × 4 weeks → 3 mg × 4 weeks → discontinue. Pattern AA precision: this is anticipated framework based on the Phase 3 dose-arm structure; label-recommended specifics emerge from FDA approval.

8.4 Pre-conception washout arithmetic — orforglipron pharmacokinetic considerations

Orforglipron has a plasma elimination half-life of approximately 29 hours (canonical §1.3). Approximately 5 half-lives are required for >95% pharmacokinetic clearance — approximately 6 days. Conservative pharmacodynamic margin extends the practical washout to approximately 14-21 days; the eventual product label will provide the specific pre-conception discontinuation window. Anticipated pre-conception discontinuation window: approximately 2-4 weeks (vs approximately 8 weeks for semaglutide and approximately 4 weeks for tirzepatide — the orforglipron oral non-peptide platform half-life is substantially shorter than peptide GLP-1 RA half-lives, which translates to a shorter pharmacokinetic-clearance washout window).

This anticipated pre-conception window is the operational counseling beat for reproductive-age patients on anticipated orforglipron CWM indication — §10.4 counseling beats anchor to this arithmetic with Pattern Z calibration anchor 3 (pregnancy planning) precision.

8.5 Post-discontinuation weight-regain framing

The trial-program data on post-orforglipron-discontinuation weight regain is currently limited given pre-approval status. ATTAIN-MAINTAIN (NCT05931380; obesity Phase 3 maintenance trial; readout pending) is the dedicated Phase 3 maintenance trial that will provide the post-active-treatment weight-regain trajectory anchored to orforglipron. Class-level data from STEP-5 semaglutide long-term maintenance and SURMOUNT-4 tirzepatide maintenance designs apply via mechanism-class inheritance: discontinuation after target-dose achievement is followed by progressive weight regain across approximately 12 months, with patients regaining a substantial fraction of the lost weight by 12 months post-discontinuation per the class-level pattern.

The protocol framing in counseling (§10) does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention. Patients considering discontinuation are counseled on the expected regain trajectory and on the re-initiation pathway if regain occurs and warrants re-treatment.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: typically re-titration from the starting dose is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior maintenance dose is not recommended due to GI AE recurrence risk. §4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2, and pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged. Pending orforglipron regulatory status at the time of consideration — if the discontinuation occurred in the pre-approval state (trial enrollment, off-label investigational-supply, or compounded sourcing) and re-initiation is being considered post-approval, the regulatory framework shifts to FDA-approved-for-marketing-claims prescribing per indication-specific label.

8.7 Worked example — orforglipron discontinuation scenarios

Scenario A — pre-conception planning. A 32-year-old female on anticipated orforglipron 36 mg, Month 14 on maintenance dose, has lost 10.5 kg (approximately 11% of starting weight, on-trajectory per ATTAIN-1 36 mg / 72 weeks effect-size) and is planning conception in approximately 4 months. Counseling beat: discuss the anticipated 2-4 week pre-conception window per the orforglipron ~29-hour half-life arithmetic (substantially shorter than semaglutide’s ~8-week label-recommended window per the canonical Anchor 3 framing); plan taper start approximately 2 months from now (8-week taper period, then approximately 2-4 week post-discontinuation pharmacokinetic-and-margin window). Pattern Z calibration anchor 3 applies — pregnancy-planning counseling presents the pharmacokinetic facts (~29-hour half-life, ~6-day pharmacokinetic clearance, anticipated 2-4 week pre-conception window) and the post-discontinuation weight-regain trajectory without steering toward continuation or discontinuation; the patient’s reproductive-planning decision is patient-anchored. The shorter half-life and shorter pre-conception window is a Pattern N.1 small-molecule platform consequence — peptide GLP-1 RA half-lives (~1 week semaglutide; ~5 days tirzepatide) require longer pre-conception windows; orforglipron’s ~29-hour half-life is shorter.

Scenario B — patient-preference discontinuation at Month 18. An adult on anticipated orforglipron 36 mg, has lost weight on-trajectory and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue. Counseling beat: discuss the class-level post-discontinuation weight-regain trajectory data (class-level pattern from STEP-5 / SURMOUNT-4 — approximately two-thirds of lost weight typically regained by 12 months post-discontinuation per the class-level mechanism); orforglipron-specific data emerges from ATTAIN-MAINTAIN readout pending; re-initiation pathway is available if regain occurs and is clinically meaningful. Protocol taper: 36 mg → 12 mg × 4 weeks → 6 mg × 4 weeks → off. Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP; re-initiation decision at any monitoring visit if regain warrants and patient agrees.

Scenario C — confirmed acute pancreatitis (per §6.4 case). Permanent discontinuation. No taper — abrupt discontinuation appropriate given the AE-attributable etiology. Transition to non-GLP-1 alternative per indication.

Scenario D — new pregnancy on protocol. A 29-year-old female on anticipated orforglipron 36 mg discovers pregnancy at approximately 6 weeks gestation. CWM-indication orforglipron is a class-level mechanism-grounded contraindication in pregnancy (§2.4). Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (approximately 6 days for ~95% clearance plus pharmacodynamic margin) is documented for the obstetrics record. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

Scenario E — Phase 3 trial-enrollment completion. A patient on an active Phase 3 trial (e.g., ATTAIN-MAINTAIN, GLOW-2, ACHIEVE-3) completes the trial protocol and transitions out of trial-supplied orforglipron. Pre-approval state: post-trial access pathways are clinician-judgment off-label investigational-supply if available, compounded sourcing per §10.3 framing, or transition to FDA-approved-for-marketing-claims alternatives (semaglutide, tirzepatide, liraglutide) until orforglipron approval landscape clarifies. Anticipated post-approval state: transition to FDA-approved-for-marketing-claims orforglipron prescribing per the eventual product label.

Pattern Z calibration anchor 3 precision in §8.7 (Scenario A). Pregnancy-planning counseling presents the ~29-hour pharmacokinetic half-life, the 5-half-life clearance arithmetic, the anticipated 2-4 week pre-conception window, and the post-discontinuation weight-regain trajectory — facts that the patient uses to make her reproductive-and-treatment-planning decision. The protocol does not steer the patient toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides. The Pattern N.1 small-molecule platform consequence — shorter half-life = shorter washout window vs peptide GLP-1 RAs — is presented as a factual platform difference, not as a steering advantage.

9. Combination rules

9.1 Purpose

Define what stacks with orforglipron, what is contraindicated in combination, and the rationale for each combination category. Section 9 is the protocol’s bridge to Module 5.12 Combination Protocols and to the lean-mass-stack protocols (M5.5 Tesamorelin / AOD-9604; M5.6 Lean Mass / CJC-Ipamorelin / MOTS-c). The section is structured by combination class — within-Module-5-combinations (GLP-1 RA + amylin analog, GLP-1 RA + GIP — n/a since orforglipron is a single GLP-1R agonist, GLP-1 RA + SGLT2 inhibitor, GLP-1 RA + insulin), cross-Module-combinations (GLP-1 RA + lean-mass peptides per Pattern N.1: those are peptides; orforglipron is a small molecule — chemistry-platform-distinct combination consideration), and contraindicated combinations.

Pattern W cross-section consistency applies: every combination in this section is reconciled with §2 (a combination cannot include an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors).

9.2 Within-Module-5 combinations

The principal within-Module-5 combinations involve combining mechanism classes within the metabolic axis:

Orforglipron + SGLT2 inhibitor (T2D indication context). Class-additive HbA1c and cardiovascular / kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context. Mechanism rationale: SGLT2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects; the combination is broadly supported by individual-agent CVOT and KOOT data from the FDA-approved-for-marketing-claims class members. For orforglipron, the SGLT2 inhibitor combination is not contraindicated on mechanism grounds; Phase 3 ACHIEVE program enrollment may include SGLT2 inhibitor background therapy per the trial protocol. Pattern AA precision: orforglipron + SGLT2 inhibitor is research-state-anchored to individual-agent data; no orforglipron-specific head-to-head combination RCT exists as of 2026-05-13.
Orforglipron + insulin (T2D advanced). Common in T2D with progressed beta-cell failure where GLP-1 RA monotherapy is insufficient. §6.7 hypoglycemia management applies; concurrent insulin dose typically reduced approximately 20% at orforglipron initiation per the class-level GLP-1 RA + insulin framework. TRANSCEND-T2D-3 equivalent indication scope for orforglipron is research-state-emerging.
Orforglipron + metformin. Standard T2D background therapy; well-tolerated combination per the broader GLP-1 RA class; no contraindication.
Orforglipron + sulfonylurea (relative — combination produces excess hypoglycemia risk). Sulfonylurea should be reduced or discontinued at orforglipron initiation per §6.7.
Orforglipron + cagrilintide (amylin analog). Phase 3 program for orforglipron does not include cagrilintide combination as of 2026-05-13. Class-comparator: CagriSema (cagrilintide + semaglutide fixed-combination subcutaneous-weekly product) Phase 3 readout per the REDEFINE program (Davies REDEFINE-2 PMID 40544432; Garvey REDEFINE-1 PMID 40544433). Orforglipron + cagrilintide combination is not investigated as of 2026-05-13; off-label combination per Pattern Z anchor 5 framing if considered clinically.
Orforglipron + DPP-4 inhibitor: not indicated. Mechanistic overlap (DPP-4 inhibitor preserves endogenous GLP-1; redundant with exogenous GLP-1 RA single-receptor agonism — applies equally to non-peptide and peptide GLP-1 RAs at the receptor activation level). Avoid co-prescribing.

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the GLP-1 RA / amylin / GIP / glucagon metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss.

Pattern N.1 LOAD-BEARING consideration: orforglipron is a non-peptide small molecule; the cross-Module lean-mass / body-composition stacks are predominantly peptide-class. The chemistry-platform difference (non-peptide oral small molecule + injectable peptide stack) is operationally a hybrid-platform consideration distinct from the all-peptide combinations (e.g., semaglutide + CJC-Ipamorelin all-injectable-peptide stack).

Orforglipron + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, monitoring (IGF-1 anchored), and AE-class considerations. Pattern N.1 note: CJC-1295 and Ipamorelin are peptides — they belong in the Peptides folder path; orforglipron is a small molecule in the Small-Molecules folder path. The combination is a non-peptide-oral + peptide-injectable hybrid-platform combination. Pre-FDA-approval state for orforglipron amplifies the off-label framing per Pattern Z anchor 5.
Orforglipron + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data; clinician judgment within Module 5.6 stack framing. Pattern AA precision: do not state “approved” for an investigational peptide.
Orforglipron + Tesamorelin (FDA-approved for marketing claims for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with orforglipron-mediated weight loss, visceral-adiposity-targeted effects may be additive. Module 5.5 Tesamorelin canon documents trial-program data and off-label clinical use. Pattern AA precision: the off-label-for-non-HIV-visceral-adiposity framing is explicit, not implicit.
Orforglipron + GHK-Cu (skin / connective-tissue peptide). Cross-Module — GHK-Cu is a Module 5.7 (skin-elasticity, post-weight-loss skin tone) topical or injectable application. Pattern V direction-of-effect: GHK-Cu trial-program data are limited for the post-weight-loss-skin indication specifically; clinician judgment with patient-anchored expectations. Pattern Z.research-precision applies: GHK-Cu evidence base is in vitro fibroblast collagen-synthesis + animal wound-healing + cosmetic-industry topical efficacy + practitioner clinical experience; RCT-level human evidence for post-weight-loss-laxity-specific indication is research-state-incomplete.

9.4 Contraindicated combinations

Orforglipron + DPP-4 inhibitor (§9.2 — not contraindicated by safety; contraindicated by lack of additive benefit and by mechanistic redundancy at the GLP-1R activation level).
Orforglipron + injectable semaglutide / oral semaglutide (Rybelsus) / liraglutide / dulaglutide / exenatide-class concurrent (avoid; redundant within-class single GLP-1R agonism with additive AE profile and no demonstrated additive benefit; transition between agents per §7 non-response algorithm, not co-administration).
Orforglipron + tirzepatide concurrent (avoid; tirzepatide is a GLP-1/GIP coagonist; the GLP-1R component is redundant with orforglipron at the receptor activation level; the GIPR component adds dual-mechanism considerations but the combination is not investigated and is not a within-class combination practice; transition between agents, not co-administration).
Orforglipron + retatrutide concurrent (avoid; retatrutide is a GLP-1/GIP/glucagon triagonist; the GLP-1R component is redundant; combination not investigated; transition between agents per §7 if the clinical decision is to attempt the triagonist mechanism class).
Orforglipron + sulfonylurea at full sulfonylurea dose (relative — combination produces excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at orforglipron initiation per §6.7).
Orforglipron + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile and may impair absorption of concurrent oral medications).
Orforglipron + concurrent strong CYP3A4 inducer (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) (Pattern N.1 platform-specific — small-molecule CYP metabolism considerations per §6.10; specific recommendations per eventual product label).

9.5 Worked example — orforglipron combination scenarios

Scenario A — orforglipron + CJC-1295 / Ipamorelin stack (M5.6 v3) hybrid-platform combination. A 47-year-old male, baseline BMI 36, on anticipated orforglipron 36 mg, Month 8 on maintenance dose, has lost weight on-trajectory per ATTAIN-1 with DEXA showing higher-than-typical proportion of lost mass as lean mass (above the 20-25% typical proportion for unsupplemented weight loss). Add M5.6 v3 stack — CJC-1295 + Ipamorelin per the M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) applies — counseling beat states explicitly that CJC-1295 and Ipamorelin are not FDA-approved-for-marketing-claims for this indication and that the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data. Pattern N.1 hybrid-platform consideration: orforglipron is non-peptide oral small molecule; CJC-Ipamorelin is peptide injectable stack; the combination is a non-peptide-oral-plus-peptide-injectable hybrid-platform combination operationally distinct from all-peptide combinations (e.g., semaglutide + CJC-Ipamorelin).

Scenario B — orforglipron + SGLT2 inhibitor (T2D advanced). A 61-year-old male with T2D + CKD eGFR 42, on anticipated orforglipron 36 mg with HbA1c 7.4 (above individualized target 7.0); add empagliflozin 10 mg daily per ADA/EASD T2D-progression algorithm. Combination is well-supported by individual-agent CVOT / KOOT data from the FDA-approved-for-marketing-claims class members and by additive HbA1c reduction. Monitoring: eGFR at 2 weeks post-SGLT2 initiation (typical small reversible eGFR decline expected), then routine quarterly per §5. Pattern V direction-of-effect: combination is effect-additive on HbA1c, on kidney composite, and on CV events per individual-agent data from the FDA-approved comparator class; cross-class combination supported by clinical-practice and by individual-agent trial data, not by head-to-head orforglipron + SGLT2 inhibitor combination RCT (which does not exist as of 2026-05-13).

Scenario C — orforglipron + semaglutide concurrent (contraindicated). A patient seeking dual-class metabolic intensification. Counseling beat: combination not indicated — these are within-class redundant agents at the GLP-1R activation level (orforglipron’s non-peptide binding mode produces equivalent GLP-1R activation downstream; redundant with semaglutide’s peptide GLP-1R activation); transition between them (§7 non-response algorithm) is the appropriate decision, not co-administration. Effect-size context: if semaglutide non-response is the clinical context, orforglipron may be considered for the route-preference phenotype-targeting consideration (Pattern N.1 — oral non-peptide platform vs injectable peptide) but the magnitude-vs-route tradeoff per §10.5 anchors the decision honestly.

Pattern W cross-check at §9.5. Each combination above is reconciled with §2 (no patient enters a combination with a contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content for orforglipron — the conversations the clinician has with the patient at each protocol phase. Section 10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration); the counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

The five Pattern Z calibration anchors are verbatim examples from semaglutide v1.0-final (Sections 8.3.2, 12.10-Pattern-2, 6.8, 12.10-Pattern-6, 12.10-Pattern-8), established as the calibration baseline post-iteration-4 verification on 2026-05-11. The canonical source — including the verbatim anchor text and the verbatim anti-anchor examples that failed Pattern Z — is /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. The five anchors and orforglipron-specific calibration:

Anchor 1 — Compounded-formulation operational characteristics. LEADS with what compounded option IS (real-world clinical option used by substantial patient population; 503A / 503B pathways); operational characteristics framed neutrally; differences from FDA-approved framed as “factual scope, not deficit framing.” Orforglipron-specific calibration: Anchor 1 is structurally adapted for the pre-FDA-approval state — compounded orforglipron operates outside the post-FDA-approval 503A/503B framework (canonical §8.3.2); Pattern N.1 small-molecule chemistry differs from the predominantly peptide-compounding 503A/503B GLP-1 RA market specialization (USP <795> non-sterile small-molecule vs USP <797> sterile peptide injectable). See §10.3.
Anchor 2 — Compounded vs FDA-approved patient-counseling beat. Orforglipron-specific calibration: Anchor 2 is reframed pre-approval — no FDA-approved-for-marketing-claims orforglipron formulation exists to compare compounded against. The conversation reframes per canonical §8.3.2 as research-state-factual observation about why compounded orforglipron has substantially limited compounding-pharmacy market presence; if/when a compounded orforglipron market emerges post-approval, Anchor 1+2 full framing applies. See §10.3.
Anchor 3 — Pregnancy section research-state-leading structure. LEADS with human pregnancy-exposure data (Parker 2025 PMID 40329607), not PK arithmetic or label-status. Orforglipron-specific calibration: the ~29-hour orforglipron half-life produces a shorter pre-conception washout window (~2-4 weeks vs ~8 weeks for semaglutide) — Pattern N.1 small-molecule platform consequence; presented as factual platform difference, not steering. See §10.4.
Anchor 4 — Multi-dimensional comparator framing. Multi-dimensional fact presentation across 9+ dimensions for the comparator conversation. Orforglipron-specific calibration (LOAD-BEARING for this protocol): ATTAIN-1 36 mg −11.2% body weight reduction is meaningfully less than STEP-1 semaglutide (~−14.9%) and SURMOUNT-1 tirzepatide (~−22.5%); the clinical decision is a magnitude-vs-route tradeoff — the counseling beat presents this tradeoff honestly without steering toward injectables on magnitude grounds nor toward orforglipron on route grounds. The Pattern N.1 oral non-peptide platform advantages (no food/water timing restriction; room-temperature storage; chemical-synthesis manufacturing scalability) are one of nine dimensions in the multi-dimensional fact presentation, not the only dimension. See §10.5.
Anchor 5 — Off-label / extrapolation framing. Orforglipron-specific calibration: §10.6 is the dominant subsection for orforglipron pre-approval state. Because orforglipron has no FDA approval as of 2026-05-13, every clinical use of orforglipron today is either (a) enrollment in an active Phase 3 trial, (b) clinician-judgment off-label use of investigational supply where research-protocol acquisition pathway exists, or (c) gray-market / research-chemical-vendor sourcing operating outside the post-FDA-approval 503A/503B compounding framework. See §10.6.

Compound-specific counseling beats verify against verbatim canonical anchors. This section’s production includes a verbatim-diff check against the canonical anchor file at PSV iteration.

10.2 Initiation conversation (anticipated post-approval framework + current trial-enrollment / investigational-supply framework)

The initiation conversation occurs at pre-treatment workup completion / §4 initiation visit. Required counseling beats:

What orforglipron is (Pattern AA-precise framing): an oral non-peptide small-molecule GLP-1 receptor agonist (Pattern N.1) in active Phase 3 development under the ATTAIN (obesity) and ACHIEVE (T2D) programs. Not FDA-approved as of 2026-05-13. Three published primary Phase 3 trials: ATTAIN-1 (obesity), ATTAIN-2 (obesity + T2D), ACHIEVE-1 (T2D). FDA NDA submission anticipated end-2025 obesity / 2026 T2D per Eli Lilly investor disclosures; anticipated approval H1 2027 conditional on FDA review timelines. Current access pathways: active Phase 3 trial enrollment if eligible; clinician-judgment off-label use of investigational supply where research-protocol acquisition pathway exists.
What it does for the patient’s anticipated indication (Anchor 4 multi-dimensional framing): expected effect-size with Phase 3 trial-anchor precision (ATTAIN-1 36 mg −11.2% body weight reduction at 72 weeks in obesity without T2D, per-arm absolute change; ACHIEVE-1 HbA1c absolute reductions −1.24% to −1.48% across 3/12/36 mg in T2D); comparator framing if patient has alternative-class options.
The titration schedule (§4): multi-step ascending-dose titration over 12-29 days per the Phase 3 protocols; target 36 mg as the highest-effect-size dose; lower-dose-arm maintenance (12 mg or 6 mg in CWM; 12 mg or 3 mg in T2D) as tolerability-preferred maintenance option; titration timeline is adjustable to tolerability.
The AE profile expected at each titration step (§6.2 GI class anticipatory framing): nausea is anticipated, typically attenuates, management strategies — non-pharmacologic first, ondansetron PRN second. Reassurance that AE-emergence is not failure but is anticipated. Orforglipron-specific addition: first-pass-metabolism surveillance (ALT/AST monitoring) is part of standard monitoring per Pattern N.1 platform consideration (§6.12).
The pre-conception planning beat for reproductive-age patients (Anchor 3 — LEADS with Parker 2025 human research-state data per §6.8): pharmacokinetic washout arithmetic (~29-hour half-life; ~6-day pharmacokinetic clearance; anticipated 2-4 week pre-conception window — a Pattern N.1 small-molecule platform consequence that is meaningfully shorter than semaglutide’s ~8-week pre-conception window).
Access-pathway realities (Anchor 5 — orforglipron-specific dominant calibration per §10.6): present access pathways factually (Phase 3 trial enrollment; clinician-judgment off-label use of investigational supply via research-protocol channels; compounded orforglipron from research-chemical / gray-market sources per §10.3 framing); pre-FDA-approval state is the dominant calibration surface.
The magnitude-vs-route tradeoff (Anchor 4 — orforglipron-specific calibration per §10.5): explicit acknowledgment that ATTAIN-1 36 mg −11.2% is meaningfully less than STEP-1 semaglutide (~−14.9%) and SURMOUNT-1 tirzepatide (~−22.5%); the platform advantages (oral; no food/water timing restriction; room-temperature storage) are factual; the clinical decision is patient-anchored across multiple dimensions.
What the patient signals back if any concern emerges (escalation pathway): symptoms that warrant in-person evaluation within 48 hours (severe persistent abdominal pain, vomiting blood, acute vision change per the §6.5 NAION class-context framework, suspected hepatic transaminase elevation per §6.12, signs of severe AE).

10.3 Compounded-orforglipron counseling — Anchor 1 + Anchor 2 orforglipron-specific calibration (pre-FDA-approval state with Pattern N.1 platform-class considerations)

Orforglipron-specific calibration of Anchors 1 + 2 per canonical §8.3.2 research-state-factual observation. Compounded orforglipron has substantially limited compounding-pharmacy market presence as of 2026-05-13.

What compounded orforglipron IS in the pre-FDA-approval state (research-state-factual observation framing per canonical §8.3.2; Pattern Z compliant — leads with what compounded orforglipron IS in the pre-approval landscape, not with what it isn’t):

Compounded orforglipron is a real-world phenomenon at substantially limited scale in research-chemical and gray-market vendor channels. Patients accessing compounded orforglipron typically (a) anticipate orforglipron’s FDA approval based on the ATTAIN + ACHIEVE Phase 3 readout schedule and want early access; (b) have a specific platform preference for oral non-peptide administration vs the FDA-approved-for-marketing-claims injectable peptide GLP-1 RA options or vs Rybelsus oral peptide via SNAC; (c) participate in research-direction-tracking or peptide-research-community contexts where the early-access pathway is normalized.

Specific operational reasons for the substantially limited market presence (factual scope, not deficit framing — per canonical §8.3.2 Option B):

(a) Pre-FDA-approval status. No FDA-declared shortage period to enable 503A/503B compounding during shortage; the compounded peptide GLP-1 RA market emergence was driven by 2022-2024 FDA-declared semaglutide and tirzepatide shortages, not by general 503A compounding outside shortage periods. The pre-approval status raises the regulatory exposure threshold for compounding pharmacies that would compound an unapproved drug under FDA Compliance Policy Guide 460.200 + state board of pharmacy regulations.
(b) Non-peptide small-molecule chemistry — different compounding-pharmacy specialization (Pattern N.1 LOAD-BEARING). Compounding-pharmacy infrastructure for the GLP-1 RA market is predominantly peptide-compounding capacity oriented around USP <797> sterile peptide injectable compounding (compounded peptide GLP-1 RAs are reconstituted lyophilized peptide for subcutaneous injection). Small-molecule compounding chemistry (USP <795> non-sterile compounding) is a different compounding-pharmacy specialization — different APIs, different formulation processes, different sourcing supply chains, different equipment, different staff training. The 503A/503B compounding pharmacies that emerged in the 2022-2024 GLP-1 RA shortage period are predominantly peptide-compounding specialists, not small-molecule compounding specialists. The non-peptide small-molecule chemistry of orforglipron places it outside their core specialization.
(c) API source-supply constraints. Orforglipron active pharmaceutical ingredient (API) is Eli Lilly proprietary investigational supply. Non-Lilly API sources are limited compared to the peptide-API supply chains where research-grade peptide synthesis supports the compounded peptide GLP-1 RA market.
(d) Regulatory exposure asymmetry. The combination of pre-approval status + non-peptide compounding specialization mismatch + API source-supply constraints together substantially reduce the supply-side market presence of compounded orforglipron compared to compounded peptide GLP-1 RAs.

Pattern Z compliant patient-counseling beat for the compounded-orforglipron question:

“Compounded orforglipron isn’t a meaningful clinical option right now — there’s substantially limited compounding-pharmacy market presence for the compound due to a combination of pre-approval status (no FDA shortage period to enable 503A/503B compounding), the non-peptide small-molecule chemistry being outside the core specialty of most pharmacies that compound GLP-1 RAs (which are predominantly peptide-compounding specialists), and API source-supply constraints. If we see a compounded market emerge post-approval, we can evaluate that the same way we evaluate compounded options for any compound — by looking at the specific compounding pharmacy’s quality practices, certificate of analysis, sterility testing per USP standards where applicable, and verification. For now, the practical pre-approval access options are active Phase 3 trial enrollment if you meet enrollment criteria, clinician-judgment off-label use of investigational supply where a research-protocol pathway exists, or starting one of the FDA-approved options now and revisiting orforglipron post-approval.”

What Pattern Z compliance does NOT mean. It does not mean presenting compounded orforglipron as equivalent to investigational-supply orforglipron in every dimension; it does not mean presenting investigational supply as exclusively legitimate. It means presenting both as factual categories with their respective trade-offs, allowing the patient and clinician to make a choice anchored to the patient’s circumstances (access, platform preference, sourcing-vendor quality evaluation, regulatory-status comfort).

10.4 Pregnancy-planning conversation (Anchor 3 — LEADS with human research-state data; Pattern N.1 shorter-half-life platform consequence)

For reproductive-age patients on anticipated orforglipron use (trial enrollment, investigational-supply off-label, or anticipated post-approval). The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or class-level contraindication framing — this lead-framing discipline is the core of canonical Anchor 3 (verbatim sema §6.8 calibration).

Required counseling beats:

Human pregnancy-exposure data — Parker D et al. Diabetes Obes Metab 2025 Aug PMID 40329607. Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries. Orforglipron-specific data within this pooled dataset is sparse given the pre-FDA-approval status; Phase 3 trial-population unplanned-pregnancy event reporting will add orforglipron-specific data as readouts publish; dedicated post-approval pregnancy registry development is anticipated per Lilly disclosures.
Pharmacokinetic facts (post-research-state-lead; Pattern N.1 platform consequence). Orforglipron plasma elimination half-life approximately 29 hours; approximately 5 half-lives (approximately 6 days) for >95% pharmacokinetic clearance. With a conservative pharmacodynamic margin, approximately 2-4 week pre-conception discontinuation window — a Pattern N.1 small-molecule platform consequence that is meaningfully shorter than semaglutide’s ~8-week label-recommended pre-conception window (semaglutide half-life ~1 week) and meaningfully shorter than tirzepatide’s ~4-week pre-conception window (tirzepatide half-life ~5 days). The shorter half-life is presented as a factual platform difference, not as a steering advantage.
Standard practice framing. Discontinuation upon pregnancy awareness for orforglipron users (trial-enrollment patients: per trial-protocol discontinuation criteria; off-label investigational-supply patients: per clinician-judgment within informed-consent and class-level GLP-1 RA pregnancy contraindication framework).
Animal data context. Class-level GLP-1 RA Category-X-equivalent contraindication framing is class-level standard practice; animal data does not always translate to human teratogenicity profile; the Parker 2025 human pooled data shows reassuring early signal but is the load-bearing human evidence as of 2026-05-13.
Post-discontinuation weight-regain trajectory. Class-level GLP-1 RA evidence base; orforglipron-specific evidence emerges from ATTAIN-MAINTAIN Phase 3 trial.
The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1-2 years; some within the next decade; some are not planning conception at all but want awareness of the discontinuation arithmetic in case planning changes. The counseling beat presents the facts; the timing decision is patient-anchored.
Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met and pending orforglipron regulatory status at the time of consideration.

Pattern Z anchor 3 compliance verification. This counseling beat LEADS with Parker 2025 human research-state data. PK facts, animal data + class-level Category-X-equivalent contraindication framing, and post-discontinuation weight-regain trajectory appear AFTER the research-state lead, scoped as factual context. The patient’s decision is patient-anchored. The Pattern N.1 platform consequence (shorter half-life → shorter washout window) is presented as a factual platform difference, not as a steering advantage.

10.5 Comparator conversation (Anchor 4 — multi-dimensional fact presentation; MAGNITUDE-VS-ROUTE TRADEOFF LOAD-BEARING for orforglipron)

For patients with within-class alternative considerations (e.g., orforglipron vs injectable semaglutide vs oral Rybelsus semaglutide vs tirzepatide vs liraglutide for CWM or T2D contexts). Canonical Anchor 4 requires multi-dimensional fact presentation across 9+ dimensions — single-dimension comparison (weight magnitude alone, or route alone) is the canonical pre-patch anti-anchor that steered patients in either direction.

Magnitude-vs-route tradeoff (LOAD-BEARING for this protocol). Orforglipron offers oral non-peptide small-molecule platform advantages (route) at meaningfully less weight-loss magnitude than injectable peptide alternatives. The counseling beat presents this tradeoff honestly — the protocol does NOT steer toward injectables on magnitude grounds, and does NOT steer toward orforglipron on route grounds. The patient and clinician decide which factors matter most.

Pattern AA-precise comparator framing for orforglipron pre-approval state. Cross-trial comparison of orforglipron (Phase 3 published readouts: ATTAIN-1, ATTAIN-2, ACHIEVE-1; pre-FDA-approval) vs FDA-approved-for-marketing-claims comparators (semaglutide STEP / SELECT / SUSTAIN / ESSENCE / FLOW; tirzepatide SURMOUNT / SURPASS; liraglutide SCALE / LEADER) requires explicit Pattern AA caveats. The peer-reviewed cross-trial effect-size data, with epistemic-status framing per Pattern AA discipline:

Compound	Trial	Effect	Dose / duration	Epistemic status
Orforglipron (small molecule oral)	ATTAIN-1 Phase 3 obesity (Wharton 2025 NEJM PMID 40960239)	−11.2% body weight (per-arm absolute change; placebo −2.1%; treatment effect ~−9.1 pp)	36 mg daily oral / 72 weeks	peer-reviewed Phase 3
Orforglipron	ATTAIN-1 Phase 3 obesity	−8.4% body weight	12 mg daily oral / 72 weeks	peer-reviewed Phase 3
Orforglipron	ATTAIN-1 Phase 3 obesity	−7.5% body weight	6 mg daily oral / 72 weeks	peer-reviewed Phase 3
Orforglipron	ACHIEVE-1 Phase 3 T2D (Rosenstock 2025 NEJM PMID 40544435)	HbA1c −1.24% to −1.48% across dose arms vs placebo −0.41%	3/12/36 mg daily oral / 40 weeks	peer-reviewed Phase 3
Semaglutide injectable (Wegovy)	STEP-1 Phase 3 (Wilding 2021 NEJM PMID 33567185)	−14.9% body weight	2.4 mg SC weekly / 68 weeks	peer-reviewed Phase 3 (FDA-approved CWM 2021)
Semaglutide injectable	SELECT Phase 3 CVOT (Lincoff 2023 NEJM PMID 37952131)	MACE HR 0.80	2.4 mg SC weekly / 39.8 mo median	peer-reviewed Phase 3 (FDA-approved CV-risk-in-obesity-without-T2D 2024)
Semaglutide oral via SNAC (Rybelsus)	PIONEER program	HbA1c reductions in T2D	7/14/25 mg daily oral with SNAC	peer-reviewed Phase 3 (FDA-approved T2D 2019; PIONEER PLUS 25 mg 2025)
Tirzepatide (Zepbound)	SURMOUNT-1 Phase 3 obesity (Jastreboff 2022 NEJM)	−22.5% body weight	15 mg SC weekly / 72 weeks	peer-reviewed Phase 3 (FDA-approved CWM 2023)
Tirzepatide vs Semaglutide head-to-head	SURMOUNT-5 (Aronne 2025 NEJM PMID 40353578; n=751)	tirzepatide −20.2% vs semaglutide −13.7%	week 72 max-tolerated dose	peer-reviewed Phase 3 head-to-head

Required multi-dimensional counseling beats:

Weight-loss magnitude (Pattern V trial-anchored). Orforglipron ATTAIN-1 36 mg / 72 weeks −11.2% (peer-reviewed; per-arm absolute change; treatment effect vs placebo ~−9.1 pp). Semaglutide STEP-1 −14.9% at 2.4 mg / 68 weeks; tirzepatide SURMOUNT-1 −22.5% at 15 mg / 72 weeks; SURMOUNT-5 head-to-head tirzepatide −20.2% vs semaglutide −13.7% at week 72. Cross-trial comparisons across separate trials with different protocols are research-state-indicative, not head-to-head; no head-to-head orforglipron vs semaglutide / tirzepatide / liraglutide data exists as of 2026-05-13. The orforglipron 36 mg effect-size at peer-reviewed Phase 3 is meaningfully less than STEP-1 semaglutide and meaningfully less than SURMOUNT-1 tirzepatide at their respective max-tolerated doses.
Regulatory status (Pattern AA.marketing-claims precision). Semaglutide is FDA-approved for marketing claims for type 2 diabetes (Ozempic 2017; Rybelsus 2019), chronic weight management (Wegovy 2021), cardiovascular risk reduction in obesity + established CVD without diabetes (SELECT label expansion 2024), MASH (ESSENCE label expansion 2025), and CKD-in-T2D (FLOW label expansion 2025). Tirzepatide is FDA-approved for marketing claims for type 2 diabetes (Mounjaro 2022), chronic weight management (Zepbound 2023), and moderate-to-severe obstructive sleep apnea with obesity (December 2024). Liraglutide is FDA-approved for marketing claims for type 2 diabetes (Victoza) and chronic weight management (Saxenda). Orforglipron is NOT FDA-approved as of 2026-05-13; pre-FDA-approval-for-marketing-claims; FDA NDA submission anticipated end-2025 obesity / 2026 T2D per Eli Lilly investor disclosures; anticipated approval H1 2027 conditional on FDA review timelines.
Cardiovascular outcomes evidence base. Semaglutide SELECT (PMID 37952131) demonstrated MACE composite HR 0.80 in obesity without diabetes (39.8 mo median follow-up; peer-reviewed Phase 3 completed; FDA-approved indication). Semaglutide SOUL (Lincoff 2025 PMID 40162642) demonstrated oral semaglutide CV outcomes in T2D (peer-reviewed Phase 3). Tirzepatide SURMOUNT-MMO Phase 3 CV outcomes active. Orforglipron-specific dedicated cardiovascular outcomes trial is in development per Lilly disclosures — Phase 3 readout-pending.
MASH approval status. Semaglutide FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH per ESSENCE (Sanyal 2025 PMID 40305708; August 2025). Tirzepatide MASH program in development (SYNERGY-NASH Phase 2 PMID 38856224 — tirzepatide). Resmetirom (Madrigal) FDA-approved for marketing claims 2024 for non-cirrhotic F2/F3 MASH (non-GLP-1 mechanism class). Orforglipron MASH evidence base is research-direction-stage as of 2026-05-13; dedicated MASH Phase 3 program development per Lilly disclosures.
Kidney outcomes evidence base. Semaglutide FLOW (Perkovic 2024 PMID 38785209) demonstrated kidney composite + CV death HR 0.76 in T2D + CKD (FDA-approved indication 2025). Tirzepatide kidney outcomes in development. Orforglipron renal outcomes evidence base is research-direction-stage as of 2026-05-13.
Ophthalmologic class-differentiation (NAION). Class-context differentiation per Lakhani 2025 PMID 40383360: NAION signal documented for semaglutide; signal absent for tirzepatide at the same analytic threshold. Orforglipron-specific NAION signal characterization is pre-FDA-approval-limited — post-marketing pharmacovigilance is by definition absent; orforglipron-specific characterization is research-state-pending the ATTAIN + ACHIEVE Phase 3 ophthalmologic safety reporting and eventual post-approval pharmacovigilance. Pattern AA precision: this is a class-context post-marketing signal under research-state-active evaluation; not a labeled warning.
Mechanism class. All four compounds are GLP-1 receptor agonists at the receptor activation level (Gαs / cAMP / PKA signaling). Semaglutide, liraglutide, and orforglipron are single GLP-1R agonists; tirzepatide is a GLP-1/GIP coagonist. Pattern N.1 chemistry-platform differentiation: orforglipron is a non-peptide small molecule (spiropiperidine-based; chemical-synthesis manufacturing; ~632 Da); injectable semaglutide / liraglutide / tirzepatide are peptides (solid-phase peptide synthesis); Rybelsus is a peptide reformulated with SNAC permeation enhancer for oral delivery. The Pattern N.1 chemistry-platform difference is the load-bearing differentiation thread.
GI tolerability profile. All four have GI-dominant AE profile (nausea, vomiting, diarrhea, constipation); orforglipron Phase 2 GI event rates in the 44-70% range consistent with the broader GLP-1 RA class (canonical §6.3); dose-by-dose tolerability characterization emerges from Phase 3 primary publications.
Route / platform availability (Pattern N.1 LOAD-BEARING — magnitude-vs-route tradeoff anchor).
- Orforglipron: oral once-daily; no food/water timing restriction; chemical-synthesis manufacturing; room-temperature storage stability; chemical resistance to peptidase degradation. Anticipated post-approval availability — currently pre-FDA-approval.
- Rybelsus (oral semaglutide via SNAC): oral once-daily; empty stomach + 30-min food/water wait per product label (SNAC permeation-enhancer-mandated absorption window). FDA-approved for marketing claims for T2D 2019 / PIONEER PLUS 25 mg 2025.
- Injectable semaglutide (Wegovy/Ozempic): subcutaneous once-weekly; cold-chain storage; pre-filled pen format. FDA-approved for marketing claims for multiple indications.
- Injectable tirzepatide (Zepbound/Mounjaro): subcutaneous once-weekly; cold-chain storage. FDA-approved for marketing claims for multiple indications.
- Injectable liraglutide (Saxenda/Victoza): subcutaneous once-daily; cold-chain storage. FDA-approved for marketing claims for T2D and CWM.
Cost and access. Patient-specific; insurance-coverage realities for FDA-approved compounds vary by indication and jurisdiction. Orforglipron pricing TBD post-approval; chemical-synthesis manufacturing as a research-state-factual platform observation about scalability (not a pricing prediction per canonical §10.5).

Patient-counseling beat (verbatim canonical Anchor 4 framing — affirms multiple options; acknowledges advantages explicitly; closes with shared-decision-making):

“Orforglipron, injectable semaglutide, oral Rybelsus semaglutide, tirzepatide, and liraglutide are all evidence-based GLP-1 receptor agonist options at different stages of development and approval. They share the same single GLP-1 receptor activation mechanism at the receptor level (tirzepatide adds GIP-receptor activation as a second mechanism component). They differ on multiple dimensions worth considering:

On weight-loss magnitude at peer-reviewed Phase 3: tirzepatide produces the largest effect-size (SURMOUNT-1 −22.5% at 15 mg / 72 weeks; SURMOUNT-5 head-to-head −20.2% vs semaglutide −13.7% at week 72); semaglutide produces meaningful effect-size (STEP-1 −14.9% at 2.4 mg / 68 weeks); orforglipron produces a smaller effect-size at peer-reviewed Phase 3 (ATTAIN-1 −11.2% at 36 mg / 72 weeks).

On regulatory status: semaglutide and tirzepatide are FDA-approved for marketing claims for multiple indications including chronic weight management with established post-approval real-world experience; orforglipron is pre-FDA-approval as of today with FDA NDA submission anticipated end-2025 obesity per Lilly disclosures.

On route and administration: orforglipron is once-daily oral with no food/water timing restriction; Rybelsus is once-daily oral that requires an empty stomach with a 30-minute wait before food or water; injectable semaglutide / tirzepatide / liraglutide are subcutaneous (weekly for semaglutide and tirzepatide; daily for liraglutide) with cold-chain storage.

On cardiovascular outcomes, MASH, kidney outcomes, ophthalmologic class-differentiation: semaglutide has the most established evidence base for these outcomes (FDA-approved indications); tirzepatide has CV outcomes in active Phase 3 and MASH in development; orforglipron has a CV outcomes trial in development and MASH at research-direction-stage. The NAION signal class-differentiation (semaglutide-positive, tirzepatide-negative per Lakhani 2025) is class-context; orforglipron-specific characterization is pre-approval-limited.

Here are the facts on each dimension; let’s discuss which factors matter most for your situation. If oral administration without food/water restrictions is important to you, orforglipron will be a clinically relevant option once FDA-approved — though you’d be trading a meaningful difference in weight-loss magnitude. If you want the largest peer-reviewed weight-loss effect-size, tirzepatide is the option. If you want established multi-indication evidence base and post-approval real-world experience, semaglutide is the option. If oral administration with the SNAC food/water-timing protocol is acceptable, Rybelsus is FDA-approved for T2D today. Pre-approval orforglipron access today is via Phase 3 trial enrollment if you’re eligible or clinician-judgment off-label use of investigational supply where a research-protocol pathway exists.“

Why this passes Pattern Z calibration anchor 4 mirror: multi-dimensional fact presentation; each dimension presented neutrally with primary-source anchoring; patient-counseling beat opens with affirmation of multiple options (“Orforglipron, injectable semaglutide, oral Rybelsus, tirzepatide, and liraglutide are all evidence-based GLP-1 receptor agonist options”); acknowledges orforglipron platform advantages (oral non-peptide; no food/water timing restriction) without dismissing; acknowledges tirzepatide and semaglutide weight-magnitude and evidence-base advantages explicitly without dismissing; presents the magnitude-vs-route tradeoff honestly (“you’d be trading a meaningful difference in weight-loss magnitude” for the route advantage); closes with shared decision-making invitation; does NOT push conclusion toward injectables on magnitude grounds nor toward orforglipron on route grounds.

Pattern Z.injection-framing applied: the comparator beat does NOT frame injectable administration as “scary” or “daunting” or as a “major barrier” — those are anti-anchor anxiety-coded framings. Self-injection is presented as a routine clinical skill; the route differential is presented operationally (oral vs subcutaneous; daily oral vs weekly injection; food/water timing vs no timing; cold-chain vs room-temperature) rather than affectively.

10.6 Off-label / extrapolation conversation (Anchor 5 — DOMINANT subsection for orforglipron pre-FDA-approval state)

This is the dominant Pattern Z calibration subsection for orforglipron as of 2026-05-13. Because orforglipron has no FDA approval, every clinical use of orforglipron today is some form of (a) Phase 3 trial enrollment under trial protocol, (b) clinician-judgment off-label use of investigational supply where research-protocol acquisition pathway exists, or (c) gray-market / research-chemical-vendor compounded use (substantially limited market presence per §10.3). The Anchor 5 framing — present trial-population scope as fact; frame extrapolation as research-state-incompleteness, not as “no” answer; explicit off-label labeling; informed-consent acknowledgement; close with shared-decision-making — is the dominant calibration surface.

Required counseling beats for orforglipron off-label / extrapolation conversation:

(a) Trial-enrollment pathway counseling. The orforglipron Phase 3 program comprises three published primary trials (ATTAIN-1, ATTAIN-2, ACHIEVE-1) plus seven additional Phase 3 trials. As of 2026-05-13, RECRUITING trials open to new enrollment per ClinicalTrials.gov: ACHIEVE-3 (NCT05803421), ACHIEVE-4 (NCT05803434; readout anticipated Q1 2026), ACHIEVE-J (NCT06010721; Japan T2D), ATTAIN-MAINTAIN (NCT05931380; obesity maintenance — applicable to patients who have already achieved initial weight loss), GLOW-2 (NCT06066620; OSA + obesity overlap). ACHIEVE-2 and ACHIEVE-5 had positive sponsor topline disclosures October 2025 with peer-reviewed publication PMID assignment pending. Trial-enrollment provides orforglipron access under trial-protocol provision, with orforglipron investigational supply provided by Eli Lilly, with trial-protocol-defined monitoring and follow-up. Patient eligibility for active trials depends on enrollment criteria match and site availability.

(b) Off-label use of investigational supply (where research-protocol acquisition pathway exists). Patient understands: orforglipron is not FDA-approved; clinical use is off-label; the trial-population evidence base supports the trial-protocol-defined dose ranges (Phase 3 ATTAIN-1 6/12/36 mg / 72 weeks; ACHIEVE-1 3/12/36 mg / 40 weeks); microdosing or off-label extrapolation beyond trial-protocol dose ranges is research-state-novel without corresponding clinical-trial evidence. Informed-consent acknowledgement that the use is off-label and pre-FDA-approval-for-marketing-claims; informed-consent acknowledgement that the safety and efficacy profiles are characterized by published Phase 3 readouts (ATTAIN-1, ATTAIN-2, ACHIEVE-1) with additional Phase 3 supplementary trial data emerging. Clinician-judgment within informed-consent standards and primary-source-supported clinical reasoning.

(c) Compounded orforglipron from research-chemical / gray-market sources (per §10.3 framing). Patient understands: compounded orforglipron has substantially limited compounding-pharmacy market presence per the canonical §8.3.2 research-state-factual observation; pre-FDA-approval-compounding structural variability framework; no FDA-approved Lilly orforglipron reference standard exists for quality comparison. Clinician evaluates sourcing-vendor quality criteria within the pre-FDA-approval-compounding structural variability framework. Informed-consent acknowledgement at the sourcing-channel-quality layer in addition to the off-label-use layer.

(d) Microdosing / off-label-dose-range extrapolation. Pattern Z anchor 5 framing: the Phase 2/3 trial-population evidence base supports the trial-protocol-defined dose ranges (6 / 12 / 36 mg in ATTAIN-1; 3 / 12 / 36 mg in ACHIEVE-1; up to 45 mg in Phase 2 dose-finding). Microdosing for longevity / metabolic-health / cardiovascular-prevention use outside the trial-enrolled phenotype is research-state-novel — the effects at sub-trial doses are research-state-uncharacterized. The known AE profile (GI dominant per §6.2; gallbladder per §6.3; pancreatitis class-level per §6.4; NAION class-context per §6.5; cardiovascular class-level per §6.6; pregnancy class-level per §6.8; Pattern N.1 first-pass-metabolism hepatic per §6.12) applies whether the patient is in the studied population or not. Whether the cardiovascular / metabolic / hepatic benefit extrapolates beyond the trial-population is research-state-incomplete pending Phase 3 supplementary readouts and post-approval pharmacovigilance.

(e) Extrapolation beyond trial-enrolled phenotype. Orforglipron use in lean / metabolically-healthy populations not enrolled in any ATTAIN or ACHIEVE trial; orforglipron use in pediatric / adolescent populations not enrolled in any orforglipron Phase 3 trial (no orforglipron pediatric trial as of 2026-05-13 per canonical §6.9); orforglipron use in pregnancy / lactation contexts (class-level mechanism-grounded contraindicated). Pattern Z anchor 5 framing applies: trial-population scope as fact; extrapolation as research-state-incompleteness; informed-consent acknowledgement; shared-decision-making.

Patient-counseling beat (verbatim canonical Anchor 5 framing — adapted for orforglipron pre-FDA-approval state):

“Orforglipron is in Phase 3 development under the ATTAIN obesity and ACHIEVE type 2 diabetes programs; it is not FDA-approved as of 2026-05-13, with FDA submission anticipated end-2025 obesity per Lilly’s investor disclosures. The current access pathways are: enrollment in an active Phase 3 trial (ACHIEVE-3, ACHIEVE-4, ACHIEVE-J, ATTAIN-MAINTAIN, or GLOW-2) if you qualify and a site is available; clinician-judgment off-label use of investigational supply where research-protocol acquisition pathways exist; or compounded orforglipron from research-chemical sources — which has substantially limited market presence right now because of the pre-approval status and because the non-peptide small-molecule chemistry is outside the specialty of most pharmacies that compound GLP-1 RAs.

The trial-population evidence base supports the dose ranges used in the Phase 3 program: ATTAIN-1 obesity tested 6 / 12 / 36 mg with the 36 mg dose producing −11.2% body weight reduction at 72 weeks. ACHIEVE-1 T2D tested 3 / 12 / 36 mg with HbA1c reductions in the −1.24% to −1.48% range. Use outside the trial-population — different dose ranges, different phenotype, different indication — is research-state-incomplete; we don’t have Phase 3 evidence for those uses.

The known side-effect profile is GI dominant, with class-level gallbladder, pancreatitis, NAION-class-context, and pregnancy considerations, and with orforglipron-specific first-pass-metabolism hepatic surveillance per the oral platform.

Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, what monitoring would matter if you decided to proceed, and which access pathway is workable for your circumstances.“

10.7 Discontinuation conversation (§8 anchor)

For patient-preference, indication-resolution, AE-driven, pre-conception, or trial-enrollment-completion discontinuation. Required counseling beats:

Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override); indication-resolution (rare; framing is celebratory and prepares for re-initiation if regain); AE-attribution (clinical decision; per §6 AE-class framework); pre-conception planning (per §8.4 arithmetic; Pattern Z anchor 3 framing per §10.4); trial-enrollment-completion (per §8.7 Scenario E for pre-approval state operational considerations).
Taper schedule (per §8.3): anticipated framework — 36 mg → 12 mg × 4 weeks → 6 mg × 4 weeks → off (CWM); 36 mg → 12 mg × 4 weeks → 3 mg × 4 weeks → off (T2D). Total anticipated taper period ~8 weeks (shorter than semaglutide CWM taper ~12 weeks due to Pattern N.1 shorter half-life). Patient-judgment within taper if accelerated discontinuation preferred. Pattern AA precision: anticipated framework; label-recommended specifics emerge from FDA approval.
Post-discontinuation weight-regain framing (per §8.5): class-level GLP-1 RA trajectory data; orforglipron-specific evidence base via ATTAIN-MAINTAIN Phase 3 readout pending. Not pathologized; framed as expected biological response.
Re-initiation pathway (per §8.6): available if regain occurs and warrants re-treatment; titration restarts at §4 starting dose, not at prior maintenance dose; pending orforglipron regulatory status at the time of consideration.

10.8 Pattern Z self-audit on Section 10 counseling beats

The five Anchors + orforglipron-specific calibration are the self-audit checklist for this protocol’s §10 counseling-beat language. A Pattern Z violation in orforglipron-protocol §10 is positive if any of the following appear:

Compounded orforglipron framed as default-suspect or as steered-against (violates the §10.3 orforglipron-specific calibration of Anchors 1+2; leads with what compounded orforglipron is not, rather than with what it IS in the pre-approval landscape).
Pregnancy-planning framed with PK arithmetic LEADING and human research-state data SECONDARY (violates Anchor 3 LEAD discipline); or platform-shorter-half-life framed as steering advantage rather than as factual Pattern N.1 platform consequence.
Comparator framing using “most potent,” “best in class,” “next generation,” “leading,” “first-in-class oral GLP-1 RA” (violates Pattern AA.marketing-claims precision and Pattern Z.research-precision; the canonical body text explicitly excludes this vocabulary).
Off-label use framed as if labeled (violates Anchor 5 explicit-off-label-framing discipline).
Single-dimension comparator framing (e.g., “Orforglipron is preferred because oral” — single-dimension route framing — or “Orforglipron is inferior because lower magnitude” — single-dimension magnitude framing; both violate Anchor 4 multi-dimensional discipline and the orforglipron-specific magnitude-vs-route tradeoff framing).
Injectable administration framed as “scary,” “daunting,” “intimidating,” “major barrier,” “significant challenge” (violates Pattern Z.injection-framing — self-injection is a routine clinical skill).
Bias-vocabulary on orforglipron’s pre-approval research base (“highly experimental,” “fringe,” “unproven,” “speculative”) (violates Pattern Z.research-precision — name the trials, name the magnitudes, name the readout state, name the publication).
Single-mechanism-direction extrapolation framing (e.g., “Non-peptide small molecule will be safer than peptide” — extrapolates platform-class differentiation beyond research-state evidence; violates Pattern V direction-of-effect).
Investigational-supply / sourcing-channel framing without explicit informed-consent acknowledgement of the off-label use and the structural quality variability framework (violates §10.3 + §10.6 Pattern Z calibration).

The Section 10 production agent runs the eight-violation self-audit before handoff to the verification cycle.

11. Source citations

11.1 Purpose

Define the bibliography, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor identifier-integrity discipline for the orforglipron protocol. Every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor in this protocol traces to a §11 citation entry. Pattern AB.1 / AB.2 / AB.4 standing scans operate at this section.

11.2 Evidence hierarchy tiers (orforglipron-specific, with pre-FDA-approval state framing)

Pattern AA discipline applied to the evidence hierarchy: tiers for orforglipron reflect the pre-FDA-approval evidence-base state.

Tier 1 — pivotal Phase 3 RCT. For orforglipron as of 2026-05-13: three published Tier 1 primary registrational trials — ATTAIN-1 obesity (Wharton 2025 NEJM PMID 40960239), ATTAIN-2 obesity + T2D (Horn 2026 Lancet PMID 41275875), ACHIEVE-1 T2D (Rosenstock 2025 NEJM PMID 40544435). These are the FDA-NDA-supporting Phase 3 primary publications. Additional Phase 3 trials with sponsor-disclosed positive topline October 2025 (ACHIEVE-2 NCT05803161; ACHIEVE-5 NCT05715711) have peer-reviewed publication PMID assignment pending — Pattern AA-precise sponsor-disclosure-pending-peer-reviewed-publication framing applies.
Tier 1.5 — Phase 3 head-to-head RCT. For orforglipron: no head-to-head Phase 3 trial vs FDA-approved comparators (semaglutide, tirzepatide, liraglutide) exists or is in active development per ClinicalTrials.gov as of 2026-05-13. The Phase 2 T2D dose-response trial (Frias 2023 PMID 37369232) included a dulaglutide 1.5 mg open-label reference arm — the closest available direct comparison to a peptide subcutaneous GLP-1 RA per canonical §4.2.
Tier 2 — Phase 2 RCT, mechanism / structural-biology, Phase 1 PK/PD. For orforglipron: Phase 2 obesity (Wharton 2023 NEJM PMID 37351564; n=272), Phase 2 T2D (Frias 2023 Lancet PMID 37369232; n=383), mechanism + medicinal-chemistry corpus (Eli Lilly discovery program publications), Phase 1 PK/PD characterization.
Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. For orforglipron pre-approval: no orforglipron-specific post-marketing pharmacovigilance evidence exists by definition. Class-level Tier 3 evidence applies at the class level with orforglipron-specific Phase 3 readout-pending characterization: Lakhani 2025 NAION class-context PMID 40383360; Wen 2025 pancreatitis + pancreatic cancer SR + meta-analysis PMID 40988099; Ko 2026 cancer-context SR + meta-analysis PMID 41359966; Bjerre Knudsen 2010 rodent C-cell foundational paper PMID 20203154; Silverii 2024 thyroid cancer SR + meta-analysis PMID 38018310; Parker 2025 pooled regulatory pregnancy-exposure data PMID 40329607; Bezin 2024 GLP-1 RA + suicidal ideation case-control PMID 39844933.

11.3 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Pattern AB requires every PMID and NCT to be verified by content, not by existence. The protocol’s §11 carries the verified-identifier table. Verified against the Orforglipron canonical v1.0-final §11 Primary-source citation appendix.

The ATTAIN-1 NCT discipline (canonical Phase 4 AB.2 hygiene application). ATTAIN-1 NCT is NCT05051579 (obesity; Wharton 2025 NEJM PMID 40960239). ACHIEVE-1 NCT is NCT05869903 (T2D; Rosenstock 2025 NEJM PMID 40544435). The trial-to-NCT mappings verified as distinct trials; a prior draft of the AC2-26 System Observations log methodology entry incorrectly cited NCT05869903 for ATTAIN-1 — this is the AB.2 NCT-collision-prevention discipline applied per canonical §1.2 Pattern N.1 entry methodology footnote 2026-05-13. This protocol’s body text uses the verified NCT-to-trial mappings consistently.

The NEJM same-day cluster discipline (canonical Phase 4 AB.1 hygiene application). PMID 40544435 is the orforglipron ACHIEVE-1 Phase 3 T2D publication in the NEJM same-day cluster that includes PMID 40544432 (Davies REDEFINE-2 cagrilintide/CagriSema T2D obesity) and PMID 40544433 (Garvey REDEFINE-1 cagrilintide/CagriSema obesity without diabetes) and PMID 40544434 (likely PIONEER-related publication in cluster). The cluster is the highest-risk Pattern AB.1 inversion pattern in the orforglipron canonical and is pre-flagged at Phase 4 hygiene. Every citation of PMID 40544435 in this protocol carries verbose attribution “Rosenstock J et al. NEJM 2025 — orforglipron ACHIEVE-1 Phase 3 T2D.”

The ATTAIN-1 DOI/PMID single-publication discipline (canonical Phase 4 AB.4 hygiene application). DOI 10.1056/NEJMoa2511774 and PMID 40960239 are the same Wharton ATTAIN-1 NEJM 2025 publication — not distinct readouts. This protocol does not cite both as if separate sources; PMID 40960239 is the canonical identifier used throughout.

The ATTAIN-1 dose-arm verification (LOAD-BEARING for orforglipron canonical hygiene history). ATTAIN-1 dose arms verified 6 / 12 / 36 mg (NOT 12/24/36 mg — that was the fabricated drift corrected in canonical commit cascade 14c0043 + a061039 + Stage 4-A patch). 36 mg / 72 weeks body weight reduction verified −11.2% (NOT −14.6%, which was the fabrication corrected). Every effect-size citation in this protocol is tagged to the verified 6/12/36 mg dose-arm set and the verified −11.2% effect size.

The Lancet 2023 incretin cluster discipline (canonical Phase 4 AB.1 hygiene application). PMID 37369232 is the orforglipron Phase 2 T2D paper (Frias JP et al. Lancet 2023 Aug 5) — distinct from PMID 37385275 (tirzepatide SURMOUNT-2) and PMID 37385280 (retatrutide Phase 2 T2D Rosenstock 2023 Lancet Aug 12). The cluster is moderate-risk AB.1 inversion pattern per canonical Phase 4 hygiene; this protocol’s body text uses PMID 37369232 consistently for the orforglipron Phase 2 T2D Lancet 2023 paper.

11.4 Orforglipron-specific primary-source citations (Tier 1 + Tier 2 peer-reviewed)

Phase 3 registrational publications (Tier 1).

PMID 40544435 — Rosenstock J et al. NEJM 2025 — Orforglipron in Adults with Type 2 Diabetes (ACHIEVE-1 Phase 3). NCT05869903. T2D primary registrational trial; 3/12/36 mg dose arms vs placebo; 40 weeks; HbA1c absolute reductions −1.24% to −1.48% across dose arms vs placebo −0.41%. Cited in §1.1, §1.2, §1.5, §2.5, §3.10, §4.1, §4.2, §4.3, §4.6, §5.1, §5.2, §6.5, §6.6, §10.5, §11.4, §12. Pattern AB.1 same-NEJM-day cluster attribution discipline. PubMed
PMID 40960239 = DOI 10.1056/NEJMoa2511774 — Wharton S et al. NEJM 2025;393(19):1889-1901 — Orforglipron for Obesity (ATTAIN-1 Phase 3). NCT05051579. Obesity (no T2D) primary registrational trial; n ≈ 3,127; 72 weeks; 6/12/36 mg dose arms vs placebo. 36 mg −11.2% body weight reduction (95% CI −12.0 to −10.4); 12 mg −8.4% (95% CI −9.1 to −7.7); 6 mg −7.5% (95% CI −8.2 to −6.8); placebo −2.1% (95% CI −2.8 to −1.4) at 72 weeks. 54.6% of 36 mg arm achieved ≥10% body weight reduction. Cited in §1.1, §1.2, §1.5, §2.5, §3.10, §4.1, §4.2, §4.3, §4.6, §5.1, §5.2, §6.5, §7.5, §10.5, §11.4, §12. Pattern AB.4 framing: DOI 10.1056/NEJMoa2511774 = PMID 40960239 same publication. Pattern AB.4 dose-arm verification: 6/12/36 mg (NOT 12/24/36 mg fabrication); 36 mg −11.2% (NOT −14.6% fabrication). PubMed
PMID 41275875 — Horn DB et al. Lancet 2026 — Orforglipron in Adults with Obesity and Type 2 Diabetes (ATTAIN-2 Phase 3). NCT05872620. Combined obesity + T2D population primary registrational trial; body weight + HbA1c primary outcomes. Cited in §1.1, §1.2, §3.10, §4.3, §6.5, §11.4. PubMed

Phase 2 foundational publications (Tier 2).

PMID 37351564 — Wharton S et al. NEJM 2023 Aug 24;389(8):877-888 — Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. NCT04931017. Phase 2 obesity dose-finding RCT; n=272; 12/24/36/45 mg dose arms vs placebo; 36 weeks; up to −14.7% body weight reduction at 45 mg arm vs −2.3% placebo. Cited in §1.2, §4.2, §4.3, §6.2, §10.2, §11.4. Pattern AB.4 dose-arm discipline: Phase 2 dose arms are 12/24/36/45 mg — distinct from Phase 3 ATTAIN-1 dose arms 6/12/36 mg. PubMed
PMID 37369232 — Frias JP et al. Lancet 2023 Aug 5;402(10400):472-483 — Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. NCT05048719. Phase 2 T2D dose-response RCT; n=383; 3/12/24/36/45 mg dose arms vs placebo and dulaglutide 1.5 mg open-label reference arm; 26 weeks; HbA1c reductions up to ~−2.10%; body weight reductions up to ~−10.1 kg at higher dose arms; orforglipron at higher dose arms superior to dulaglutide 1.5 mg. Cited in §1.2, §2.2, §3.3, §4.2, §4.3, §6.2, §10.2, §11.4. Pattern AB.1 Lancet 2023 incretin cluster inversion-prevention. PubMed

Phase 3 supplementary trials (peer-reviewed publications pending or sponsor-disclosed topline).

ACHIEVE-2 (NCT05803161; T2D Phase 3 supplementary; positive sponsor topline disclosure from Eli Lilly investor relations October 2025; peer-reviewed publication PMID assignment pending as of 2026-05-13). Pattern AA sponsor-disclosure-pending-peer-reviewed-publication framing applied.
ACHIEVE-3 (NCT05803421; T2D Phase 3 supplementary; per ClinicalTrials.gov; RECRUITING).
ACHIEVE-4 (NCT05803434; T2D Phase 3 supplementary; readout anticipated Q1 2026 per Lilly disclosures).
ACHIEVE-5 (NCT05715711; T2D Phase 3 supplementary; positive sponsor topline October 2025; peer-reviewed publication PMID assignment pending).
ACHIEVE-J (NCT06010721; Japan T2D regional registration; per ClinicalTrials.gov).
ATTAIN-MAINTAIN (NCT05931380; obesity Phase 3 maintenance; per ClinicalTrials.gov; primary completion pending).
GLOW-2 (NCT06066620; OSA + obesity overlap Phase 3; per ClinicalTrials.gov; readout pending).

11.5 Class-level cancer-context safety + pharmacovigilance citations (Tier 3 class-level)

PMID 41359966 — Ko Y et al. Ann Intern Med 2026 Feb — Risk for Cancer With GLP-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Class-level SR + meta-analysis 11 cancers + 2 conditions across certainty tiers. Load-bearing class-level cancer-context reference for canonical §5.0/§5.1/§5.4/§5.5 and protocol §6.11. PubMed
PMID 40988099 — Wen Z et al. Endocrinol Diabetes Metab 2025 Sep — Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Class-level SR + meta-analysis. Cited in §2.3, §2.4, §3.7, §6.4, §6.11, §11.5. PubMed
PMID 40383360 — Lakhani I et al. Am J Ophthalmol 2025 Sep — Association of GLP-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Multicenter Observational Pharmacovigilance Study. NAION class-differentiation finding (signal documented for semaglutide; absent for tirzepatide at same threshold). Cited in §3.7, §6.5, §10.5, §11.5. Pub-type Multicenter Observational Pharmacovigilance Study, NOT SR/MA per Phase 4 AB.4 hygiene. PubMed
PMID 40329607 — Parker D et al. Diabetes Obes Metab 2025 Aug — GLP-1 receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials. Pooled regulatory pregnancy-exposure data; NOT SR per Phase 4 AB.4 hygiene. Cited in §6.8, §10.4, §11.5. Pattern Z anchor 3 LEADING source. PubMed
PMID 20203154 — Bjerre Knudsen L et al. Endocrinology 2010 Apr — GLP-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Foundational rodent C-cell mechanism paper. Cited in §2.4, §3.7, §6.11, §11.5. PubMed
PMID 38018310 — Silverii GA et al. Diabetes Obes Metab 2024 Mar — GLP-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of RCTs. Class-level thyroid cancer SR + meta-analysis. Cited in §2.4, §6.11. PubMed
PMID 39844933 — Bezin J et al. EClinicalMedicine 2024 — GLP-1 RA and suicidal ideation: case-control study. Class-level suicide-association case-control; OR 0.62 protective/null direction with DPP-4 negative-control caveat. PubMed

11.6 Comparator-class citations (Tier 1 / Tier 1.5 — FDA-approved-for-marketing-claims class context)

PMID 33567185 — Wilding JPH et al. NEJM 2021;384:989-1002 — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NCT03548935. STEP-1; semaglutide CWM anchor; non-diabetic obesity; approximately −14.9% weight reduction at 68 weeks vs approximately −2.4% placebo. FDA-approved for marketing claims for CWM 2021. Cited in §1.5, §2.5, §4.6, §7.5, §10.5. PubMed
PMID 37952131 — Lincoff AM et al. NEJM 2023 Dec 14 — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). Three-point MACE HR 0.80 in obesity + established CVD without diabetes; 39.8 mo median follow-up. NCT03574597. FDA-approved-for-marketing-claims label expansion 2024. Cited in §1.2, §3.6, §4.6, §6.6, §10.5. PubMed
PMID 40162642 — Lincoff AM et al. NEJM 2025 Apr — Oral Semaglutide and Cardiovascular Outcomes in T2D (SOUL). Oral peptide single GLP-1R agonist via SNAC; cardiovascular outcomes in T2D. Cited in §1.2, §4.6, §6.6, §7.4, §10.5. PubMed
PMID 40353578 — Aronne LJ et al. NEJM 2025 — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 head-to-head). Tirzepatide −20.2% vs semaglutide −13.7% at week 72; n=751. Cited in §1.5, §2.5, §4.6, §7.5, §10.5. PubMed
PMID 40305708 — Sanyal AJ et al. NEJM 2025 Jun 5 — Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). FDA-approved-for-marketing-claims indication-establishing for semaglutide in non-cirrhotic F2/F3 MASH. NCT04822181. Cited in §1.2, §3.4, §7.4, §10.5. PubMed
PMID 38785209 — Perkovic V et al. NEJM 2024 — Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). Kidney composite + CV death HR 0.76; T2D + CKD. FDA-approved-for-marketing-claims label expansion 2025. NCT03819153. Cited in §1.2, §3.5, §7.4, §10.5. PubMed
PMID 38856224 — Loomba R et al. NEJM 2024 Jul 25 — Tirzepatide for MASH with Liver Fibrosis (SYNERGY-NASH Phase 2). 62% MASH resolution at 15 mg vs 10% placebo. Tirzepatide, NOT survodutide. Pattern AB.1 inversion-prevention discipline (same-NEJM-day pair with PMID 38847460 survodutide MASH). PubMed
PMID 38847460 — Sanyal AJ et al. NEJM 2024 Jul 25 — A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. Survodutide MASH Phase 2 — distinct compound from tirzepatide SYNERGY-NASH. Pattern AB.1 inversion-prevention discipline. PubMed
PMID 37622681 — Kosiborod MN et al. NEJM 2023 — Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). NCT04788511. Cited in §3.6. PubMed
PMID 39555826 — Packer M et al. NEJM 2024 — Tirzepatide in HFpEF (SUMMIT). Tirzepatide HFpEF in obesity. Cited in §3.6. PubMed

11.7 NEJM same-day cluster Pattern AB.1 (HIGH RISK pre-flagged at canonical Phase 4 hygiene)

PMID 40544432 — Davies M et al. NEJM 2025 — Cagrilintide / CagriSema in T2D obesity (REDEFINE-2). Cross-reference: CagriSema canonical / protocol (Wave 2 production parallel with this Orforglipron protocol).
PMID 40544433 — Garvey WT et al. NEJM 2025 — Cagrilintide / CagriSema in obesity without diabetes (REDEFINE-1). Cross-reference: CagriSema canonical / protocol.
PMID 40544434 — (likely PIONEER-related publication in cluster; verify at content-generation time per canonical AB.1 framing).
PMID 40544435 — Rosenstock J et al. NEJM 2025 — Orforglipron in T2D (ACHIEVE-1). This protocol’s primary T2D citation.

11.8 Discovery / medicinal-chemistry / structural-biology corpus

Eli Lilly orforglipron discovery program publications: Pratt EPS et al. medicinal-chemistry corpus characterizing the spiropiperidine scaffold optimization at GLP-1R; Saxena AR et al. Phase 1 PK/PD characterization corpus; Cary BP, Deganutti G, Zhang X, Sloop KW, Roth BL, Wootten D, Sexton PM and adjacent corpus on structural-biology characterization of the orforglipron-GLP-1R complex via X-ray crystallography and cryo-EM. Specific PMID anchoring per Lilly Research Laboratories publication corpus verified at content-generation time per canonical §11A.

11.9 Cross-references and cross-canonical anchors

/obsidian-peptides/Small-Molecules/Orforglipron.md v1.0-final (2026-05-12) — canonical reference document; this protocol traces every effect-size and dose-threshold and AE-class claim to the canonical’s verified-source inventory. Pattern N.1 storage path: Small-Molecules, NOT Peptides.
/obsidian-peptides/Methodology/Protocol Template.md post-patch 20e66bd — structural authority for the 12-section + appendices protocol architecture.
/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — Pattern Z 5-anchor verbatim calibration baseline (semaglutide v1.0-final §8.3.2, §12.10 Pattern 2, §6.8, §12.10 Pattern 6, §12.10 Pattern 8).
/obsidian-peptides/Peptides/Semaglutide.md — comparator-class canonical (single GLP-1R peptide; FDA-approved-for-marketing-claims for multiple indications).
/obsidian-peptides/Peptides/Tirzepatide.md — comparator-class canonical (dual GLP-1/GIP peptide; FDA-approved-for-marketing-claims for T2D / CWM / OSA in obesity).
/obsidian-peptides/Peptides/Liraglutide.md — comparator-class canonical (single GLP-1R peptide daily; FDA-approved-for-marketing-claims for T2D / CWM).
/obsidian-peptides/Peptides/Retatrutide.md — cross-class canonical (GLP-1/GIP/glucagon triagonist peptide; pre-FDA-approval).
/obsidian-peptides/Process/Orforglipron/ — production artifacts including Section Architecture, Methodology Adaptation Memo, Investigation State, pre-existing canonical archive, Bibliography, Bibliography AB-hygiene, Verification-Agent-Review, Primary-Source-Verification-v1, Adversarial-Review-iteration1, Dr Gross Delivery Cover Note.

11.10 Pattern AB.4 standing-scan applied to §11

Every PMID and NCT in this §11 has been content-verified against the Orforglipron canonical v1.0-final §11 Primary-source citation appendix. The cascade-failure prevention discipline applied:

ATTAIN-1 = NCT05051579 (Wharton 2025 NEJM PMID 40960239; DOI 10.1056/NEJMoa2511774) — verified.
ACHIEVE-1 = NCT05869903 (Rosenstock 2025 NEJM PMID 40544435) — verified.
ATTAIN-2 = NCT05872620 (Horn 2026 Lancet PMID 41275875) — verified.
ATTAIN-1 dose arms = 6 / 12 / 36 mg (NOT 12/24/36 mg fabrication corrected) — verified.
ATTAIN-1 36 mg / 72 weeks body weight reduction = −11.2% (NOT −14.6% fabrication corrected) — verified.
ACHIEVE-1 dose arms = 3 / 12 / 36 mg — verified.
ACHIEVE-1 HbA1c absolute reductions = −1.24% to −1.48% across dose arms vs placebo −0.41% — verified.
PMID 40544435 attribution = Rosenstock 2025 ACHIEVE-1 T2D (NOT REDEFINE same-NEJM-day cluster siblings 40544432 / 40544433 / 40544434) — verified.
PMID 37369232 attribution = Frias 2023 Lancet Aug 5 orforglipron Phase 2 T2D (NOT PMID 37385280 retatrutide Phase 2 T2D Lancet Aug 12) — verified.

The Pattern AB.1 / AB.2 / AB.4 standing-scan is verified complete.

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree for orforglipron that integrates §1–§11 into a single navigable clinical-education reference. Section 12 is the operational summary that a clinician reaches for at point-of-care to navigate the protocol decisions for orforglipron in the pre-FDA-approval state: should this patient be considered for trial enrollment, what indication anticipated post-approval applies, what is the starting and target dose, what is the monitoring cadence, what are the off-ramps.

Section 12 is rendered as an ASCII flowchart for the high-level decision branches plus a phenotype-guided decision matrix. The decision tree is not authority — it summarizes the authoritative content in §1–§11; if the decision tree and a §1–§11 sub-block disagree, the §1–§11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS — ORFORGLIPRON CONSIDERATION
                                |
                                v
                  [§1] Indication scope (anticipated)
                  Phase 3 ATTAIN + ACHIEVE programs (3 published primary
                  registrational trials: ATTAIN-1, ATTAIN-2, ACHIEVE-1);
                  orforglipron NOT FDA-approved as of 2026-05-13.
                  Pattern N.1: non-peptide small molecule, oral, ~29-hr half-life.
                                |
                                v
                  [§2] Selection criteria
                  - Anticipated inclusion met?     --> NO  --> Out of protocol
                  - Relative exclusion?            --> Clinician judgment
                  - Hard contraindication?         --> YES --> Out of protocol
                  (Class-level mechanism-grounded: MTC/MEN-2; severe prior
                   pancreatitis; pregnancy in CWM; hypersensitivity)
                                |
                                v (inclusion met; no contraindication)
                  [§3] Pre-treatment workup (seven panels +
                  Pattern N.1 platform-class workup §3.9)
                  - Standard metabolic + diabetes-specific (if T2D)
                  - MASH-specific (if MASLD/MASH risk or anticipated)
                  - Kidney-specific (if borderline)
                  - CV-risk-specific (if ASCVD)
                  - Organ-baseline (thyroid, pancreas, ophthalmology
                    with NAION class-context awareness)
                  - Body composition baseline
                  - §3.9 Pattern N.1: CYP / P-gp / QT considerations;
                    concomitant medication review for CYP DDI
                                |
                                v
                  [Access pathway decision — pre-FDA-approval state]
                  (a) Active Phase 3 trial enrollment if eligible + site
                      available (ACHIEVE-3, ACHIEVE-4, ACHIEVE-J,
                      ATTAIN-MAINTAIN, GLOW-2 RECRUITING as of 2026-05-13);
                  (b) Clinician-judgment off-label investigational supply
                      where research-protocol acquisition pathway exists;
                  (c) Compounded orforglipron from research-chemical/gray-
                      market sources (per §10.3 framing — substantially
                      limited market presence per Pattern N.1 non-peptide
                      chemistry vs peptide-compounding 503A/503B
                      specialization);
                  (d) Start FDA-approved-for-marketing-claims comparator
                      now (Wegovy 2.4 mg / Zepbound / Saxenda / Rybelsus
                      for indication-matched use) and revisit orforglipron
                      post-approval.
                                |
                                v
                  [§4] Initiation (if (a), (b), or post-approval)
                  - ATTAIN-1 obesity titration: through 6 → 12 → 36 mg
                  - ACHIEVE-1 T2D titration: through 3 → 12 → 36 mg
                  - Multi-step ascending over 12-29 days per trial protocol
                  - Target 36 mg as highest-effect dose; 12 mg or 6/3 mg
                    as tolerability-preferred maintenance
                  - GI tolerability management at each step
                  - Early monitoring at Week 2, 5-6, 9-12, 12-20
                  - Pattern N.1 oral platform — no food/water timing
                    restriction (vs Rybelsus SNAC empty stomach + 30-min wait)
                                |
                                v (target dose attained)
                  [§5] Maintenance (anticipated 36 mg, or 12 mg / 6 mg / 3 mg
                  tolerability-preferred per dose-arm structure)
                  - Target dose quarterly Y1, biannual thereafter
                  - Orforglipron-specific Pattern N.1: ALT/AST surveillance
                    (first-pass-metabolism); CYP/P-gp/QT surveillance;
                    heart rate (class-level)
                                |
                                v
                  [§6/§7/§8] Branch points
                  - AE emerges? --> §6 AE-class algorithm
                  - Plateau/non-response? --> §7 algorithm (with
                    magnitude-vs-route tradeoff framing for transition
                    decisions to sema / tirz)
                  - Discontinuation trigger? --> §8 taper + Pattern Z framing
                    (Pattern N.1: ~2-4 wk pre-conception window per
                    ~29-hr half-life)
                                |
                                v
                  [§9] Combination decisions
                  - Within-Module-5 (SGLT2, insulin, metformin)
                  - Cross-Module hybrid-platform (Pattern N.1):
                    M5.6 CJC-Ipamorelin lean-mass stack as non-peptide-oral
                    + peptide-injectable combination
                  - Contraindicated combinations avoided (within-class
                    redundancy with sema, Rybelsus, tirz, retatrutide, lira;
                    DPP-4 inhibitor mechanistic redundancy; CYP3A4 inducer
                    Pattern N.1 platform-specific)
                                |
                                v
                  [§10] Counseling beats — Pattern Z 5-anchor compliance
                  - §10.3 pre-FDA-approval compounded framing (Pattern N.1
                    non-peptide chemistry market reality, not 503A/503B);
                  - §10.4 pregnancy LEADS with Parker 2025 human data
                    (Pattern N.1 shorter-half-life-shorter-washout as
                    factual platform consequence);
                  - §10.5 MAGNITUDE-VS-ROUTE TRADEOFF multi-dimensional
                    comparator (9-axis; ATTAIN-1 36mg −11.2% vs STEP-1
                    sema ~−14.9% vs SURMOUNT-1 tirz ~−22.5%);
                  - §10.6 OFF-LABEL DOMINANT for orforglipron pre-approval.
                                |
                                v
                  [§11] All claims source-anchored
                  - Tier 1 (peer-reviewed Phase 3 published: ATTAIN-1,
                    ATTAIN-2, ACHIEVE-1)
                  - Tier 2 (Phase 2 peer-reviewed)
                  - Tier 3 (class-level inherited via mechanism class)
                  - Pattern AB.1/AB.2/AB.4 identifier-integrity verified
                                |
                                v
                  [Appendix A] Verification gate (4-step cycle)

12.3 Phenotype-guided decision matrix

A markdown table mapping the §1.3 phenotype dimensions to the orforglipron consideration framework. The matrix is a clinical-education navigation aid for the pre-FDA-approval state, not a current-prescribing decision authority.

Phenotype dimension	Pattern	Orforglipron fit (anticipated post-approval)	Current access pathway (2026-05-13)	Comparator-class option (FDA-approved-for-marketing-claims)
Indication = obesity, BMI ≥30, no T2D	Anticipated ATTAIN-1	Anticipated CWM scope; 36 mg target (−11.2% / 72 wk); 12 mg / 6 mg tolerability-preferred	No RECRUITING trial for new-enrollment obesity-without-T2D Phase 3 as of 2026-05-13 (ATTAIN-1/-2 COMPLETED; ATTAIN-MAINTAIN for maintenance-phase patients)	Wegovy 2.4 mg (STEP-1 −14.9%); Zepbound 15 mg (SURMOUNT-1 −22.5%); SURMOUNT-5 head-to-head
Indication = obesity + T2D	Anticipated ATTAIN-2	Anticipated CWM + T2D scope; 36 mg target	ATTAIN-2 COMPLETED; primary publication Horn 2026 PMID 41275875	Wegovy 2.4 mg + concurrent T2D management; Mounjaro / Zepbound 15 mg
Indication = T2D + diet/exercise or background metformin	Anticipated ACHIEVE-1	Anticipated T2D scope; HbA1c −1.24% to −1.48%; 36 mg target	ACHIEVE-1 published Rosenstock 2025 PMID 40544435; ACHIEVE-2/-5 sponsor topline; ACHIEVE-3/-4/-J Phase 3 RECRUITING or readout-pending	Ozempic 1.0-2.0 mg (SUSTAIN); Mounjaro 15 mg (SURPASS-2 head-to-head higher); Rybelsus 7/14/25 mg oral peptide with SNAC
Indication = obesity maintenance after initial weight loss	Anticipated ATTAIN-MAINTAIN	ATTAIN-MAINTAIN scope; Phase 3 readout pending	ATTAIN-MAINTAIN NCT05931380 RECRUITING	Wegovy continued; Zepbound continued (STEP-5 / SURMOUNT-4)
Indication = OSA + obesity overlap	Anticipated GLOW-2	GLOW-2 scope; Phase 3 readout pending	GLOW-2 NCT06066620 RECRUITING	Zepbound (SURMOUNT-OSA FDA-approved-for-marketing-claims December 2024)
Indication = MASLD / MASH	Mechanism-class hypothesis	Research-direction-stage as of 2026-05-13	No active orforglipron MASH Phase 3 enrollment	Wegovy ESSENCE PMID 40305708 FDA-approved-for-marketing-claims for non-cirrhotic F2/F3 MASH; resmetirom
Indication = cardiovascular outcomes (BMI ≥27 + ASCVD)	Mechanism-class hypothesis	Dedicated CV outcomes trial in development per Lilly	No active orforglipron CV outcomes Phase 3 enrollment	Wegovy SELECT PMID 37952131; Rybelsus SOUL PMID 40162642; SURMOUNT-MMO active
Phenotype: MTC / MEN-2 personal/family hx	Class-level mechanism-grounded hard contraindication	OUT OF PROTOCOL	OUT OF PROTOCOL	Non-GLP-1 alternative
Phenotype: severe prior pancreatitis	Class-level mechanism-grounded hard contraindication	OUT OF PROTOCOL	OUT OF PROTOCOL	Non-GLP-1 alternative
Phenotype: pregnancy / lactation	Class-level pregnancy contraindication	OUT OF PROTOCOL — immediate discontinuation if pregnancy on protocol	OUT OF PROTOCOL	Pre-pregnancy / post-pregnancy reinitiation per §8.6
Phenotype: pre-conception planning	Anchor 3 framing — Pattern N.1 shorter half-life	~2-4 week washout per ~29-hr half-life + margin (shorter than sema ~8 wk; tirz ~4 wk)	Trial-protocol contraception requirements	Same arithmetic class with peptide-specific half-life windows
Phenotype: route-preference for oral on practical-logistical grounds	Pattern N.1 platform advantage	Oral non-peptide; no food/water timing restriction; room-temp storage	Awaiting FDA approval; trial enrollment if indication-matched	Rybelsus oral peptide (empty stomach + 30-min wait per SNAC); injectables for higher effect-size
Phenotype: Rybelsus-experienced with SNAC timing-restriction adherence difficulty	Pattern N.1 phenotype-targeting	Anticipated orforglipron no SNAC; no timing restriction	Trial enrollment if eligible; off-label investigational supply	Continue Rybelsus with timing discipline reinforcement; or transition to injectable for higher effect-size
Phenotype: cost / access barrier	Anchor 5 framing	Pre-FDA-approval pricing TBD; chemical-synthesis platform observation	Trial enrollment if eligible; compounded sourcing per §10.3 (substantially limited)	Compounded semaglutide / tirzepatide where 503A/503B framework applies; insurance-coverage variation
Phenotype: prior non-response or intolerance to sema/tirz	Pattern V signal	Mechanism class is single GLP-1R agonism (same class as sema); GIPR-component-tolerability not applicable	Trial enrollment if indication-matched	Liraglutide (Saxenda); retatrutide trial enrollment (different mechanism class); bariatric pathway
Phenotype: lean-mass concern	M5.6 stack consideration; Pattern N.1 hybrid-platform	Hybrid-platform stack: orforglipron oral + CJC-Ipamorelin injectable	M5.6 v3 stack consideration per §9.3 + Anchor 5 framing	All-peptide combination: sema + CJC-Ipamorelin; tirz lean-mass sub-analyses

12.4 Worked example — decision-tree walkthrough for the §1.5 route-preference patient

The 46-year-old female with BMI 31, no T2D, hypertension and dyslipidemia (on lisinopril + atorvastatin), no ASCVD, eGFR 88, UACR 12, post-menopausal, oral-platform-preference on practical-logistical grounds (international travel; no refrigeration access; airline baggage constraints on needle disposal — not anxiety-related per Pattern Z.injection-framing).

Decision-tree walkthrough.

Step 1 — Indication scope (§1). Anticipated CWM (obesity without T2D) indication per ATTAIN-1 framework matches her phenotype (BMI 31; weight-related comorbidities). Monocondition phenotype.

Step 2 — Selection criteria (§2). Inclusion criteria met for the anticipated CWM (obesity without T2D) indication scope. No hard contraindications. No relative exclusions.

Step 3 — Pre-treatment workup (§3). Standard metabolic panel (CMP, lipid panel, HbA1c 5.7); MASH-screen FIB-4 from CMP (FIB-4 not yet calculated; advance to FibroScan only if indeterminate or high); CV-risk panel baseline ECG (also covers Pattern N.1 platform-class QT baseline per §3.9); organ-baseline TSH + pancreas baseline + ophthalmology with NAION-context awareness; body-composition DEXA. Pattern N.1 platform-class workup (§3.9): concomitant medication review — atorvastatin is CYP3A4 substrate; orforglipron-specific CYP-mediated DDI consideration per eventual label; QT baseline ECG.

Step 4 — Access pathway decision. As of 2026-05-13, her access options per the matrix:

ATTAIN-MAINTAIN (NCT05931380; RECRUITING) — not applicable to her phenotype (she has not yet achieved initial weight loss; this trial is for maintenance-phase patients).
GLOW-2 (NCT06066620; RECRUITING) — not applicable (no documented OSA).
ACHIEVE-3 / ACHIEVE-4 / ACHIEVE-J (T2D Phase 3) — not applicable (no T2D).
Clinician-judgment off-label use of investigational supply — pending whether such pathway is available; not commonly accessible for routine CWM use as of 2026-05-13.
Compounded orforglipron from research-chemical / gray-market sources — per §10.3 framing, substantially limited market presence; not a meaningful access option.
Start FDA-approved-for-marketing-claims comparator now — Wegovy 2.4 mg semaglutide injectable (STEP-1 −14.9% at 68 weeks per Wilding 2021 NEJM PMID 33567185) or Zepbound tirzepatide injectable (SURMOUNT-1 −22.5% at 15 mg / 72 weeks; SURMOUNT-5 head-to-head higher than sema per Aronne 2025 NEJM PMID 40353578). Both are subcutaneous weekly with cold-chain storage — operational logistical constraint per her route-preference rationale.
Wait for anticipated orforglipron FDA approval (anticipated end-2025 obesity NDA / 2026 T2D NDA; anticipated approval H1 2027 conditional). Pros: full Pattern N.1 platform advantages (oral; no food/water timing restriction; room-temperature stable; chemical-synthesis manufacturing). Cons: ATTAIN-1 36 mg effect-size −11.2% is meaningfully below STEP-1 sema (~−14.9%) and SURMOUNT-1 tirz (~−22.5%); pre-approval timing uncertainty; no orforglipron-specific CV / kidney / MASH outcomes evidence base.

Step 5 — Counseling beats (§10). Initiation conversation per §10.2 with explicit pre-FDA-approval framing and access-pathway shared decision-making. Compounded framing per §10.3 (substantially limited market presence; not a meaningful current option). Pregnancy-planning not applicable (post-menopausal). Comparator conversation per §10.5 — MAGNITUDE-VS-ROUTE TRADEOFF LOAD-BEARING: present the multi-dimensional 9-axis comparison honestly. Her decision likely hinges on weighting: route advantages (oral; no timing restriction; portable for international travel) vs effect-size magnitude (semaglutide / tirzepatide larger effect-size at peer-reviewed Phase 3) vs regulatory-state timing (FDA-approved now vs anticipated H1 2027) vs CV/MASH/kidney established evidence base (semaglutide established; orforglipron research-direction-stage). Off-label / extrapolation conversation per §10.6 dominant framing given the pre-FDA-approval state.

Step 6 — Clinician-patient shared decision. Pattern Z calibration: protocol presents facts; clinicians and patients decide. Reasonable decisions might be:

Start Wegovy now if effect-size magnitude is the patient’s priority; accept logistical adaptation (cold-chain travel kit; airline-compliant needle disposal protocols); revisit orforglipron transition post-approval if the route-preference rationale outweighs the established evidence base.
Wait for anticipated orforglipron approval if the patient’s circumstances allow deferral and the route-preference rationale dominates her preference structure; interim management via lifestyle intervention; revisit at approval landscape clarification.
Start Zepbound now if the patient prioritizes largest peer-reviewed weight-loss effect-size; same logistical-adaptation considerations.
Trial enrollment is not currently a viable access option for her phenotype.

Step 7 — Source citations (§11). All claims traced: ATTAIN-1 Wharton 2025 PMID 40960239; STEP-1 Wilding 2021 PMID 33567185; SURMOUNT-1 Jastreboff 2022 NEJM; SURMOUNT-5 Aronne 2025 PMID 40353578; class-comparator FDA-approval-status citations.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with anticipated effect-size estimates and explicit pre-FDA-approval qualification at every step. The route-preference rationale is presented as a real and legitimate factor (Pattern Z.injection-framing: not framed as resolving “needle anxiety” but as practical-logistical preference). The magnitude-vs-route tradeoff is presented honestly without steering toward injectables on magnitude grounds nor toward orforglipron on route grounds. The patient and clinician decide. No “approved” / “FDA-approved” claim slipped through for orforglipron; every orforglipron regulatory framing carries the anticipated / Phase 3 readout-published-or-pending / pre-FDA-approval-for-marketing-claims qualification. Every class-comparator FDA-approved claim carries the “for marketing claims for [indication X]” full expansion at first mention per Pattern AA.marketing-claims discipline.

Appendix A. Verification gate

A.1 Verification cycle reference

This protocol passes through the Module 5 four-step verification cycle per /Methodology/Protocol Template.md Appendix A: (1) Production-agent draft (this protocol); (2) Primary-Source-Verification-Agent iteration; (3) Independent-Adversarial-Reviewer-Agent iteration; (4) Dr. Gross verification gate.

The protocol’s verification chain is informed by the Orforglipron canonical v1.0-final verification chain (Phase 10 Dr. Gross simulation CLEAN; Phase 10.5 PSV iter 1 CLEAN — AB.1/AB.2/AB.4 hygiene compliance verified; Phase 11 Independent Adversarial Reviewer iter 1 READY TO SHIP; Phase 12 v1.0-final committed). Protocol-specific verification re-runs the cycle against the protocol’s specific structural authority (Protocol Template post-patch 20e66bd).

A.2 Self-audit findings (production-agent step)

See Appendix C.

Appendix B. Pattern discipline summary

B.1 Pattern R / R.1 / R.2

§1 opens with what orforglipron IS (oral non-peptide small-molecule GLP-1R agonist in active Phase 3 with three published primary registrational trials) and the clinical-education framing; not with regulatory deficits.
§2 ordering: §2.2 inclusion → §2.3 relative exclusion → §2.4 contraindication.
§6 opens with anticipatory framing per AE-class.
§6.8 pregnancy LEADS with Parker 2025 human research-state data (Pattern Z anchor 3).
§7 opens with diagnostic distinctions (pseudo-plateau vs true plateau vs non-response).
§8 opens with discontinuation triggers framed as legitimate clinical pathway.

B.2 Pattern V

Every effect-size claim is anchored to its primary source with population qualification and epistemic-status framing.

ATTAIN-1 obesity (Wharton 2025 NEJM PMID 40960239; NCT05051579; n ≈ 3,127; 72 weeks): 36 mg −11.2% body weight reduction (95% CI −12.0 to −10.4); 12 mg −8.4%; 6 mg −7.5%; placebo −2.1%; between-group treatment effect ~−9.1 pp. Pattern V.metric-axis disclosure applied (per-arm absolute change as load-bearing metric; between-group treatment effect disclosed). 54.6% of 36 mg arm achieved ≥10% body weight reduction.
ACHIEVE-1 T2D (Rosenstock 2025 NEJM PMID 40544435; NCT05869903; 40 weeks): HbA1c absolute reductions −1.24% to −1.48% across 3/12/36 mg dose arms vs placebo −0.41%.
ATTAIN-2 obesity + T2D (Horn 2026 Lancet PMID 41275875; NCT05872620): body weight + HbA1c primary outcomes per primary publication.
Phase 2 obesity (Wharton 2023 NEJM PMID 37351564; NCT04931017; n=272; 36 weeks): up to −14.7% at 45 mg arm.
Phase 2 T2D (Frias 2023 Lancet PMID 37369232; NCT05048719; n=383; 26 weeks): HbA1c up to ~−2.10%; body weight up to ~−10.1 kg.

Cross-trial comparisons explicitly framed per Pattern AA cross-trial caveat: no head-to-head orforglipron vs FDA-approved-for-marketing-claims comparators (semaglutide, tirzepatide, liraglutide) as of 2026-05-13.

B.3 Pattern W

Structural-count claims locked at §1.2 and reconciled end-to-end: three published primary Phase 3 trials (ATTAIN-1 obesity; ATTAIN-2 obesity + T2D; ACHIEVE-1 T2D) plus seven additional Phase 3 trials (ACHIEVE-2, ACHIEVE-3, ACHIEVE-4, ACHIEVE-5, ACHIEVE-J, ATTAIN-MAINTAIN, GLOW-2) plus two foundational Phase 2 trials (PMID 37351564 obesity; PMID 37369232 T2D). Reconciled at §3.10, §4.2, §4.3, §5.2, §7.4, §10.5, §11.4, §12.3.

B.4 Pattern Z 5-anchor calibration

Anchor 1 (compounded operational characteristics). Orforglipron-specific calibration at §10.3 — pre-FDA-approval compounded framing per canonical §8.3.2 research-state-factual observation; Pattern N.1 non-peptide chemistry specialization mismatch with the predominantly peptide-compounding 503A/503B GLP-1 RA market.
Anchor 2 (compounded vs FDA-approved counseling beat). Orforglipron-specific calibration at §10.3 — reframed pre-approval as research-state-factual observation about substantially limited compounded orforglipron market presence; full Anchor 1+2 framing applies if/when post-approval market emerges.
Anchor 3 (pregnancy section research-state-leading structure). Applied at §6.8 and §10.4 — LEADS with Parker 2025 PMID 40329607 human research-state data; PK arithmetic (Pattern N.1 ~29-hr half-life; ~2-4 wk pre-conception window) and class-level Category-X-equivalent framing appear AFTER the research-state lead.
Anchor 4 (multi-dimensional comparator framing). Applied at §10.5 — 9-dimension fact presentation; MAGNITUDE-VS-ROUTE TRADEOFF LOAD-BEARING; affirms all compounds; closes with shared-decision-making invitation; honest acknowledgment that ATTAIN-1 36 mg −11.2% is meaningfully less than STEP-1 sema (~−14.9%) and SURMOUNT-1 tirz (~−22.5%) at peer-reviewed Phase 3.
Anchor 5 (off-label / extrapolation transparency). DOMINANT subsection at §10.6 for orforglipron pre-approval state; trial-enrollment + off-label investigational-supply + compounded sourcing + microdosing extrapolation + phenotype extrapolation all framed per Anchor 5 discipline.

B.5 Pattern AA — regulatory-claim precision (CRITICAL for orforglipron pre-FDA-approval state)

Every regulatory claim carries the pre-FDA-approval-for-marketing-claims qualification. Body-text vocabulary excluded: “approved” / “FDA-approved” for orforglipron (except in the negative “not yet approved” / “NOT FDA-approved as of 2026-05-13” or when referring to FDA-approved-for-marketing-claims class comparators); “first-in-class” / “best-in-class” / “next-generation” / “leading-class” / “most potent” / “emerging” / “promising” / “first oral non-peptide GLP-1 RA” (used as factual-historical context anchored to specific Phase 3 publications, NOT as promotional comparative claim in headers / executive summaries). Body-text vocabulary defaults: “investigational,” “Phase 3 readout published / pending,” “anticipated FDA submission end-2025 obesity / 2026 T2D per Eli Lilly investor disclosures,” “anticipated approval H1 2027 conditional on FDA review timelines,” “sponsor-disclosure-pending-peer-reviewed-publication” (for ACHIEVE-2 / ACHIEVE-5 October 2025 topline), “research-state-pending” (for Phase 3 readout-pending characterization).

Pattern AA.marketing-claims full expansion at first mention for class comparators per Editorial Framework §1.2.1 + AC2-26 Pattern AA.marketing-claims (added 2026-05-13): semaglutide is FDA-approved for marketing claims for T2D (Ozempic 2017; Rybelsus 2019), CWM (Wegovy 2021), CV risk reduction (SELECT 2024), MASH (ESSENCE 2025), CKD-in-T2D (FLOW 2025); tirzepatide is FDA-approved for marketing claims for T2D (Mounjaro 2022), CWM (Zepbound 2023), moderate-to-severe OSA with obesity (December 2024); liraglutide is FDA-approved for marketing claims for T2D (Victoza) and CWM (Saxenda); resmetirom is FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH (2024).

B.6 Pattern AB.1 / AB.2 / AB.4

Pattern AB.1: NEJM same-day cluster discipline. PMID 40544435 verified as Rosenstock 2025 orforglipron ACHIEVE-1 T2D (NOT REDEFINE same-NEJM-day cluster siblings PMID 40544432 Davies REDEFINE-2 cagrilintide/CagriSema T2D obesity; PMID 40544433 Garvey REDEFINE-1 cagrilintide/CagriSema obesity without diabetes; PMID 40544434 likely PIONEER-related). Verbose attribution applied at every citation of PMID 40544435.
Pattern AB.1: Lancet 2023 incretin cluster discipline. PMID 37369232 verified as Frias 2023 orforglipron Phase 2 T2D Lancet Aug 5 (NOT PMID 37385275 tirzepatide SURMOUNT-2; NOT PMID 37385280 retatrutide Phase 2 T2D Rosenstock 2023 Lancet Aug 12).
Pattern AB.1: NEJM 2024 Jul 25 MASH same-day pair. PMID 38856224 verified as Loomba tirzepatide SYNERGY-NASH; PMID 38847460 verified as Sanyal survodutide MASH — distinct compounds, same-NEJM-day pair.
Pattern AB.2: ATTAIN-1 / ACHIEVE-1 NCT-collision-prevention. ATTAIN-1 = NCT05051579 (obesity); ACHIEVE-1 = NCT05869903 (T2D); ATTAIN-2 = NCT05872620 (obesity + T2D). The trial-to-NCT mappings verified; canonical §1.2 Pattern N.1 methodology footnote documents the prior-version AB.2 NCT-collision (NCT05869903 incorrectly cited for ATTAIN-1 in a prior draft) — corrected.
Pattern AB.4: ATTAIN-1 dose-arm cascade discipline. ATTAIN-1 dose arms verified 6 / 12 / 36 mg (NOT 12/24/36 mg fabrication corrected in commit cascade 14c0043 + a061039 + Stage 4-A patch). 36 mg / 72 weeks body weight reduction verified −11.2% (NOT −14.6% fabrication corrected). Every dose-arm and effect-size citation in this protocol carries the verified data.
Pattern AB.4: ATTAIN-1 DOI/PMID single-publication discipline. DOI 10.1056/NEJMoa2511774 = PMID 40960239 same Wharton ATTAIN-1 NEJM 2025 publication (not distinct readouts).
Pattern AB.4: Publication-type-drift discipline. Lakhani 2025 PMID 40383360 framed as Multicenter Observational Pharmacovigilance Study (NOT SR/MA); Parker 2025 PMID 40329607 framed as pooled regulatory pregnancy-exposure data (NOT SR).

B.7 Pattern V.metric-axis disclosure

Applied at every ATTAIN-1 36 mg / 72 weeks effect-size citation: per-arm absolute change (36 mg −11.2%; placebo −2.1%) is the load-bearing metric used throughout this protocol; between-group treatment effect (~−9.1 pp) is disclosed where the cross-trial comparator framing requires it. The arithmetic reconciles (−11.2 − (−2.1) ≈ −9.1 pp); both metrics are valid; consistent use of per-arm absolute change as the load-bearing metric prevents cross-surface metric-axis drift.

B.8 Pattern N.1 — small-molecule structural classification

Carried at every load-bearing platform reference:

Frontmatter: structural-classification field explicit; canonical lives at /Small-Molecules/.
§1.1: protocol opens with “oral non-peptide small-molecule GLP-1 receptor agonist.”
§1.6: dedicated subsection on Pattern N.1 small-molecule classification.
§3.9: orforglipron-specific platform-class workup considerations.
§4.5: oral-platform clinical-practice implications.
§6.10: DDI considerations Pattern N.1 small-molecule platform-specific (no SNAC; CYP/P-gp/QT).
§6.12: hepatic safety Pattern N.1 first-pass-metabolism.
§8.4: pre-conception washout Pattern N.1 shorter half-life consequence.
§9.3: cross-Module hybrid-platform combination consideration.
§10.3: compounded counseling — Pattern N.1 non-peptide chemistry specialization vs peptide-compounding 503A/503B.
§10.5: comparator framing — Pattern N.1 platform advantages as one of nine dimensions in multi-dimensional fact presentation.

B.9 Pattern Z.injection-framing

Applied throughout — self-injection framed as routine clinical skill, not as anxiety-coded barrier. §1.3 phenotype-targeting framing: “Pattern Z.injection-framing applies: this is not about ‘needles being scary’; it is about logistical access conditions for which oral platform is operationally simpler.” §10.5 comparator beat: route differential presented operationally (oral vs subcutaneous; daily oral vs weekly injection; food/water timing vs no timing; cold-chain vs room-temperature) rather than affectively.

B.10 Pattern Z.research-precision

Applied throughout — no “highly experimental” / “fringe” / “unproven” / “speculative” / “untested” / “uncharted territory” vocabulary on orforglipron’s pre-approval research base. Body-text framing names the trials (ATTAIN-1, ATTAIN-2, ACHIEVE-1, Phase 2 trials), the magnitudes (−11.2% at 36 mg / 72 weeks; HbA1c −1.24% to −1.48%; etc.), the readout state (peer-reviewed Phase 3 published; sponsor topline pending peer-reviewed publication; Phase 3 readout pending), and the publication (NEJM 2025; Lancet 2026; specific PMIDs).

B.11 Cross-canonical consistency (module-level audit reference)

Cross-canonical consistency framework applies at module-level audit per /Internal/Module-5-Pipeline/README.md. This protocol’s calibration is consistent with:

Orforglipron canonical v1.0-final (cross-referenced at every citation).
Pattern Z calibration anchor file v1.0 (anchor structure mirrored with orforglipron-specific calibrations per §10.1 framework).
Module 5 Protocol Template post-patch 20e66bd (12-section + appendices architecture mirrored).
AC2-26 System Observations v2.4.2+ (Pattern AA.marketing-claims, Pattern Z.injection-framing, Pattern Z.research-precision new sub-patterns 2026-05-13 applied vault-wide).
Retatrutide Protocol v1.0-draft (Wave 1 third pre-approval-state precedent; analogous Anchor 5 dominant calibration applied).

Module-level audit will run when all 9 Module 5 protocols complete.

Appendix C. Self-audit findings

C.1 Pattern AA scan — “approved” / “FDA-approved” body-text usage

The protocol body text uses “FDA-approved” only in the following contexts (Pattern AA.marketing-claims compliant):

In the negative for orforglipron. “Orforglipron is NOT FDA-approved as of 2026-05-13” (and equivalent constructions: “pre-FDA-approval-for-marketing-claims”). Body-text appears in §1.1, §1.2, §1.5, §2.4, §2.5, §3.7, §6.5, §6.13, §8.7, §10.1, §10.2, §10.3, §10.5, §10.6, §10.7, §11.2, §11.4, §11.10, §12.1, §12.3, §12.4, Appendix B.5.
For FDA-approved-for-marketing-claims class comparators (semaglutide for T2D / CWM / CV / MASH / CKD; tirzepatide for T2D / CWM / OSA; liraglutide for T2D / CWM; resmetirom for non-cirrhotic F2/F3 MASH; dulaglutide for T2D). Full Pattern AA.marketing-claims expansion at first mention per Editorial Framework §1.2.1.
For class-level FDA boxed warning framing (MTC / MEN-2 contraindication). Body-text appears in §2.4 and §3.7.
For anticipated orforglipron FDA approval scenarios (with explicit “anticipated” / “post-approval” / “pending FDA approval” qualification). Body-text appears in §1.1, §1.2, §4.3, §4.6, §5.2, §6.5, §8.3, §8.6, §10.2, §10.5.

No orforglipron regulatory claim in the body text uses “approved” / “FDA-approved” without explicit qualification. Self-audit CLEAN.

C.2 §10 framing-discipline diff against canonical anchors

§10.3 orforglipron-specific compounded framing diff against canonical Anchor 1 (semaglutide §8.3.2): orforglipron-specific reframing operates per canonical §8.3.2 research-state-factual observation about substantially limited compounded orforglipron market presence — leads with what compounded orforglipron IS in the pre-FDA-approval landscape (real-world phenomenon at substantially limited scale); operational differences from the post-FDA-approval 503A/503B framework presented as factual scope (Pattern N.1 non-peptide chemistry specialization mismatch; pre-approval status; API source-supply constraints), not deficit framing; closes with shared-decision-making invitation. Calibration consistent with canonical Anchor 1 orforglipron-specific calibration. Self-audit CLEAN.

§10.4 pregnancy framing diff against canonical Anchor 3 (semaglutide §6.8): pregnancy section LEADS with Parker 2025 PMID 40329607 human research-state data (“Incidence of congenital abnormalities appears relatively low”). PK arithmetic (Pattern N.1 ~29-hr half-life; ~2-4 wk pre-conception window), animal-data + class-level Category-X-equivalent contraindication framing, and post-discontinuation weight-regain trajectory appear AFTER the research-state lead. Pattern N.1 shorter-half-life-shorter-washout consequence presented as factual platform difference, not as steering advantage. Patient’s decision is patient-anchored. Calibration consistent with canonical Anchor 3. Self-audit CLEAN.

§10.5 comparator framing diff against canonical Anchor 4 (semaglutide §12.10 Pattern 6): 9-dimension fact presentation (weight magnitude, regulatory status with Pattern AA.marketing-claims full expansion, CV outcomes, MASH approval, kidney outcomes, NAION class-differentiation, mechanism class + Pattern N.1 chemistry-platform, GI tolerability, route / platform availability, cost). Opens with affirmation of multiple options; acknowledges tirzepatide and semaglutide weight-magnitude advantages explicitly (SURMOUNT-1 −22.5%; SURMOUNT-5 head-to-head; STEP-1 −14.9%); MAGNITUDE-VS-ROUTE TRADEOFF presented honestly (“you’d be trading a meaningful difference in weight-loss magnitude” for the route advantage); closes with shared-decision-making invitation. Does NOT push conclusion toward injectables on magnitude grounds nor toward orforglipron on route grounds. Calibration consistent with canonical Anchor 4 + orforglipron-specific magnitude-vs-route tradeoff calibration. Self-audit CLEAN.

§10.6 off-label / extrapolation framing diff against canonical Anchor 5 (semaglutide §12.10 Pattern 8): off-label-dominant framing per orforglipron pre-approval state. Trial-population scope as fact (ATTAIN-1 6/12/36 mg / 72 weeks; ACHIEVE-1 3/12/36 mg / 40 weeks); extrapolation as research-state-incompleteness; explicit off-label labeling; informed-consent acknowledgement; closes with shared-decision-making invitation. Calibration consistent with canonical Anchor 5 orforglipron-specific dominant calibration. Self-audit CLEAN.

Every PMID and NCT in §11.4 / §11.5 / §11.6 / §11.7 / §11.10 verified against Orforglipron canonical v1.0-final §11 Primary-source citation appendix (which was itself verified at canonical Phase 10.5 PSV iter 1 CLEAN). Cascade-failure prevention applied:

ATTAIN-1 = NCT05051579 (NOT NCT05869903 — Pattern AB.2 NCT-collision-prevention).
PMID 40544435 = Rosenstock ACHIEVE-1 (NOT REDEFINE 40544432/40544433/40544434 — Pattern AB.1 same-NEJM-day cluster discipline).
PMID 37369232 = Frias orforglipron Phase 2 T2D Lancet Aug 5 (NOT PMID 37385280 retatrutide Lancet Aug 12 — Pattern AB.1 incretin cluster discipline).
DOI 10.1056/NEJMoa2511774 = PMID 40960239 same publication (NOT distinct readouts).
ATTAIN-1 dose arms = 6/12/36 mg (NOT 12/24/36 mg fabrication).
ATTAIN-1 36 mg / 72 weeks effect = −11.2% (NOT −14.6% fabrication).
Lakhani 2025 PMID 40383360 framed as Multicenter Observational Pharmacovigilance Study (NOT SR/MA per Phase 4 AB.4 hygiene).
Parker 2025 PMID 40329607 framed as pooled regulatory pregnancy-exposure data (NOT SR per Phase 4 AB.4 hygiene). Self-audit CLEAN.

C.4 §1 Purpose pre-FDA-approval clinical-education framing

§1.1 opens with: “This protocol prepares clinicians for orforglipron’s anticipated availability based on the Phase 3 ATTAIN (obesity) and ACHIEVE (T2D) program readout data and provides a clinical-education framework… Current prescribing reality (2026-05-13). Orforglipron is in Phase 3 with three published primary registrational trials… FDA NDA submission is anticipated end-2025 (obesity indication) and 2026 (T2D indication) per Eli Lilly investor disclosures; anticipated approval H1 2027 conditional on FDA review timelines… What this protocol IS NOT. It is not a current-prescribing protocol for a population at large. Current prescribing of orforglipron is restricted to (a) enrollment in an active ATTAIN-MAINTAIN, GLOW-2, ACHIEVE-3, ACHIEVE-4, or ACHIEVE-J Phase 3 trial under the trial protocol’s investigational-supply provision; or (b) off-label clinical use of investigational supply where research-protocol acquisition pathways exist…”

The §1 Purpose carries the pre-FDA-approval clinical-education framing explicitly per the task-brief Pattern AA requirement. Self-audit CLEAN.

C.5 ATTAIN-1 dose-arm + effect-size verification (LOAD-BEARING)

ATTAIN-1 dose arms verified at every citation: 6 / 12 / 36 mg (NOT 12/24/36 mg fabrication). Effect sizes verified at every citation:

36 mg / 72 weeks: −11.2% body weight reduction (per-arm absolute change; 95% CI −12.0 to −10.4) — NOT −14.6%.
12 mg / 72 weeks: −8.4% (95% CI −9.1 to −7.7).
6 mg / 72 weeks: −7.5% (95% CI −8.2 to −6.8).
Placebo / 72 weeks: −2.1% (95% CI −2.8 to −1.4).
Between-group treatment effect (36 mg vs placebo): ~−9.1 pp.
54.6% of 36 mg arm achieved ≥10% body weight reduction.

ACHIEVE-1 dose arms verified at every citation: 3 / 12 / 36 mg. Effect sizes verified: HbA1c absolute reductions −1.24% to −1.48% across dose arms vs placebo −0.41%.

Self-audit CLEAN. No reintroduction of the corrected fabrications.

C.6 Items for Dr. Gross verification

The following items are flagged for Dr. Gross verification at the Step 4 gate:

Anticipated FDA approval timing claim (“anticipated FDA submission end-2025 obesity / 2026 T2D per Eli Lilly investor disclosures; anticipated approval H1 2027 conditional on FDA review timelines”) — verify against current Eli Lilly SEC filings and press releases. Pattern P pre-publication verification discipline applies. If specific submission has occurred or specific timing has been Lilly-disclosed in a recent (post-2026-05-12) communication, update the protocol accordingly.
Anticipated post-approval titration schedule (§4.3 and §4.6 — multi-step ascending through 6 → 12 → 36 mg in CWM; 3 → 12 → 36 mg in T2D) — verify against the eventual FDA label at approval.
Anticipated post-approval maintenance dose framework (§5.2 — 6 mg, 12 mg, 36 mg in CWM; 3 mg, 12 mg, 36 mg in T2D) — verify against the eventual FDA label.
Anticipated taper schedule (§8.3 — 36 mg → 12 mg → 6/3 mg → off over ~8 weeks) and anticipated pre-conception washout window (§8.4 — ~2-4 weeks per ~29-hr half-life) — verify against the eventual FDA label and against the broader GLP-1 RA class taper / washout framework.
ATTAIN + ACHIEVE program enrollment status updates (§1.2, §1.5, §12.3) — verify against current ClinicalTrials.gov v2 API status at the time of clinical use. RECRUITING / ACTIVE_NOT_RECRUITING / COMPLETED status as of 2026-05-13 may have changed by the time of clinical-education delivery.
Voice Profile calibration — review §10.2 / §10.3 / §10.4 / §10.5 / §10.6 / §10.7 counseling-beat language against /Methodology/Voice Profile - Dr. Jeff Gross MD.md for tone, framing, and voice. Adjust as needed.
Pre-FDA-approval compounded orforglipron framing (§10.3) — verify the canonical §8.3.2 research-state-factual observation framing language is consistent with Dr. Gross’s clinical experience and judgment regarding patient-discourse triage for compounded orforglipron sourcing questions in the pre-FDA-approval state.
Pattern N.1 first-pass-metabolism hepatic surveillance framework (§5.3, §6.12, §6.13) — verify the ALT/AST monitoring posture against current hepatology consultation patterns. Phase 3 surveillance data may refine the specific monitoring intervals; the current framing is research-state-anchored to the canonical §6.12.
Pattern N.1 CYP / P-gp / QT DDI surveillance framework (§3.9, §5.3, §6.10) — verify the CYP-mediated DDI surveillance posture given the orforglipron-specific Phase 1 DDI characterization (Lilly Phase 1 development program; specific CYP-mediated DDI considerations apply per eventual product label).
Pattern AA.marketing-claims precision on all class-comparator claims — verify that every “FDA-approved” claim for semaglutide, tirzepatide, liraglutide, dulaglutide, resmetirom uses the full expansion “FDA-approved for marketing claims for [indication X]” at first mention per Editorial Framework §1.2.1 + AC2-26 Pattern AA.marketing-claims (2026-05-13).
Pattern Z.injection-framing audit — verify no anti-anchor anxiety-coded vocabulary (“scary,” “daunting,” “intimidating,” “major barrier,” “significant challenge”) used in §10 counseling beats for injectable comparators.
Pattern Z.research-precision audit — verify no bias-vocabulary (“highly experimental,” “fringe,” “unproven,” “speculative,” “untested”) used in §10 or §11 for orforglipron’s pre-approval research base.
Magnitude-vs-route tradeoff framing audit (§10.5) — verify the counseling beat is honest in both directions: does NOT steer toward injectables on magnitude grounds; does NOT steer toward orforglipron on route grounds. The patient-counseling beat sample text should be evaluated for whether it reads as honestly presenting the tradeoff or as soft-steering in either direction.

C.7 Production audit summary

File path: /Users/dariapechaiko/Documents/VirtuDigital/Projects/Pepteon Academy/Synergy-Health-Academy/obsidian-peptides/Protocols/Orforglipron Protocol.md
Word count target: 22,000-27,000 words (Wave 2 pre-approval-state protocol).
Production discipline: 6 strict incremental commits per the production-discipline standard.
Pattern Z 5-anchor verbatim-anchor compliance: verified per §C.2.
Pattern AA.marketing-claims pre-approval-state precision: verified per §C.1 + §C.4.
Pattern AB.4 identifier-integrity (LOAD-BEARING dose-arm + effect-size verification): verified per §C.3 + §C.5.
Pattern N.1 small-molecule structural classification: carried at every load-bearing platform reference per Appendix B.8.
§1 Purpose pre-FDA-approval clinical-education framing: verified per §C.4.
Magnitude-vs-route tradeoff framing (LOAD-BEARING for this protocol): verified per §C.2 (§10.5).
Cross-canonical consistency: verified against Orforglipron canonical v1.0-final.

End of Orforglipron Clinical Protocol v1.0-draft.

Orforglipron Protocol